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ABSTRACT 
 
Akinyemi Oni-Orisan: Translational Approaches to Understanding the Role of Cytochrome 
P450-Derived Epoxyeicosatrienoic Acids in Coronary Artery Disease 
(Under the direction of Craig R. Lee) 
 
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in 
the United States (US). Most notably, coronary artery disease (CAD) including its clinical 
complications (acute myocardial infarction [AMI] and heart failure) is the primary source of this 
public health burden. This burden highlights the need for new therapies that target biological 
pathways integral to the pathophysiology of CAD and its consequences. However, a more 
thorough understanding of the mechanisms underlying the pathophysiology is necessary to 
facilitate the development of new therapeutic strategies. 
Epoxyeicosatrienoic acids (EETs) are cytochrome P450 (CYP)-derived metabolites of 
arachidonic acid that are hydrolyzed by soluble epoxide hydrolase (sEH) into the less 
biologically active dihydroxyeicosatrienoic acids (DHETs). EETs yield potent cardiovascular 
protective effects in preclinical models of atherosclerosis, ischemia reperfusion (IR) injury, and 
post-AMI ventricular remodeling, suggesting that increasing EET levels may be a viable 
therapeutic strategy for CAD, AMI, and post-AMI maladaptive ventricular remodeling. Key 
questions, however, remain to be addressed prior to translation of therapeutic EET-promoting 
strategies into successful clinical trials. 
The overall aim of this dissertation is to advance our understanding of the role of the EET 
metabolic pathway across the full spectrum of CAD and post-AMI consequences as a means to 
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determine the biological and therapeutic importance of EETs in the progression of this disease 
cascade. We used both pre-clinical and human studies to complete the specific aims of this work. 
We found that obstructive CAD is significantly and independently associated with lower 
circulating EET levels. In addition, we observed that a functionally relevant polymorphism 
linked with enhanced EET hydrolysis was potentially associated with mortality in a population 
of AMI patients. Moreover, we showed that mice with cardiomyocyte-specific overexpression of 
human sEH exhibited enhanced IR-induced myocardial collagen deposition. Overall, we 
demonstrated that the EET metabolic pathway may play a role in the pathophysiology of CAD 
and its associated complications including the development of coronary atherosclerosis, post-
AMI early ventricular remodeling, and post-AMI mortality. These findings set the stage for 
future studies that investigate the therapeutic utility of modulating EETs in CAD patients. 
 v 
 
ACKNOWLEDGMENTS 
I would like to start off by thanking my major adviser Dr. Craig Lee for working 
tirelessly to hone my research skills and providing me with numerous opportunities to grow over 
the past five years. I am grateful for my committee chair Dr. Tim Wiltshire and the other 
members of my team including Dr. Brian Jensen, Dr. Jo Ellen Rodgers, Dr. John Seubert, and 
Dr. Darryl Zeldin for sharing their wisdom, challenging me, offering constructive feedback on 
this project, and for their overwhelming support of my career aspirations. 
I would like to thank the current members of the Craig Lee lab including Kim Vendrov, 
Michael Wells, Erin Christensen, and Bobbie Nguyen for their hard work and dedication. I 
would like to thank past members of the lab including Dr. Robert Schuck, Dr. Katie Theken, Dr. 
Weibin Zha, and Dr. Yangmei Deng for teaching me a great deal of labotratory techniques. It 
was also a privilege working with the drug development fellows Dr. Melissa Polasek, Dr. John 
Andrew Lee, Dr. Robert Wittorf, Dr. Brian Simmons, and Dr. Savannah Steele. 
I would also like to thank our collaborators at the National Institute of Environmental 
Health Sciences (NIEHS) including Dr. Artiom Gruzdev and Dr. Matthew Edin as well as Dr. 
George Stouffer from the UNC School of Medicine for their contribution to the projects. I would 
like to thank Dr. Mauricio Rojas, Ashley Ezzell, and Kirk Mcnaughton for all of their wonderful 
service. I would like to thank members of the Bruce Hammock lab, the Joan Taylor lab, and 
personnel of the TRIUMPH cohort for their helpful advice and assistance. 
 vi 
I would like to thank the Division of Pharmacotherapy and Experimental Therapeutics 
including the excellent faculty, staff, and trainees for being the best source of help a student 
could ask for. I would also like to thank the Center for Pharmacogenomics and Individualized 
Therapy for playing a key role in shaping my interests as a researcher. Furthermore, the UNC 
Eshelman School of Pharmacy has provided a world-class research training environment with 
excellent facilities and resources to work with. 
I would like to acknowledge the financial support of my training including an American 
Heart Association pre-doctoral fellowship, an American Foundation for Pharmaceutical 
Education pre-doctoral fellowship, a NIH research supplement to promote diversity in health-
related research, and a Royster Society of Fellows interdisciplinary fellowship. 
I would also like to especially thank my close friends and family who were critical to my 
training as a PhD student well before I decide to pursue a PhD. In particular, I want to thank 
Mom and Dad for giving me life, for reading to me as a toddler, for sheltering us from the 
neighborhood that we grew up in, for encouraging me to embrace education, and for giving me 
confidence through positive feedback. I would like to thank Dapo, Deola, Debola, and Cecily for 
their continued encouragement throughout this process and for motivating me through their own 
work ethic and incredible accomplishments. Lastly, I would like to thank Baby Lana for being 
my key source of inspiration over the past 6 months.  
 vii 
   
TABLE OF CONTENTS 
LIST OF TABLES ........................................................................................................................ xii 
 
 
LIST OF FIGURES ..................................................................................................................... xiv 
 
 
LIST OF ABBREVIATIONS ...................................................................................................... xvi 
 
 
CHAPTER 1 - INTRODUCTION .................................................................................................. 1 
 
The full cascade of coronary artery disease and its public health impact ........................................ 1 
The epoxyeicosatrienoic acid metabolic pathway and parallel pathways of eicosanoid  
metabolism ..................................................................................................................................... 12 
Perspective ..................................................................................................................................... 19 
Specific Aims ................................................................................................................................. 21 
Figures ........................................................................................................................................... 23 
REFERENCES .............................................................................................................................. 29 
CHAPTER 2 - CYTOCHROME P450-DERIVED EPOXYEICOSATRIENOIC ACID 
BIOMARKERS ARE ASSOCIATED WITH THE EXTENT OF CORONARY  
ARTERY DISEASE IN HUMANS: A TARGETED METABOLOMICS STUDY ................... 39 
 
Introduction .................................................................................................................................... 39 
Materials and Methods ................................................................................................................... 41 
Results ............................................................................................................................................ 47 
 viii 
Discussion ...................................................................................................................................... 51 
Figures ........................................................................................................................................... 57 
Tables ............................................................................................................................................. 63 
REFERENCES .............................................................................................................................. 69 
CHAPTER 3 - THE RELATIONSHIP BETWEEN EPHX2 P.LYS55ARG  
POLYMORPHISM AND SURVIVAL IN PATIENTS FOLLOWING AN ACUTE 
MYOCARDIAL INFARCTION .................................................................................................. 74 
 
Introduction .................................................................................................................................... 74 
Materials and methods ................................................................................................................... 78 
Results ............................................................................................................................................ 81 
Discussion ...................................................................................................................................... 84 
Figures ........................................................................................................................................... 90 
Tables ............................................................................................................................................. 96 
 REFERENCES…………………………………………………………………………106 
CHAPTER 4 - CHARACTERIZATION OF MALADAPTIVE VENTRICULAR 
REMODELING IN AN IN VIVO MOUSE MODEL OF MYOCARDIAL  
ISCHEMIA REPERFUSION INJURY ...................................................................................... 111 
 
Introduction .................................................................................................................................. 111 
Materials and Methods ................................................................................................................. 117 
Results .......................................................................................................................................... 124 
Discussion .................................................................................................................................... 128 
 ix 
Figures ......................................................................................................................................... 134 
Tables ........................................................................................................................................... 142 
REFERENCES ............................................................................................................................ 144 
CHAPTER 5 - THE CONTRIBUTION OF CARDIOMYOCYTE SOLUBLE  
EPOXIDE HYDROLASE TO ACUTE MYOCARDIAL INFARCTION- 
INDUCED MALADAPTIVE VENTRICULAR REMODELING IN MICE ............................ 149 
 
Introduction .................................................................................................................................. 149 
Materials and Methods ................................................................................................................. 151 
Results .......................................................................................................................................... 157 
Discussion .................................................................................................................................... 161 
Figures ......................................................................................................................................... 169 
Tables……………………………………………………………………………………………176 
REFERENCES ............................................................................................................................ 179 
CHAPTER 6 - DISCUSSION AND PERSPECTIVE ................................................................ 183 
 
Summary and Scope .................................................................................................................... 183 
Key Findings ................................................................................................................................ 185 
Clinical Implications .................................................................................................................... 192 
Conclusions .................................................................................................................................. 194 
REFERENCES ............................................................................................................................ 195 
 x 
APPENDIX A - PHARMACOGENOMICS IN HEART FAILURE: WHERE  
ARE WE NOW AND HOW CAN WE REACH CLINICAL APPLICATION ........................ 198 
 
Introduction .................................................................................................................................. 198 
Beta adrenergic antagonists ......................................................................................................... 200 
Drugs targeting the renin-angiotensin-aldosterone system .......................................................... 207 
Other heart failure therapies ......................................................................................................... 209 
Future prospects for pharmacogenomics ..................................................................................... 211 
Tables ........................................................................................................................................... 214 
REFERENCES ............................................................................................................................ 215 
APPENDIX B - EPOXYEICOSATRIENOIC ACIDS AND CARDIOPROTECTION:  
THE ROAD TO TRANSLATION ............................................................................................. 223 
 
Introduction .................................................................................................................................. 223 
The CYP epoxygenase pathway .................................................................................................. 225 
Acute EET effects following IR .................................................................................................. 227 
Chronic EET effects following ischemia reperfusion .................................................................. 232 
Chronic EET effects in non-ischemic cardiomyopathy ............................................................... 234 
EET action in cardiac non-myocytes ........................................................................................... 235 
Clinical studies investigating the role of EETs in the progression of CVD ................................. 239 
Discussion: key considerations prior to initiation of proof-of-concept clinical trials .................. 242 
Summary/ Conclusion .................................................................................................................. 249 
 xi 
Figures ......................................................................................................................................... 251 
Tables ........................................................................................................................................... 255 
REFERENCES ............................................................................................................................ 256 
  
 xii 
LIST OF TABLES 
Table 2.1 Characteristics of the total study population and across the angiographic  
extent of coronary artery disease (CAD) .............................................................................. 63 
Table 2.2 List of all eicosanoid metabolites ................................................................................. 64 
Table 2.3 Comparison of plasma cytochrome P450 (CYP) epoxygenase-derived  
and soluble epoxide hydrolase (sEH)-derived arachidonic acid metabolite  
biomarkers across coronary artery disease (CAD) extent ..................................................... 65 
Table 2.4 Multivariate relationships between clinical factors and plasma  
epoxyeicosatrienoic acids (N=162)....................................................................................... 66 
Table 2.5 Comparison of plasma eicosanoid metabolites across obstructive coronary  
artery disease (CAD) status .................................................................................................. 67 
Table 2.6 Quantitative enrichment analysis (QEA) results on eicosanoid metabolic  
pathways ............................................................................................................................... 68 
Table 3.1 Characteristics of the acute coronary syndrome (ACS) study population  
from the INFORM cohort by genotype ................................................................................ 96 
Table 3.2 Characteristics of the TRIUMPH cohort overall and by race ....................................... 97 
Table 3.3 Characteristics of the TRIUMPH cohort overall and by genotype using  
a dominant mode of inheritance ............................................................................................ 98 
Table 3.4 Characteristics of the TRIUMPH cohort overall and by genotype using  
a dominant mode of inheritance in Caucasian patients only................................................. 99 
Table 3.5 Characteristics of the TRIUMPH cohort overall and by genotype using  
a dominant mode of inheritance in African American patients only .................................. 100 
Table 3.6 Mortality follow-up status in TRIUMPH ................................................................... 101 
Table 3.7 Hazard ratios between EPHX2 Lys55Arg and 3-year mortality using a  
dominant mode of inheritance ............................................................................................ 102 
 xiii 
Table 3.8 Hazard ratios between EPHX2 Lys55Arg and 3-year mortality using  
an additive mode of inheritance .......................................................................................... 103 
Table 3.9 Relationship between EPHX2 Lys55Arg and biomarkers of myocardial  
injury, inflammation, and ventricular remodeling .............................................................. 104 
Table 3.10 Power calculations .................................................................................................... 105 
Table 4.1 Impact of myocardial ischemia reperfusion (IR) on mitral pulse Doppler  
parameters of cardiac dysfunction ...................................................................................... 142 
Table 4.2 Impact of myocardial ischemia reperfusion (IR) on cardiac structure over  
time ..................................................................................................................................... 143 
Table 5.1 Impact of cardiomyocyte soluble epoxide hydrolase (sEH) overexpression  
on Pulsed Wave Doppler image-derived parameters of systolic function following  
ischemia-reperfusion (IR) injury ......................................................................................... 176 
Table 5.2 Impact of cardiomyocyte soluble epoxide hydrolase (sEH) overexpression  
on Pulsed Wave Doppler image-derived parameters of diastolic and global  
function following ischemia-reperfusion (IR) injury .......................................................... 177 
Table 5.3 Impact of cardiomyocyte soluble epoxide hydrolase (sEH) overexpression  
on cardiac structure following ischemia-reperfusion (IR) injury. ...................................... 178 
  
 xiv 
LIST OF FIGURES 
Figure 1.1 The full cascade of coronary artery disease (CAD) and its associated  
consequences......................................................................................................................... 23 
Figure 1.2 Myocardial fibrosis post-acute myocardial infarction (AMI) ..................................... 24 
Figure 1.3 Cytochrome P450 (CYP)-derived epoxyeicosanoids .................................................. 26 
Figure 1.4 The eicosanoid metabolism pathway. .......................................................................... 28 
Figure 2.1. Correlation matrix of eicosaniods. ............................................................................. 57 
Figure 2.2 Plasma biomarkers of cytochrome P450 (CYP)-mediated  
epoxyeicosatrienoic acids (EETs) biosynthesis and hydrolysis across  
coronary artery disease (CAD) extent................................................................................... 59 
Figure 2.3 Enrichment of eicosanoid pathways across obstructive coronary  
artery disease (CAD) status. ................................................................................................. 60 
Figure 2.4 Coronary artery disease (CAD) extent, epoxyeicosatrienoic acid  
(EETs), and risk of subsequent cardiovascular events.......................................................... 62 
Figure 3.1 Mortality in acute myocardial infarction (AMI) patients from the  
INFORM cohort by genotype using a dominant mode of inheritance.................................. 90 
Figure 3.2 Mortality in acute myocardial infarction (AMI) patients from the  
TRIUMPH cohort by genotype using a dominant mode of inheritance. .............................. 93 
Figure 3.3 Mortality in acute myocardial infarction (AMI) patients from the  
TRIUMPH cohort by genotype using an additive mode of inheritance. .............................. 95 
Figure 4.1 Impact of myocardial ischemia reperfusion (IR) on myocardial cell  
death. ................................................................................................................................... 134 
Figure 4.2 Impact of myocardial ischemia reperfusion (IR) on acute inflammatory  
responses. ............................................................................................................................ 135 
 xv 
Figure 4.3 Impact of myocardial ischemia reperfusion (IR) on early maladaptive  
ventricular remodeling. ....................................................................................................... 136 
Figure 4.4 Impact of myocardial ischemia reperfusion (IR) on systolic function. ..................... 137 
Figure 4.5 Impact of myocardial ischemia reperfusion (IR) on diastolic function. .................... 138 
Figure 4.6 Correlation between staining methods of fibrosis. .................................................... 139 
Figure 4.7 Impact of myocardial ischemia reperfusion (IR) on fibrosis. .................................... 140 
Figure 4.8 Impact of myocardial permanent occlusion (PO) on maladaptive  
ventricular remodeling. ....................................................................................................... 141 
Figure 5.1 Characterization of cardiomyocyte-specific soluble epoxide hydrolase  
(sEH) overexpressing transgenic mice................................................................................ 169 
Figure 5.2 Impact of myocardial ischemia reperfusion (IR) on soluble epoxide  
(sEH) expression. ................................................................................................................ 171 
Figure 5.3 Impact of cardiomyocyte sEH overexpression on myocardial necrosis. ................... 172 
Figure 5.4 Impact of cardiomyocyte soluble epoxide hydrolase (sEH)  
overexpression on M-mode image-derived parameters of systolic function. ..................... 173 
Figure 5.5 Impact of cardiomyocyte soluble epoxide hydrolase (sEH)  
overexpression on diastolic function. ................................................................................. 174 
Figure 5.6 Impact of cardiomyocyte soluble epoxide hydrolase (sEH)  
overexpression on fibrosis. ................................................................................................. 175 
  
 xvi 
LIST OF ABBREVIATIONS 
α-SMA   α-smooth muscle actin 
14,15-EEZE   14,15-epoxyeicosa-5(Z)-enoic acid 
A   atrial 
AA   arachidonic acid 
ACS   acute coronary syndrome 
AET   aortic ejection time 
AMI   acute myocardial infarction 
ANCOVA  analysis of covariance 
ANOVA  analysis of variance 
ANF   atrial natriuretic factor 
Bax   B‑cell lymphoma 2‑associated X protein 
Bcl-2   B-cell lymphoma-2 
BHT   butylated hydroxytoluene 
BNP   b-type natriuretic peptide 
CABG   coronary artery bypass graft 
CAD   coronary artery disease 
cAMP   cyclic AMP 
cDNA   complementary DNA 
COPD   chronic obstructive pulmonary disease 
COX   cyclooxygenase  
CRP   C-reactive protein 
CV   cardiovascular 
 xvii 
CVD   cardiovascular disease 
CYP   cytochrome P450 
DHA   docosahexaenoic acid 
DHET   dihydroxyeicosatrienoic acids 
DHOME  dihydroxyoctadecaenoic acid 
DiHN   dihydroxynondecanoic acid 
Dr   deceleration rate 
Dt   deceleration time 
E   early 
ECG   electrocardiogram 
ECM   extracellular matrix 
EET   epoxyeicosatrienoic acid 
EF   ejection fraction 
EGR-1   early growth response-1 
EPA   eicosapentaenoic acid 
EpHep   epoxyheptadecanoid acid 
EpOME  epoxyoctadecaenoic acid  
FDR   false discovery rate  
FFR   fractional flow reserve 
FGF-2   fibroblast growth factor-2 
FS   fractional shortening 
HDL   high density lipoprotein 
HFpEF   heart failure with preserved ejection fraction 
 xviii 
HFrEF   heart failure with reduced ejection fraction  
HR   hazard ratio 
hs-CRP  high sensitivity C reactive protein 
ICAM-1  intercellular adhesion molecule-1 
IL   interleukin 
IQR   interquartile range 
IR   ischemia reperfusion 
IVCT   isovolumic contraction time 
IVSd   inter ventricular septum at diastole 
IVRT   isovolumic relaxation time 
IVSs   inter ventricular septum at systole 
LAD   left anterior descending 
LC-MS/MS  liquid chromatography-tandem mass spectrometry 
LDL   low-density lipoprotein 
LO   lipoxygenase 
LOX   lysyl oxidase 
LSD   least significant difference 
LV   left ventricle 
LVDP   left ventricular developed pressure 
LVIDd   left ventricular internal diameter at diastole 
LVIDs   left ventricular internal diameter at systole  
LVPWd  left ventricular posterior wall at diastole  
LVPWs  left ventricular posterior wall at systole 
 xix 
MAF   minor allele frequency 
MHC   myosin heavy chain 
MIP-2α  macrophage inflammatory protein-2α 
MCP-1  monocyte chemoattractant protein-1 
MMP   matrix metalloproteinases 
MPI   myocardial performance index 
MPO   myeloperoxidase 
NF-κB   nuclear factor-kappaB 
NSTEMI  non-ST-segment elevation myocardial infarction 
PCI   percutaneous coronary intervention 
PGE2-d4  prostaglandin E2-d4 
PI3K   phosphoinositide-3-kinase 
PKA   cAMP-dependent protein kinase 
PO   permanent occlusion 
proBNP  pro-B-type natriuretic peptide 
QEA   quantitative enrichment analysis  
qPCR   quantitative real-time polymerase chain reaction 
RAAS   renin–angiotensin–aldosterone system 
sEH   soluble epoxide hydrolase 
SEM   standard error of the mean 
SNP   single nucleotide polymorphisms 
STEMI  ST-segment elevation myocardial infarction 
t-PA   tissue plasminogen activator 
 xx 
TGF-β   transforming growth factor-β 
TIMP   tissue inhibitor of matrix metalloproteinase 
US   United States 
Vols   volume at systole 
Vold   volume at diastole 
  
  
1 
 
CHAPTER 1 – INTRODUCTION 
 
The full cascade of coronary artery disease and its public health impact 
 
Health burden of coronary artery disease 
Despite advances in evidence-based medical therapies, cardiovascular disease (CVD) as a 
whole remains the leading cause of mortality in the United States (US). CVD has been the 
leading cause of death for over a century (causing 800 thousand deaths in 2011) and its 
prevalence (at 86 million adults) is expected to continue to rise tremendously. Most notably, 
coronary artery disease (CAD), which includes acute myocardial infarction (AMI) and angina 
pectoris (chest pain), is the primary source of this public health burden causing almost half (375 
thousand) of all CVD deaths in 2011 (1). Of those who have not already developed CAD at the 
early age of 40, about 25% will develop some manifestation of CAD within 6 years (2). AMI 
alone was responsible for 120 thousand deaths in 2011 and it is estimated that death from a 
coronary event occurs every 84 seconds in America. The survival rate of AMI has improved, 
largely due to advances in revascularization and secondary prevention therapies; however, the 
prevalence of heart failure, a key clinical outcome of CAD, is estimated to now be at almost 6 
million (1). Approximately 25% of patients that experience a first AMI develop heart failure 
within 30 days (3). CAD and heart failure together are responsible for 116 billion dollars in 
direct and 99 billion dollars in indirect health care costs annually (1). The extensive health and 
economic burden associated with CAD highlights the need for new therapies that target 
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biological pathways integral to the pathogenesis and progression of CAD. However, a more 
thorough understanding of the mechanisms underlying the pathophysiology of CAD is necessary 
to facilitate the development of new therapeutic strategies that mitigate atherosclerosis, prevent 
AMI events, delay the progression of cardiac remodeling to heart failure, and ultimately improve 
public health outcomes. 
 
Coronary atherosclerosis 
Atherosclerosis is the progressive deposition of plaque along the walls of the arteries 
(Figure 1.1a). When this plaque buildup occurs in the coronary arteries in particular, this is 
termed CAD. Coronary atherosclerosis pathogenesis is a complex inflammatory process that 
develops over decades (4). Briefly, atherosclerosis begins when low-density lipoprotein (LDL) is 
retained in the arterial intima and oxidized causing the activation of endothelial cells. Activated 
endothelial cells then trigger an inflammatory response through the expression of cellular 
adhesion molecules, which promote the accumulation of monocytes and neutrophils into the 
plaque (5). Differentiated monocytes (macrophages) drive the pathogenesis of atherosclerosis by 
producing inflammatory cytokines and chemoattractants such as monocyte chemoattractant 
protein-1 (MCP-1). This leads to the further accumulation of leukocytes into the plaque (6). 
Macrophages accumulate lipids thereby transforming into isolated lipid-laden foam cells which 
eventually come together to form what is known as the ‘fatty streak’ (7, 8). The lesion continues 
to develop with the infiltration of smooth muscle cells and connective tissue. Development of the 
early lesion occurs over decades and is accelerated by the presence of conditions such as 
hypertension, hyperlipidemia, smoking, and diabetes mellitus, which are known as 
cardiovascular (CV) risk factors. When extracellular lipids and cholesterol esters become a major 
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component of the developing lesion, an atheroma develops (8). Symptoms of stable angina occur 
when the atheroma grows to the point that it causes chronic narrowing of the artery (stenosis) 
and blood flow reduction, thereby limiting supply of oxygen to the myocardium (ischemia). 
Symptoms are especially evident in the setting of increased oxygen demand such as exercise and 
emotional stress (9). Thus, for some individuals, this stage of atherosclerosis development is 
when stenosis can first be visualized by coronary angiography and when symptoms first manifest 
(8). The clinical definition of nonobstructive CAD is having one or more lesions that are not 
anatomically (<50% stenosis in the left main and <70% stenosis in all non-left main coronary 
arteries) or functionally (fractional flow reserve [FFR] that reduces blood flow mildly by ≥0.8) 
‘significant’. Revascularization by percutaneous coronary intervention (PCI) or coronary artery 
bypass graft (CABG) in nonobstructive CAD patients to improve symptoms/mortality has been 
found to cause more harm than benefit and is not recommended (10). The risk of developing 
stable angina pectoris increases as the degree of artery stenosis increases in size. When the lesion 
advances to the extent that stenosis is anatomically ‘significant’ (≥50% in the left main coronary 
artery or ≥70% in any of the other major epicardial coronary arteries), patients are said to have 
obstructive CAD. Patients may also have functionally obstructive CAD if the lesion reduces 
blood flow to less than 80% of its original pressure (FFR<0.8). Obstructive CAD patients are 
thought to have lesions that have advanced to the point that blood flow is ‘significantly’ 
obstructed and thus have a highest likelihood of suffering from anginal symptoms. Consequently, 
obstructive CAD patients meet the anatomical and functional criteria for coronary artery 
revascularization by PCI or CABG to improve symptoms (10). 
 
Acute myocardial infarction 
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Atheromatous plaques are protected from the coronary artery lumen by a fibrous cap. A 
thin fibrous cap reduces the stability of the atherosclerotic lesion making it more prone to 
rupture. The thickness of the fibrous cap is correlated with the degree of stenosis where 
obstructive lesions have the thickest fibrous caps. Thus, although obstructive lesions are more 
likely to cause anginal symptoms, as described earlier, nonobstructive lesions are more prone to 
plaque rupture (4). Indeed, obstructive CAD patients have the highest risk of lesion disruption 
only because they usually also have the greatest amount of nonobstructive lesions, which are 
spread throughout the coronary vasculature (4, 11). That being said, it is becoming more 
appreciated that nonobstructive CAD patients are also at increased risk of experiencing plaque 
rupture of a nonobstructive lesion. As a patient’s CAD status progresses from no CAD to 
nonobstructive CAD to obstructive CAD, the risk of rupture and resultant cardiovascular 
onsequences increases in a stepwise fashion (11). 
When a ruptured atheromatous plaque is exposed to the lumen, it activates platelets and 
the coagulation cascade acutely producing an occlusive intracoronary thrombus (Figure 1.1b) 
(4). Often a formed thrombus does not affect blood flow or spontaneously resolves and the 
patient experiences no symptoms (8). When a thrombus causes profound myocardial ischemia, a 
key adverse event of CAD, this is known as an acute coronary syndrome (ACS) (4, 8). 
Consequences of ACS ranging from unstable angina to AMI (including non-ST-segment 
elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction 
[STEMI]) depend on the degree, location, and duration of the occlusion (8). All ACS patients 
experience chest pain and electrocardiogram (ECG) changes consistent with ischemia (12). 
Unstable angina causes chest pain at rest, often characterized by occlusion by a labile thrombus 
that may only last 15 minutes on average. Infarcted tissue is not a result of unstable angina. A 
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prolonged period of ischemia from a coronary thrombus results in AMI (13). Myocardial cell 
necrosis is exclusive to AMI and typically occurs in myocardial tissue of the left ventricle (LV) 
(12). The presence of cardiac troponin in blood is an indicator of myocardial necrosis and the 
preferred diagnostic biomarker of AMI (14). STEMI patients have a total occlusion of the artery 
from an intracoronary thrombus (15). These patients require immediate PCI to restore blood 
flow, reduce infarct expansion, and prevent death (14). The majority of patients who die from 
sudden ischemic death (death from CAD within 6 hours of symptom onset) have evidence of 
intracoronary thrombus formation based on autopsy reports (16, 17). The development of 
ventricular arrhythmia is also a cause of sudden ischemic death (8, 16). 
 
Consequences following acute myocardial infarction 
The restoration of blood flow by revascularization, termed ischemia-reperfusion (IR), is 
imperative to prevent expansion of the myocardial infarct. Paradoxically, IR also triggers injury 
to the myocardium (18). Injury initially causes cardiomyocyte necrosis (uncontrolled cell death) 
and apoptosis (programmed cell death), each of which independently contribute to the resulting 
infarct (Figure 1.1c) (19). Changes in the myocardial expression of the anti-apoptotic B-cell 
lymphoma (Bcl-2) and the pro-apoptotic B‑cell lymphoma 2‑associated X protein (Bax) 
regulate activation of the caspase family which is primarily pro-apoptotic. An agent is considered 
to be ‘cardioprotective’ if it reduces IR-induced infarct size by preventing myocardial cell death 
(20). Necrosis but not apoptosis is recognized as the primary mediator of the acute inflammatory 
response (Figure 1.1c) (19). 
Inflammatory-mediated induction of a class of chemoattractants called chemokines 
promotes leukocyte recruitment to the site of injury. Notably, MCP-1 and macrophage 
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inflammatory protein-2α (MIP-2α), which are chemotactic for monocytes and neutrophils, 
respectively, are induced by myocardial necrosis (21). Recruited leukocytes subsequently initiate 
the cytokine cascade including the synthesis of interleukin (IL)-6 in leukocytes and 
cardiomyocytes. Cytokines induce the myocardial expression of adhesion molecules such as 
intercellular adhesion molecule-1 (ICAM-1), which specifically aid in the recruitment of further 
neutrophils to the site of infarct and mediate neutrophil-derived cytotoxicity (22). In tandem, IL-
1β inhibits the activation of fibrosis by preventing the expression of α-smooth muscle actin (α-
SMA). It is also becoming recognized that fibroblasts are phenotypically pro-inflammatory 
during this stage (from stimulation by IL-1β) and producing cytokines/chemokines (23). 
This marked inflammatory response is followed by maladaptive ventricular remodeling 
(22). In particular, transforming growth factor-β (TGF-β) and IL-10 are important mediators 
involved in the resolution of the inflamed myocardium. The resolution of inflammation is 
followed by rapid proliferation (mediated by fibroblast growth factor-2 [FGF-2]) and activation 
(largely mediated by TGF-β) of fibroblasts which soon become the predominant cell type in the 
heart (Figure 1.2). Activated myofibroblasts are distinguished from their quiescent precursors via 
the expression of TGF-β/Smad3 pathway-induced α-SMA. Following activation, fibroblasts 
infiltrate the infarct zone of the myocardium where they function to produce extracellular matrix 
(ECM) proteins that ultimately cause scar formation (23). Levels of the structural components of 
ECM including collagens, glycoproteins, proteoglycans, glycosaminoglycans, and matricellular 
proteins are increased post-AMI contributing to dynamic changes in the matrix. The ECM also 
includes proteases that are involved in the degradation of these structural components and are 
also altered post-AMI, contributing to further changes in the matrix. In addition to 
myofibroblasts which are the most abundant source of ECM proteins post-AMI, endothelial 
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cells, neutrophils, mast cells, lymphocytes, and macrophages are other major sources of ECM 
proteins. Collagens are considered the structural backbone of the ECM and are present at low 
levels in the normal, non-infarcted heart. Post-AMI, collagen expression increases in all regions 
of the heart, with the greatest magnitude of expression in the infarct zone (24). Only 
myofibroblasts synthesize collagen. Lysyl oxidase (LOX) mediates the maturation of scar tissue 
by cross-linking collagen fibrils. However, before the maturation of the fibrotic scar, ECM 
remodeling can occur as a consequence of mediators such as osteopontin, fibronectin, tissue 
inhibitor of matrix metalloproteinases (TIMPs), and matrix metalloproteinases (MMPs) that 
regulate ECM turnover (25). Only MMP can degrade collagen (26). Following scar tissue 
maturation, myofibroblasts halt production of further profibrotic mediators and become less 
abundant in the myocardium, potentially through apoptosis (23). 
The development of fibrosis is often accompanied by activation of the fetal gene 
program, which results in the dysregulation of a set of genes associated with maladaptive 
ventricular remodeling. Increased b-type natriuretic peptide (BNP) expression and a “switch” 
from expression of the adult α-myosin heavy chain (MHC) to the fetal β-MHC are biomarkers of 
this process (27). BNP promotes compensatory vasodilator and natriuretic responses that indicate 
that myocardial strain (i.e. an abnormal structural change) is occurring (28). Fetal gene activation 
begins early and is thought to be promoted at least partially by initial mechanical stretch-induced 
activation of early growth response-1 (EGR-1) (29). It is evident that the induction of these 
mediators during the acute phase following IR activates responses that promote ventricular 
remodeling during the chronic stages. Together, myocardial fibrosis and cardiac structural 
changes from fetal gene activation ultimately lead to adverse consequences, notably the first 
signs/symptoms of heart failure (Figure 1.1c) (22).  
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Heart failure is a clinical syndrome that manifests in patients as dyspnea (shortness of 
breath) and/or fluid retention (edema). Symptoms of heart failure result primarily from structural 
or functional deficits from advanced ventricular remodeling that lead to a reduced ability in 
ventricular filling (diastolic dysfunction) or ejection of blood (systolic dysfunction). It is 
important to note that structural abnormalities in heart failure patients range from having no 
changes at all to having marked ventricular dilation. Likewise, functional impairment may or 
may not coexist with structural changes and range from having a normal ability to eject blood 
(commonly measured as ejection fraction [EF]) to having severely reduced EF. Thus there is no 
definitive test to diagnose heart failure. Both the evaluation of signs/symptoms and cardiac 
structure/function testing (most commonly via echocardiography) are necessary to diagnose heart 
failure. Heart failure patients who have reduced EF are categorized as having ‘Heart failure with 
reduced ejection fraction’ (HFrEF). One of the most common causes of HFrEF is AMI. The 
specific definition of HFrEF in terms of EF varies between <35%, <40%, and ≤40%. Heart 
failure patients who have preserved EF have structural and/or functional deficits that 
compromise ventriclular relaxation and are categorized as ‘Heart failure with preserved ejection 
fraction’ (HFpEF) (30). 
In addition to promoting the development of heart failure, early ventricular remodeling 
responses also elevate the risk of a subsequent AMI and myocardial electrical conduction 
abnormalities that promote sudden cardiac death (31). Indeed, the degree of scar tissue formation 
and cardiac dysfunction are each predictors of the risk of cardiac events following AMI (32-34). 
Importantly, progression can occur quickly (35) and clinical trial data show that the development 
of heart failure in first-time AMI patients with no history of heart failure can occur within a week 
(36). Consequently, early treatment post-AMI has been found to reduce the occurrence of heart 
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failure (37, 38), likely due to attenuation of the early maladaptive ventricular remodeling 
response. 
Moreover, established and emerging biomarkers of inflammation and ventricular 
remodeling processes have been found to have prognostic and therapeutic utility in patients (28). 
Circulating biomarkers of inflammation such as MCP-1, myeloperoxidase (MPO), IL-6, C-
reactive protein (CRP) and ICAM-1 are independent predictors of poor prognosis following an 
AMI in humans (39-44). Biomarkers of myocardial remodeling including cardiac β- and α-MHC 
expression as well as circulating BNP levels are associated with the presence and severity of 
heart failure and AMI in humans (45, 46). Novel biomarkers of fibrosis such as circulating ST2 
offer prognostic value in heart failure patients on top of traditional biomarkers and established 
risk factors (47). Consequently, these biomarkers of inflammation and myocardial remodeling 
are valuable phenotypic endpoints in pre-clinical and human studies, and inhibition of these 
responses has enormous potential to improve prognosis in AMI patients. It is clear that early and 
aggressive therapy well before the manifestation of symptomatic heart failure improves 
outcomes. 
 
The need for novel therapeutic strategies and novel drug development approaches 
It is evident that novel therapies which further delay the development of coronary 
atherosclerosis, prevent the expansion of IR-induced infarct (‘cardioprotective’ therapies), slow 
the progression of post-infarct early ventricular remodeling, or facilitate a combination of the 
above will reduce poor complications associated with CAD. These therapeutic strategies for the 
treatment of CAD and its complications have been in development for decades. However, the 
majority of these drug candidates have failed. For example, the cornerstone therapies for AMI 
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have consisted of antiplatelet agents, beta blockers, statins, and renin-angiotensin aldosterone 
system inhibitors post-AMI for decades (48-50), but drug candidates from novel therapeutic 
classes for AMI have not been successfully translated to standard practice guidelines (49). 
Furthermore, in the realm of cardioprotective therapies, no pharmacological therapies and only 
early reperfusion (as a strategy to reduce infarct size) has been successfully translated into 
clinical practice (10). 
One explanation for poor success rates is flawed preclinical research. For example, 
preclinical models of post-AMI myocardial remodeling are critical tools to screen/develop novel 
therapeutic strategies (51). Induction of AMI in rodents in vivo is feasible and produces injury 
comparable to the more established large animal models of AMI. However, full characterization 
of the pathophysiology of the disease in post-AMI models is necessary to determine how 
predictive and translational the model is to humans. Surprisingly, the acute and chronic impact of 
some of the most commonly used AMI models have not been fully characterized in the literature 
and requires further investigation. A more thorough understanding of the pathophysiology of 
myocardial remodeling following AMI in mice will facilitate the design of experimental studies 
that elucidate the role of therapeutic pathways in the disease. 
These failures also suggest that innovative approaches during late drug development 
(clinical trials) are needed to mitigate increasing attrition rates and more successfully translate 
novel therapies into clinical practice (18, 52, 53). Compared to the conventional ‘one-size fits 
all’ methodology to drug development, a precision medicine approach has the potential to 
increase the probability of success for promising therapeutic candidates (54). Although targeted 
therapies are routinely used in oncology, this strategy has not been readily adopted in CVD, but 
opportunities exist to implement precision medicine in heart disease (Appendix A) (55). 
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Biomarkers offer considerable promise to prospectively identify subsets of CAD patients at high 
risk of experiencing a cardiovascular event that exhibit dysfunction in a specific pathway 
(putative responders), consequently enabling novel therapies that target the pathway to maximize 
their therapeutic effect and improve outcomes.  
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The epoxyeicosatrienoic acid metabolic pathway and parallel pathways of eicosanoid 
metabolism 
 
The epoxyeicosatrienoic acid metabolic pathway 
Epoxyeicosatrienoic acids (EETs) are cytochrome P450 (CYP)-derived metabolites of 
arachidonic acid. Specifically, CYP epoxygenases from the CYP2C and CYP2J subfamilies 
metabolize arachidonic acid into four EET regioisomers (5,6-, 8,9-, 11,12- and 14,15-EET). 
EETs have a variery of biological functions, but are rapidly hydrolyzed by soluble epoxide 
hydrolase (sEH, EPHX2) into the less biologically active dihydroxyeicosatrienoic acids (DHETs) 
(56). The CYP epoxygenases known to metabolize arachdidonic acid in humans are CYP2J2, 
CYP2C8, and CYP2C9. These enzymes as well as sEH are expressed in the cardiovascular 
system including the myocardium and blood vessels (57-59). 
 
Epoxyeicosatrienoic acid action in coronary artery disease and acute myocardial infarction 
EETs are endogenous lipid mediators that elicit potent vasodilatory effects by 
hyperpolarizing vascular smooth muscle cells (60, 61), anti-inflammatory effects by attenuating 
nuclear factor-kappaB (NF-κB) signaling (62, 63), fibrinolytic effects by induction of tissue 
plasminogen activator (t-PA) expression (64), antimigratory effects on smooth muscle cells 
through the cAMP-dependent protein kinase (PKA) pathway (65), anti-apoptotic effects by 
promoting phosphoinositide-3-kinase (PI3K)/Akt signaling (66, 67), and pro-survival effects by 
preserving mitochondrial function (68). Concordant with these basic mechanistic effects, 
therapeutically promoting the effects of EETs yields potent cardiovascular protective effects in 
preclinical models of cardiovascular disease (69). For example, inhibition of sEH genetically or 
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pharmacologicallay increased plasma EET levels and prevented femoral artery neointima 
formation in a mouse model of vascular inflammation (70). In addition, pharmacological 
administration of a sEH inhibitor reduced lesion accelerated lesion formation in a mouse model 
of cardiovascular atherosclerosis (71). Moreover, Ephx2−/− mice had improved recovery of left 
ventricular developed pressure (LVDP) and reduced infarct size following IR. This was reversed 
by 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE), a putative EET receptor antagonist, 
implicating EETs as the mediator of the effect (72). Furthermore, pharmacological sEH 
inhibition attenuated collagen deposition in a preclinical model of post-IR maladaptive 
ventricular remodeling. This effect was found to be independent of infarct size reduction (73). 
Taken together, these data suggest that increasing EET levels may be a viable therapeutic 
strategy for CAD, AMI, and post-AMI ventricular remodeling. However, the direct contribution 
of increased cardiomyocyte sEH expression to the pathogenesis and progression of maladaptive 
ventricular remodeling post-AMI in vivo has not been investigated. 
 
Other pathways of eicosanoid metabolism 
In addition to arachidonic acid, another ω-6 fatty acid (linoleic acid) and ω-3 fatty acids 
(docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) are metabolized by CYP 
epoxygenase enzymes into a variety of epoxy-derivatives (74). These epoxyeicosanoids (Figure 
1.3) are also potent biological mediators in the cardiovascular system and may be subsequently 
metabolized into vicinal diols by epoxide hydrolases (75, 76). Moreover, these fatty acids are 
also metabolized by cyclooxygenase (COX), lipoxygenase (LO), and CYP hydroxylase enzymes 
to produce biologically active metabolites that play a functional role in CVD (Figure 1.4) (77-
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79). The role of EETs in the initiation and progression of CAD relative to other eicosanoids 
remains unknown and requires further investigation. 
 
CYP epoxygenases and soluble epoxide hydrolase in human CAD 
Since pharmacological tools that directly and specifically manipulate sEH to modulate 
EET levels are currently not available for clinical use, investigators have relied on genetic 
observational studies to understand the role of the EET metabolic pathway in human CVD.  
Multiple functionally relevant polymorphisms in genes responsible for EET biosynthesis 
(CYP2C8, CYP2J2) and EET hydrolysis (EPHX2) have been identified and found to alter 
enzyme expression or activity. At the population level, associations between genetic 
polymorphisms in the EET metabolic pathway and the risk of developing CAD have been 
reported in humans (80).  
G-50T is a common functional polymorphism in CYP2J2 within the promoter region that 
leads to decreased expression of the enzyme in vitro (81). It has been found to be associated with 
increased the risk of CAD development as well as the premature onset of AMI (before the age of 
45) (82, 83). The CYP2C8 p.Lys399Arg variant allele reduces CYP-derived EET biosynthesis in 
vitro (84). Subjects carrying CYP2C8 Arg399 had a higher risk of incident CAD in Caucasian 
smokers and a  higher risk of AMI in a Scandinavian cohort compared to wildtype individuals 
(85, 86). 
The two most common non-synonymous single nucleotide polymorphisms (SNPs) in 
EPHX2 have been found to decrease (p.Arg287Gln) or increase (p.Lys55Arg) the activity of sEH 
in vitro (87, 88). Specifically, the Arg287Gln polymorphism is thought to reduce the stability of 
the homodimer (87) which is necessary for hydrolase activity (89). The Lys55Arg polymorphism 
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is located in a domain that allows for increased stabilization of the dimer (90). Lys55Arg and 
Arg287Gln are not in linkage disequilibrium (91). 
The allele frequencies for Arg287Gln are approximately 8% and 10% in African 
American and Caucasian populations respectively (80). Lys55Arg has been studied less 
extensively then Arg287Gln, but it is the most common functional SNP in the population (87, 
91). The allele frequencies for Lys55Arg are approximately 22% and 7% in African Americans 
and Caucasians (80). 
Associations between functional genetic polymorphisms in EPHX2 and the risk of 
developing CVD have been reported in humans (91-96). The Arg287Gln variant has been linked 
to reduced plasma cholesterol and triglyceride concentrations in patients with familial 
hypercholesterolemia (97), reduced risk of coronary artery calcification in African-Americans 
(93, 94), increased ischemic stroke risk in white Europeans (98), carotid artery calcified plaque 
in Europeans  (99), improved vascular dysfunction in African Americans (95), and increased risk 
of atrial fibrillation recurrence after catheter ablation (100). The Lys55Arg polymorphism is 
associated with higher sEH metabolic function in vivo and is linked to development of CAD in 
Caucasian patients (91), ischemic stroke in Swedish men (96), and vascular dysfunction in 
Caucasian volunteers (95). 
Taken together, these data suggest that the EET metabolic pathway may be important in 
the pathogenesis of CAD in humans and that therapeutic interventions that promote the 
cardioprotective effects of EETs by modulation of sEH offer considerable promise as a novel 
therapeutic strategy to reduce sequelae following AMI; however, key questions remain to be 
addressed prior to translation of EET-promoting strategies into successful proof-of-concept 
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phase I and II clinical trials. Evaluation of functional variants in EPHX2 and prognosis in AMI 
patients has not been completed. 
In collaboration with Dr. John Spertus (Mid America Heart Institute) and Dr. Sharon 
Cresci (Washington University School of Medicine), the Craig Lee lab has previously 
investigated the association of CYP2J2 -50G>T, CYP2C8 Lys399Arg, EPHX2 Lys55Arg, and 
EPHX2 Arg287Gln genotype with 5-year survival in a 2-center cohort of CAD patients 
hospitalized for an ACS event (INvestigation oF Outcomes from acute coronary syndRoMes 
study [INFORM]). Consistent with our hypothesis that variants which result in lower EET 
biosynthesis or greater EET hydrolysis would have a deleterious effect on cardiovascular disease 
risk and survival, EPHX2 Arg55 variant allele carriers had a significantly higher risk of death 
following an ACS compared to noncarriers (HR 1.50, 95% CI 1.02-2.22, P=0.042). In contrast to 
our hypothesis, CYP2J2 -50G>T genotype was significantly associated with survival such that 
variant allele carriers had lower 5-year mortality compared to noncarriers (HR 0.51, 95% CI 
0.26-0.99, P=0.049). Furthermore, no association was observed with CYP2C8 Lys399Arg (HR 
0.87, 95% CI 0.55-1.41, P=0.598) or EPHX2 Arg287Gln (HR 0.88, 95% CI 0.55-1.41, P=0.597). 
A race-stratified analysis was conducted to account for the potential confounding effects of 
population stratification. Associations in Caucasians were consistent with the overall cohort, and 
persisted after adjusting for demographic and clinical covariates predictive of prognosis. The 
magnitude of the associations were comparable to established prognostic predictors (e.g., 
diabetes: HR 2.2, 95% CI 1.5-3.2, P<0.01). However, associations were not evaluated in African 
Americans, due to a small sample size (N=124) and suboptimal power (101). Validation of the 
association found with EPHX2 Lys55Arg in an independent population remains necessary to 
substantiate these preliminary observations. 
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Systemic levels of cytochrome P450-derived EETs in humans 
We recently reported that multiple clinical factors were associated with EET levels in 
patients with established CAD (102). Furthermore, it is well-established that inflammatory 
stimuli suppress CYP metabolism through a variety of mechanisms, including cytokine-mediated 
down-regulation of CYP expression (103). Moreover, hepatic and extra-hepatic CYP2C/2J 
expression and EET biosynthesis were suppressed in an endotoxin mouse model of acute 
inflammation (104). Taken together, these data suggest multiple factors (beyond germline 
genetic polymorphisms) regulate EET biosynthesis and hydrolysis and that quantifying EET 
levels may provide important insight into the role of these mediators in the pathogenesis and 
progression of CAD. However, due to the technical complexity of quantifying EETs, which are 
present at low concentrations in blood and tissue, these metabolites are not commonly quantified 
on traditional metabolomic or eicosanoid analytical platforms (105). As a consequence, major 
gaps in knowledge surrounding the biological and therapeutic importance of CYP-derived EETs 
in human CAD exist. 
 
Translational approaches to understanding the role of EETs in CAD 
Therapeutic interventions that promote the cardioprotective effects of EETs offer 
considerable promise as a novel therapeutic strategy to delay the pathogenesis/progression of 
CAD and reduce sequelae following AMI. Importantly, agents that promote the effects of EETs 
have not reached clinical trials for the indication of CAD or AMI, thus an opportunity exists to 
gain a more thorough understanding of the role of the EET metabolic pathway across the full 
course of CAD and post-AMI myocardial remodeling prior to translation of EET-promoting 
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strategies into successful proof-of-concept phase I and II clinical trials. In general addressing 
these aforementioned gaps would lay the foundation for the design of clinical trials that select the 
EET-promonting agent, dosing strategy, and patient population most likely to circumvent clinical 
failure (Appendix B discusses the key questions that remain to be addressed in greater detail) 
(69). Both preclinical and human investigations are necessary to address this gap in knowledge 
and improve the probability of translational success from a rapidly emerging body of evidence 
into a clinically applicable therapeutic strategy for CAD patients.  
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Perspective 
 
Despite advances in its detection and management, CAD remains a major health burden 
in the US (1). Consequently, novel therapeutic strategies are needed to further improve 
outcomes. A more thorough understanding of the mechanisms underlying the pathogenesis of 
CAD, AMI, and its associated sequelae are necessary for the development of new therapeutic 
strategies that mitigate this devastating disease across its full spectrum and ultimately improve 
public health outcomes. Precision medicine is a promising therapeutic approach that may 
increase the probability of success for prospective therapeutic candidates. Thus, the discovery of 
biomarkers involved in the pathogenesis of CAD offers considerable promise to facilitate the 
development of novel therapeutics by identifying subsets of high-risk patients who would derive 
the greatest benefit from therapy. Increasing EET levels has emerged as a viable therapeutic 
strategy for CAD, AMI, and post-AMI ventricular remodeling in preclinical models; however, 
key questions remain to be addressed prior to translation of therapeutic EET-promoting strategies 
into successful proof-of-concept phase I and II clinical trials. We hypothesize that promoting the 
beneficial effects of EETs offers therapeutic potential in CAD patients and that subsets of the 
population predisposed to low EET levels will derive the greatest benefit from this therapeutic 
strategy. 
Thus, the overall aim of this dissertation is to advance our understanding of the role of 
the EET metabolic pathway across the full spectrum of CAD and post-AMI consequences as a 
means to determine the biological and therapeutic importance of EETs in the progression of this 
disease cascade. We seek to accomplish this aim using an integrated combination of targeted 
metabolomics (Aim 1) and candidate gene (Aim 2) approaches in humans, as well as a genetic 
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manipulation (Aim 3) approach in mice. Aim 1 will provide some insight into the role of the 
EET metabolic pathway in the coronary vasculature; Aims 2 and 3 are focused more on the role 
of the pathway in myocardiocytes post-AMI. 
Completion of this dissertation will (1) identify individuals across the full spectrum of 
CAD predisposed to a deficiency in the EET metabolic pathway and poor prognosis, who may 
derive the greatest benefit from EET promoting strategies using a precision medicince approach 
to drug development; (2) determine the role of sEH/EPHX2 in the pathophysiology of post-AMI 
ventricular remodeling as a means to determine the therapeutic potential of promoting EETs 
following AMI; and (3) promote precision medicine and pharmacogenomics as a future avenue 
for cardiovascular drug development by laying the foundation for clinical trials that evaluate the 
therapeutic utility of a novel strategy.  
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Specific Aims 
 
1) Elucidate the relationship between the extent (stenosis) of CAD and CYP-derived EET 
levels in patients referred for coronary angiography 
Hypotheses: 
a. Increasing CAD extent will be significantly and independently associated with 
lower circulating EET levels. 
b. The association between increasing CAD extent and lower EET levels will 
correlate with both lower CYP-derived EET biosynthesis and higher sEH-derived EET 
hydrolysis. 
c. The association between CAD extent and EET levels will be more pronounced 
than the association between CAD extent and eicosanoids from other metabolism 
pathways. 
 
2) Determine the relationship between the EPHX2 p.Lys55Arg polymorphism and survival 
in AMI patients 
Hypothesis: 
a. Carriers of the EPHX2 Arg55 variant allele will exhibit higher risk of mortality 
following hospitalization for an AMI 
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3) Determine the contribution of cardiac sEH to maladaptive ventricular remodeling in 
mice post-AMI in vivo 
Hypotheses: 
a. The 30-minute left anterior descending (LAD) coronary artery ligation ischemia-
reperfusion model of in vivo AMI in mice will induce ventricular remodeling including 
the induction of fibrosis, structural changes, and cardiac dysfunction. 
b. Mice with transgenic overexpression of sEH in cardiomyocytes and enhanced 
cardiac EET hydrolysis will have worsened ventricular remodeling post-AMI including 
enhanced fibrosis, structural changes, and cardiac dysfunction.  
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Figures 
 
 
 
Figure 1.1 The full cascade of coronary artery disease (CAD) and its associated 
consequences 
 
(a) Atherosclerosis, the progressive buildup of plaque along the walls of the arteries, initiates 
CAD and correlates with the risk of stable angina. (b) Atheromatous lesions with thin fibrous 
caps are more like to rupture and lead to acute myocardial infarction. (c) Infarcted tissue from an 
AMI activates an inflammatory response which promotes the development of maladaptive 
ventricular remodeling. Adapted/modified from Nature. 2002 Dec 19-26;420(6917):868-74 and J 
Am Heart Assoc. 2012 Oct;1(5):e004408.  
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Figure 1.2 Myocardial fibrosis post-acute myocardial infarction (AMI)  
Following AMI, fibroblast proliferation is mediated by fibroblast growth factor (FGF). 
Thereafter, transforming growth factor (TGF)-β mediates the transformation of fibroblasts to 
differentiated myofibroblasts. Profibrotic myofibroblasts synthesize collagen fibers, which are 
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ultimately cross-linked by lysyl oxidase (LOX) into mature scar tissue. Proteases (matrix 
metalloproteinases [MMPs] and tissue inhibitor of matrix metalloproteinases [TIMPs]) can alter 
the extent of collagen deposition before final maturation. Adapted/modified from J Mol Cell 
Cardiol. 2014 May;70C:74-82.  
 26 
 
 
Figure 1.3 Cytochrome P450 (CYP)-derived epoxyeicosanoids. 
Bioactive epoxyeicosanoids from arachidonic acid (AA), linoleic acid (LA), docosahexaenoic 
acid (DHA), and eicosapentaenoic acid (EPA) elicit various biological effects in the 
cardiovascular system and are extensively hydrolyzed by soluble epoxide hydrolase. DHEQ, 
dihydroxy-eicosatetraenoic acid; DHOME, dihydroxyoctadecaenoic acid; DiHDPA, dihydroxy-
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docosapentaenoic acid; EDP, epoxydocosapentaenoic acid; EEQ, epoxyeicosatetraenoic acid; 
EpOME, epoxyoctadecaenoic acid. Adapted from J Mol Cell Cardiol. 2014 Sep;74:199-208. 
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Figure 1.4 The eicosanoid metabolism pathway. 
ω-3 and ω-6 fatty acids are metabolized by cyclooxygenase (COX), lipoxygenase (LO), and 
cytochrome P450 (CYP) enzymes to produce biologically active eicosanoids that play a 
functional role in cardiovascular disease (CVD). cPLA2, cytosolic phospholipases A2; DHET, 
dihydroxyeicosatrienoic acid; DHOME, dihydroxyoctadecaenoic acid; DiHDPA, dihydroxy-
docosapentaenoic acid; EET, epoxyeicosatrienoic acid; EpDPE, epoxydocosapentaenoic acid; 
EpOME, epoxyoctadecaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE, 
hydroxyoctadecadienoic acids; TriHOME, trihydroxyoctadecenoic acid.  
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CHAPTER 2 - CYTOCHROME P450-DERIVED EPOXYEICOSATRIENOIC ACID 
BIOMARKERS ARE ASSOCIATED WITH THE EXTENT OF CORONARY ARTERY 
DISEASE IN HUMANS: A TARGETED METABOLOMICS STUDY 
 
Introduction 
 
Despite significant advances in its treatment, CAD remains the leading cause of 
morbidity and mortality worldwide (1). Consequently, novel therapeutic strategies are needed to 
further improve outcomes. The discovery of biomarkers involved in the pathogenesis of CAD 
offers considerable promise to facilitate the development of novel therapeutics by identifying 
subsets of high-risk patients who would derive the greatest benefit from therapy (2, 3). 
In addition to their well-established role as xenobiotic metabolizing enzymes, CYP also 
metabolize fatty acids to bioactive lipids that regulate numerous cellular and physiologic 
processes relevant to the pathogenesis of CAD (4). Most notably, CYP epoxygenases from the 
CYP2C and CYP2J subfamilies metabolize arachidonic acid (AA) into four epoxyeicosatrienoic 
acid regioisomers (5,6-, 8,9-, 11,12- and 14,15-EET) (5). The EETs elicit potent vasodilatory, 
anti-inflammatory and cellular protective effects in the cardiovascular system, but are rapidly 
hydrolyzed by sEH into less biologically active DHETs (6, 7). 
An accumulating body of preclinical evidence has demonstrated that promoting the 
effects of EETs yield potent cardiovascular protective effects in multiple preclinical models (8) 
including models of vascular inflammation (9), atherosclerosis (10), and myocardial ischemia-
reperfusion injury (11). In epidemiologic studies, associations between functional 
 40 
polymorphisms in genes responsible for EET biosynthesis (CYP2C8, CYP2J2) and EET 
hydrolysis (EPHX2) and the development of CAD have been reported (12-14). Taken together, 
these data suggest that modulation of CYP-derived EET levels may be a viable therapeutic 
strategy for CAD. 
We recently reported that multiple clinical factors were associated with low EET levels in 
patients with established CAD (15), suggesting that quantifying EET metabolite levels may 
provide insight into factors associated with inter-individual variation in EET biosynthesis and 
EET hydrolysis (beyond germline genetic polymorphisms). Unfortunately, due to the technical 
complexity of quantifying EETs, which are present at low concentrations in blood and tissue, 
these metabolites are not commonly quantified on traditional metabolomic or eicosanoid 
analytical platforms (16). As a consequence, major gaps in knowledge surrounding the biological 
and therapeutic importance of CYP-derived EETs in human CAD exist. Thus, a more thorough 
understanding of the relationship between inter-individual variation in EET levels and extent of 
CAD in humans is needed to facilitate the translation of these promising therapies into rationally 
designed clinical trials. 
The primary objective of the current study was two-fold: (1) to elucidate the relationship 
between CYP-derived EET levels and the extent of CAD in patients referred for coronary 
angiography, and (2) to evaluate the strength of this association relative to eicosanoids derived 
from the parallel COX, LO, and CYP4A/4F hydroxylase metabolic pathways. In order to 
accomplish these objectives, a panel of 28 CYP-, COX-, and LO-derived lipid metabolites was 
quantified in 162 patients with suspected or worsening obstructive CAD using a targeted 
metabolomics approach.  
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Materials and Methods 
 
Study population 
A cohort of individuals 18-80 years of age referred for coronary angiography to detect 
new or worsening CAD were identified in the cardiac catheterization laboratories at the 
University of North Carolina-Chapel Hill between September 2012 and February 2014. 
Exclusion criteria included severe concurrent illness (such as active pneumonia and acute 
decompensated heart failure), systemic inflammatory disease, malignancy with active treatment, 
hematologic disorders affecting platelet function, prior heart transplantation, hematocrit <30%, 
STEMI, end-stage liver disease, end-stage renal disease on dialysis, and corticosteroid use. 
Eligible participants provided written informed consent. The study protocol was approved by the 
UNC Biomedical Institutional Review Board and was completed in accordance with the 
Declaration of Helsinki. 
 
Classification of CAD extent 
Obstructive CAD was defined according to anatomical or physiological ‘criteria for 
revascularization’ in recent clinical practice guidelines (17). Briefly, the anatomic criteria for 
revascularization (PCI or CABG) are the presence of ≥50% stenosis in the left main coronary 
artery or ≥70% stenosis in one or more of the non-left main coronary arteries. The classification 
of nonobstructive CAD included those without obstructive CAD that had mild stenosis (10-69% 
in one or more non-left main coronary arteries and/or 10-49% stenosis in the left main coronary 
artery), whereas the classification of no apparent CAD included those with no angiographic 
evidence of CAD (<10% stenosis in all coronary arteries). Coronary stenting impacts the 
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inflammatory state in the index lesion. Indeed, in-stent restenosis is an inflammatory response to 
stent placement which can reocclude the artery and drug-eluting stents reduce the risk of 
restenosis due to their immunosuppressive properties (18). Thus, in order to reflect the extent of 
CAD at the time of blood sampling unrelated to prior revascularization, only unprotected lesions 
(lesions not bypassed by collateral vessels, CABG, or stents) in native coronary arteries were 
considered for classification. 
 
Quantification of eicosanoid metabolite concentrations 
Whole blood was drawn in the catheterization lab from the indwelling arterial sheath that 
had been placed as part of the coronary angiography procedure. Plasma was immediately 
separated by centrifugation and stored at -80°C for future biomarker analysis. Plasma eicosanoid 
metabolite concentrations were quantified by targeted liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) as previously described, with minor modifications (19, 20). Brielfy, 
plasma (0.25 mL) was diluted in 0.1% acetic acid/5% methanol solution (0.25 mL) containing 
0.009 mM butylated hydroxytoluene (BHT), spiked with internal standards (3 ng each of 
prostaglandin E2-d4 [PGE2-d4; Cayman Chemical, Ann Arbor, MI], 10,11- 
dihydroxynondecanoic acid [DiHN] and 10,11- epoxyheptadecanoid acid [EpHep; kindly 
provided by Dr. Bruce Hammock, University of California-Davis (21)]), and processed by 
liquid-liquid extraction (0.1% acetic acid/5% methanol and ethyl acetate) to isolate lipids. 
Extracts in ethyl acetate were then dried by centrifugation under vacuum, covered in argon, and 
stored at -80°C for future processing. Dried extracts were reconstituted in 80% methanol 
(containing 10mg/ml BHT) for elution through phospholipid removal columns (Phree, 
Phenomenex, Torrance, CA), as directed by the manufacturer, for enhanced purification of the 
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extracts. Extracts were then dried a second time by centrifugation under vacuum and stored at -
80°C for future analysis. At the time of analysis, extracts were reconstituted in 50 μL of 30% 
ethanol and a panel of 34 eicosanoid metabolites (Table 2.2) was quantified by targeted LC-
MS/MS as previously described (19, 20). Data was acquired and concentrations were quantified 
with Analyst software, version 1.5 (Applied Biosystems) using analyte and internal standard 
peaks for each sample. Extraction efficiency for each sample was determined based on the 
recovery of the internal standards. Concentration values falling below the lower limit of 
quantitation were imputed as a concentration equal to half of the lowest standard. Analytes with 
more than 50% of the values below or above the lower or upper limit of quantitation, 
respectively, were not included in the analysis (Table 2.2) (19). Among the 28 metabolites that 
met these criteria, 24 of 28 (86%) had <10% values out of the quantitation range. 
 
Longitudinal evaluation of cardiovascular events 
The incidence of cardiovascular events over time was abstracted from the electronic 
medical record from the time of the index angiography through August 2014. Those who did not 
present to a hospital or clinic in the UNC health care system (for routine follow-up or emergent 
care) after the index coronary angiography visit were considered to be lost to follow-up, and 
were excluded from the analysis. The prespecified primary endpoint was the time to the first 
occurrence of death due to a cardiovascular cause, hospitalization for a non-fatal ACS event 
(unstable angina, NSTEMI, STEMI), or hospitalization for a coronary revascularization 
procedure (PCI or CABG). Clinician reported outcomes were verified from the electronic 
medical records by two individuals. 
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Statistical analysis 
Data are presented as mean ± standard deviation, median (interquartile range), or count 
(%) unless otherwise indicated. Study population characteristics were compared across CAD 
extent using one-way ANOVA, chi-squared test, or Fisher’s exact test as appropriate. All 
analyses were performed using SAS 9.3 (SAS Institute, Cary, NC) unless otherwise indicated. 
Metabolite levels and epoxide:diol ratios were not normally distributed and thus log-
transformed prior to statistical analysis. Pearson correlations were conducted to determine the 
correlation between individual metabolites. Established biomarkers of metabolic function within 
the EET metabolic pathway were used as previously described (19, 22). Briefly, the 
concentrations of EET regioisomers (14,15-EET; 11,12-EET; and 8,9-EET) and DHET 
regioisomers (14,15-DHET; 11,12-DHET; 8,9-DHET; and 5,6-DHET) were summed to evaluate 
total plasma concentrations of EETs and DHETs, respectively. 
The primary (sum EETs, sum EETs+DHETs, and 14:15-EET:DHET ratio) and secondary 
biomarkers of EET biosynthesis and hydrolysis (Table 2.3) were compared across CAD extent 
by ANOVA. Post-hoc pairwise comparisons were conducted using Fisher’s LSD test. A 
secondary analysis was conducted using a model that adjusts for demographic factors (age, race, 
sex), clinical factors (diabetes, peripheral artery disease, and prior MI), and medication use (beta 
blocker, angiotensin-converting enzyme inhibitor) that were independently associated with CAD 
extent (P<0.15) in a multivariable model. 
To determine the magnitude of the association between EET levels and CAD extent 
relative to other demographic and clinical factors, multiple regression analysis was performed. 
Potential covariates included demographic factors (age, gender, race), indices of CAD extent 
(index revascularization, index ACS, prior revascularization, presence of collaterals, maximum 
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coronary artery stenosis), cardiovascular risk factors (obesity, hypertension, diabetes, cigarette 
smoking, hyperlipidemia, peripheral artery disease, prior acute myocardial infarction, prior 
transient ischemia attack/stroke), comorbidities (lung disease, heart failure), body mass index, 
and chronic medication use pre-angiography (angiotensin-converting enzyme inhibitor, 
angiotensin receptor blockers, aspirin, beta blockers, statins, calcium channel blockers, P2Y12 
inhibitors, metformin, nitrates, non-statin lipid modifiers, fish oil, proton pump inhibitors). Only 
covariates with P<0.15 in univariate analysis were carried forward into a stepwise multivariate 
analysis. Collinear variables were removed and covariates with P<0.15 were included in the final 
model. 
All metabolomic analyses (global student t-test and FDR analyses, quantitative 
enrichment analysis [QEA], and Pearson correlations) were performed with Metaboanalyst 3.0 
(23). For these analyses where indicated, biomarker comparisons between those with obstructive 
CAD (N=72) and other patients (N=90) were conducted. Global student t-test analyses were 
conducted on each of the 28 metabolites in the full panel. Metabolites with P<0.05 and FDR 
q<0.05 were considered significantly different across obstructive CAD status. Metabolites were 
then assigned to 9 distinct eicosanoid metabolic pathways according to their parent substrate and 
biosynthesis enzyme. QEA was conducted to determine the relative impact of obstructive CAD 
on the 9 eicosanoid metabolic pathways. P-values (Holm’s corrected) were generated from 
estimated Q-statistics, and pathways were considered significantly enriched when P<0.05 and 
corresponding FDR q<0.05.  
Longitudinal analyses were conducted in the cohort of patients with reliable follow-up 
data (N=121). The relationship between baseline CAD extent and time to occurrence of the 
primary endpoint was assessed with Cox proportional hazards regression. Due to the low number 
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of events in those with no apparent (0 events) or nonobstructive (4 events) CAD, we proceeded 
to explore the association between baseline EET levels (tertiles) and risk of future cardiovascular 
events exclusively within the obstructive CAD patients that had reliable follow-up data (N=63). 
Likewise, due to the low number of events, the longitudinal analyses were unadjusted and 
considered exploratory in nature. Kaplan-Meier curves were generated using GraphPad Prism 
6.0.  
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Results 
 
Study population 
The demographic and clinical characteristics of the study population are shown in Table 
2.1. The extent of CAD was classified based on the results of the coronary angiography. 
Seventy-two (44%) patients were diagnosed with obstructive CAD (≥70% stenosis in ≥1 major 
coronary artery), whereas 51 (31%) patients were diagnosed with nonobstructive CAD (10-69% 
stenosis) and 39 (24%) patients exhibited no apparent CAD (<10% stenosis). Several indices of 
CAD burden were significantly more prevalent with increasing CAD extent including history of 
a prior revascularization procedure (P=0.009) and diagnosis of an ACS during the index visit 
(P<0.001). The prevalence of CAD risk factors and medication use were comparable to 
previously reported coronary angiography cohorts and reflected clinical practice guidelines (24, 
25). 
 
Quantification of eicosanoid metabolite biomarkers 
Of the total eicosanoid panel, 28 of the 34 metabolites met the criteria for further analysis 
(Table 2.2). Plasma concentrations ranged from nM to μM. Plasma EET and DHET regioisomers 
were positively correlated with each other (Figure 2.1). To minimize redundancy, the sum of the 
8,9-, 11,12- and 14,15-EET regioisomers (sum EETs) was calculated and used as a single 
biomarker (19). In addition, the sum of the EET and DHET regioisomers (sum EETs+DHETs) 
and the ratio of 14,15-EET to 14,15-DHET (14,15-EET:14,15-DHET ratio) were calculated and 
used as the primary biomarkers of CYP epoxygenase and sEH metabolic function, respectively 
(22). 
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Association of EET metabolic pathway biomarkers and CAD extent 
Sum EET levels (the sum of 8,9-, 11,12- and 14,15-EET regioisomers) were inversely 
associated with CAD extent, such that EET levels in obstructive CAD patients were significantly 
lower than EET levels in patients with either no apparent CAD or nonobstructive CAD (Figure 
2.2a, Table 2.3). After adjusting for covariates (demographic factors, clinical factors, and 
medication use), the difference between no CAD and obstructive CAD remained significant 
whereas the difference between nonobstructive CAD and obstructive CAD was not statistically 
significant (P=0.069). A significant difference in EET levels was not observed between patients 
with no apparent CAD and nonobstructive CAD. Consistent results were observed with the 
individual 8,9-, 11,12- and 14,15-EET regioisomers and the DHET metabolites (Table 2.3). 
Furthermore, higher maximum coronary artery stenosis (the percent narrowing of the most 
obstructed coronary artery and another indicator of CAD extent) was significantly associated 
with lower sum EETs (Pearson’s r=-0.26, P=0.001). 
A similar inverse relationship was observed between CAD extent and sum EETs+DHETs 
(Figure 2.2b, Table 2.3). In contrast, 14,15-EET:DHET ratio (a biomarker of sEH metabolic 
function) was not significantly associated with CAD extent (Figure 2.2c, Table 2.3). Similarly, 
no association was observed between CAD extent and either the sum EET:DHET ratio (Table 
2.3) or the 12,13-epoxyoctadecaenoic acid to dihydroxyoctadecaenoic acid (EpOME:DHOME) 
ratio biomarkers of sEH metabolic function (P=0.992). 
In a multivariate analysis, the strongest predictor of EET levels was CAD extent; there 
was an inverse association (Table 2.4). A similar relationship existed with sum EETs+DHETs 
(r2=0.08, P<0.001). The presence of collaterals, compensatory anastomotic connections between 
the distal portion of an occluded coronary artery and a different coronary artery without an 
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intervening capillary bed (26), was also associated with lower EET levels. Female sex was 
associated with significantly higher EET levels. Moreover, use of certain medications was 
associated with higher (statins, calcium channel blockers) and lower (beta blockers, angiotensin-
converting enzyme inhibitors) EET levels (Table 2.4). 
 
Identification of altered eicosanoid pathways across obstructive CAD status 
Among all of the individual eicosanoid metabolites quantified, 11 were significantly 
altered across obstructive CAD status (Figure 2.3a and 2.3b; Table 2.5). The three EET (8,9-, 
11,12-, and 14,15-EET) and four DHET (5,6-, 8,9-, 11,12-, and 14,15-DHET) regioisomers were 
among the 11 analytes associated with CAD extent. In order to determine the most enriched 
eicosanoid metabolic pathways across obstructive CAD status, we subsequently grouped the 
metabolites into pathways based on their parent substrate and biosynthesis enzyme. Metabolites 
within the same pathway tended to be positively correlated with each other (Figure 2.1). QEA 
revealed that only the AA-derived CYP epoxide and AA-derived sEH diol pathways were 
significantly associated with the presence of obstructive CAD (Figure 2.3c; Table 2.6). 
 
Risk of Future Cardiovascular Events 
Participants were prospectively followed to determine the relationship between CAD 
extent and risk of subsequent cardiovascular events. Follow-up data was available in 121 (75%) 
of the enrolled participants, and the median length of follow-up was 1.0 years. Cardiovascular 
death, a non-fatal ACS event or a coronary revascularization procedure occurred in 21 
participants (0, 10, and 11 events, respectively). CAD extent at baseline was significantly 
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associated with incidence of a cardiovascular event, with 17 of the 21 events occurring in those 
with obstructive CAD (Figure 2.4a), similar to previous studies (25). 
Although the presence of obstructive CAD is associated with lower EET levels, 
considerable inter-individual variability in EET levels existed within the obstructive CAD group 
(median [IQR]: 639 [286] pg/mL). Consequently, we explored the relationship between baseline 
EET levels and risk of a future cardiovascular event exclusively within the subset of patients 
with obstructive CAD. A stepwise inverse relationship between EET levels and cardiovascular 
event incidence appeared to exist, such that the highest number of events was observed in those 
in the lowest EET level tertile (Figure 2.4b); however, this relationship was not statistically 
significant.  
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Discussion 
 
This is the first study that reports a relationship between circulating EET metabolite 
levels and the extent of CAD in humans. In a well characterized CAD population, we observed 
that the presence of obstructive CAD is significantly and independently associated with lower 
circulating EET levels. Furthermore, the association between obstructive CAD and lower EET 
levels (a) correlates with lower CYP epoxygenase metabolic function, but not higher sEH 
metabolic function, and (b) is significantly more pronounced than other eicosanoid metabolism 
pathways. Collectively, these findings demonstrate that patients with obstructive CAD are 
predisposed to low EET metabolite levels secondary to suppressed EET biosynthesis, and 
suggest that novel strategies that promote the effects of EETs may have therapeutic promise in 
patients with obstructive CAD. 
It has become increasingly clear that CYPs metabolize AA into bioactive eicosanoids 
with potent cellular and physiologic effects in the cardiovascular system (27). Most notably, 
CYP epoxygenase-derived EETs elicit protective effects in preclinical models (6, 7), including 
vasodilation by hyperpolarizing vascular smooth muscle cells (28, 29), anti-inflammation by 
attenuating NF-κB signaling (30, 31), and anti-apoptosis by promoting PI3K/Akt signaling (32, 
33). Consequently, promoting the effects of EETs, most notably by inhibiting sEH and 
increasing endogenous EET levels, has emerged as a cardiovascular protective therapeutic 
strategy with potential clinical utility (34). Due to the technical complexity of measuring EETs, 
which are not quantified on traditional metabolomic or eicosanoid panels (16), major gaps in 
knowledge surrounding the biological and therapeutic importance of this pathway in human 
cardiovascular disease remain (8). Importantly, characterizing the relationship between EET 
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metabolite levels and CAD extent in humans is central to a better understanding of the functional 
role of this pathway in the initiation and progression of CAD. Through application of a highly 
sensitive and specific targeted LC-MS/MS assay that simultaneously quantifies CYP-, COX-, 
and LO-derived lipid metabolites in human plasma, the current study identified a significant 
inverse relationship between EET levels and angiographic extent of CAD. Moreover, pathway 
analyses revealed that these differences were significantly more pronounced than metabolites 
derived from COX, LO and CYP hydroxylase pathways. Taken together, these findings suggest 
that CYP-derived EETs may play an important role in the pathogenesis and progression of CAD 
in humans. 
In the current study, CAD extent was also associated with lower sum EETs+DHETs, but 
surprisingly not EET:DHET ratios. These data suggest that the inverse association between EET 
levels and CAD extent was mediated by suppression of CYP epoxygenase metabolic function 
(EET biosynthesis), and not an increase in sEH metabolic function (EET hydrolysis). 
Accordingly, it is well-established that inflammatory stimuli suppress CYP-mediated xenobiotic 
metabolism through a variety of mechanisms, including cytokine-mediated transcriptional 
downregulation of CYP expression (35); fittingly, inflammatory stimuli also drive the 
development and progression of CAD (36). We recently demonstrated that hepatic CYP 
epoxygenase expression, hepatic CYP epoxygenase metabolic function, and plasma EET levels 
are suppressed in an atherogenic diet mouse model of inflammatory non-alcoholic fatty liver 
disease (37). In contrast, no changes in sEH expression or EET hydrolysis were observed. 
Although most studies have investigated the impact of inflammation on hepatic CYP expression 
and function, cytokines have also been reported to downregulate CYP epoxygenase expression in 
endothelial cells of the vasculature (38). Moreover, hepatic, renal, pulmonary and myocardial 
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Cyp2c/2j expression and EET biosynthesis were suppressed in an endotoxin mouse model of 
acute inflammation (39). Altogether, these findings suggest that suppression of CYP-mediated 
EET biosynthesis may be a key pathological consequence of the inflammation-mediated 
development and progression of CAD. Future studies are necessary to elucidate the mechanisms 
underlying the association between lower EET levels and advanced CAD in humans. 
A few additional studies have quantified plasma EET levels in patients at risk for or with 
established cardiovascular disease. Ramirez et al. found that presence of the metabolic syndrome 
was associated with lower circulating EET levels (40). Furthermore, Minuz et al. reported that 
patients with renovascular disease had lower circulating EETs compared to both healthy 
volunteer and essential hypertension controls (41). In contrast, we previously reported that 
patients with established stable CAD (≥50% coronary artery stenosis or a prior revascularization 
procedure) had significantly higher plasma EET levels compared to a population of healthy 
volunteer controls at low risk for CAD (15). This observed increase in EET levels was driven by 
suppressed sEH metabolic function, such that the median 14,15-EET:DHET ratio was 
significantly higher in patients with established CAD compared to controls (0.37 versus 0.18, 
respectively). In the present study, no differences in sEH metabolic function were observed 
across CAD extent, and the median 14,15-EET:DHET ratio observed in those with no apparent 
(0.35), nonobstructive (0.33) and obstructive (0.34) CAD was comparable to the CAD 
population of the prior study. It is important to note that the controls in the previous study were 
healthy volunteers that had no risk factors for cardiovascular disease or chronic medication use. 
Consequently, multiple potential confounding factors may have driven the observed suppression 
of sEH metabolic function in CAD cases in the previous study. The present study, however, 
employed a cross-sectional design within a population of patients referred for coronary 
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angiography; thus, the reference population with no apparent angiographic evidence of CAD had 
similar CAD risk factors and medication use compared to those with non-obstructive and 
obstructive CAD. Importantly, the inverse association between EET levels and CAD extent was 
independent of clinical factors and medication use in an adjusted model. Future prospective 
studies will be needed to delineate the direct effects of risk factor control and medications on 
EET biosynthesis and hydrolysis over time in patients at risk for or with established CAD. 
The relationship between metabolite biomarkers of the EET metabolic pathway and 
prognosis in patients with established CAD has not been studied to date. Consequently, in a 
secondary analysis, we explored the relationship between inter-individual variation in EET 
metabolite levels and risk of a future adverse cardiovascular event in patients with obstructive 
CAD at baseline. We observed a stepwise relationship across the EET tertiles where the highest 
event incidence occurred in those with the lowest EET levels at baseline. Although this 
relationship was not statistically significant and should be observed with caution due to the small 
number of events, these findings are biologically plausible considering the anti-inflammatory and 
protective effects of EETs in numerous preclinical models of cardiovascular disease. 
Furthermore, these data are consistent with a previously reported inverse association between 
circulating EET and MCP-1 concentrations (a pro-inflammatory chemokine predictive of poor 
prognosis in CAD (42)), in which patients with stable CAD in the lowest and middle EET tertiles 
had significantly higher MCP-1 levels compared to those in the highest EET tertile (22). These 
preliminary observations underscore the need to rigorously evaluate the relationship between 
EET metabolite levels and the risk of cardiovascular events in a larger population. 
Although the current study is the largest to date evaluating the relationship between CYP-
derived eicosanoid metabolites and CAD in humans, our analysis has limitations that must be 
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acknowledged. The cross-sectional design precludes us from establishing causality between 
increasing CAD extent and lower EET levels because there is no data on which event occurred 
first.  Furthermore, coronary angiography is an inexact method to quantify the burden and extent 
of CAD. Our analysis also included multiple statistical comparisons. To account for the 
possibility of false-positive findings, a false discovery rate (FDR) was calculated for each 
comparison. The association between obstructive CAD and lower EET and DHET levels had a 
FDR of 5% or less, which enhances confidence in our results. Lastly, this was a single-center 
study and our results may not be generalizable to other CAD populations. Validation of the 
observed relationships in an independent cohort will ultimately be necessary. 
Recent failures in CAD drug development suggest that innovative approaches are needed 
to mitigate increasing attrition rates and more successfully translate novel therapies into clinical 
practice (43-45). Compared to the conventional ‘one-size fits all’ methodology to drug 
development, a precision medicine approach has the potential to increase the probability of 
success for promising therapeutic candidates (46). Although targeted therapies are routinely used 
in oncology, this strategy has not been readily adopted in CAD. Biomarkers offer considerable 
promise to prospectively identify subsets of CAD patients at high risk of experiencing a 
cardiovascular event that exhibit dysfunction in a specific pathway (putative responders), thereby 
enabling novel therapies that target the pathway to maximize their therapeutic effect and improve 
outcomes. Our findings collectively demonstrate that obstructive CAD is significantly and 
independently associated with lower circulating EET levels secondary to suppressed EET 
biosynthesis. These results offer important insight into the potential functional role of CYP-
derived EETs in the pathogenesis and progression of CAD in humans, and suggest that 
promoting the effects of EETs may have therapeutic utility in CAD patients predisposed to low 
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EET levels. Importantly, agents that promote the effects of EETs are in development for a 
variety of therapeutic indications (47-49). In parallel, technology for the high-throughput 
quantification of CYP-derived eicosanoids in the clinical setting is advancing (50). 
Consequently, our results set the foundation for future clinical research in this area, including the 
rational design of prospective, biomarker-guided interventional studies in targeted subsets of the 
CAD population (low EET levels) with enriched potential to derive clinical benefit from 
emerging EET-promoting therapies.  
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Figures 
 
 
 
Figure 2.1. Correlation matrix of eicosaniods. Scale above indicates Pearson correlation 
coefficients on log-transformed data. Dark and light indicate positive and negative correlations, 
respectively. All 28 quantafiable metabolites are listed. Analyses revealed that eicosanoids 
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within the same pathway (by class and substrate) tend to be positively correlated (white borders 
indicate strongest clusters). DHET, dihydroxyeicosatrienoic acid; DHOME, 
dihydroxyoctadecaenoic acid; DiHDPA, dihydroxy-docosapentaenoic acid; DiHETE, 
dihydroxytetraenoic acid; EET, epoxyeicosatrienoic acid; EpDPE, epoxydocosapentaenoic acid; 
EpOME, epoxyoctadecaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE, 
hydroxyoctadecadienoic acids; PGF1α, prostaglandin F1alpha; PGF2α, prostaglandin F2alpha; 
TriHOME, trihydroxyoctadecenoic acid  
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Figure 2.2 Plasma biomarkers of cytochrome P450 (CYP)-mediated epoxyeicosatrienoic 
acids (EETs) biosynthesis and hydrolysis across coronary artery disease (CAD) extent. (a) 
Sum EETs were inversely associated with CAD extent across no apparent CAD (N=39), 
nonobstructive CAD (N=51), and obstructive CAD (N=72) patients (ANOVA: unadjusted 
P=0.003, adjusted P=0.004). (b) A significant inverse association was also observed with sum 
EETs+DHETs (ANOVA: unadjusted P=0.001, adjusted P=0.001). (c) In contrast, the 14,15-
EET:DHET ratio was not associated with CAD extent (ANOVA: unadjusted P=0.693, adjusted 
P=0.859). Untransformed data are presented as median (line), interquartile range (box), and 95% 
confidence intervals (whiskers) on a log scale. *P<0.05 in unadjusted pairwise comparisons. 
†P<0.05 in adjusted pairwise comparisons. DHET, dihydroxyeicosatrienoic acid  
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Figure 2.3 Enrichment of eicosanoid pathways across obstructive coronary artery disease 
(CAD) status. Twenty-eight eicosanoid metabolites were assigned to 9 distinct eicosanoid 
metabolic pathways according to their parent substrate (arachidonic acid [AA], linoleic acid 
[LA], eicosapentaenoic acid [EPA]/docosahexaenoic acid [DHA] fatty acids) and biosynthesis 
enzyme (cytochrome P450 [CYP], lipoxygenase [LO], cyclooxygenase [COX], soluble epoxide 
hydrolase [sEH]), and compared between obstructive CAD patients (N=72) and all other patients 
(N=90). The EPA and DHA derived metabolites (all derived from CYP or sEH biosynthesis) 
were combined into one pathway due to the low number of metabolites in that group. (a) A 
volcano plot shows how each of the 28 individual metabolites within pathways differs between 
obstructive CAD patients and all other patients. Metabolites in the upper left box (fold 
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change>1.2 and P<0.05) were considered to be significantly altered. P-value decreases as Y-axis 
value increases. (b) A list (rank ordered by p-value with accompanying false discovery rate 
[FDR] and fold change) of the top metabolites that significantly differed by obstructive CAD 
status is provided. (c) Quantitative enrichment analysis (QEA) revealed that AA-derived 
epoxides (P=0.01; FDR q=0.01) and AA-derived diols (P=0.049; FDR q=0.03) were enriched 
across obstructive CAD status relative to parallel pathways. *QEA P<0.05 (Holm’s corrected) 
and FDR q<0.05. DHET, dihydroxyeicosatrienoic acid; EET, epoxyeicosatrienoic acid; FC, fold 
change; HETE, hydroxyeicosatetraenoic acid  
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Figure 2.4 Coronary artery disease (CAD) extent, epoxyeicosatrienoic acid (EETs), and 
risk of subsequent cardiovascular events. Kaplan-Meier curves were generated for incidence 
of the primary endpoint (time to the occurrence of death from cardiovascular causes, acute 
coronary syndrome event, or coronary revascularization procedure) according to (a) CAD extent 
at baseline in all patients with reliable follow-up data (N=121) and (b) EET levels at baseline 
(tertiles) exclusively within the subset of patients with obstructive CAD (N=63). The log rank P-
value (unadjusted) for each Kaplan-Meier curve is provided. Below the curves, the number and 
frequency of events within each CAD extent and EET tertile group, along with the unadjusted 
hazard ratio (HR), 95% confidence interval (CI) and P-value, is provided. Due to the lack of 
events in those with no apparent CAD at baseline, the no apparent CAD and nonobstructive 
CAD groups were combined and served as a single referent group.  
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Tables 
 
Table 2.1 Characteristics of the total study population and across the angiographic extent of coronary artery disease (CAD) 
 
Characteristic     Total  No apparent CAD Nonobstructive CAD Obstructive CAD P 
      (N=162) (N=39)   (N=51)   (N=72)  
Demographics 
 Age (years)    61.8 ± 10.3 58.2 ± 10.4  62.1 ± 9.9  63.6 ± 10.2  0.028 
 Female     70 (43.2%) 18 (46.2%)  22 (43.1%)  30 (41.7%)  0.901 
 African American    34 (21.0%) 10 (25.6%)  11 (21.6%)  13 (18.1%)  0.640 
Past medical history 
 Current/recent (<1 year) smoker  46 (28.4%) 11 (28.2%)  15 (29.4%)  20 (27.8%)  0.980 
 Obese (body mass index ≥30 kg/m2) 79 (48.8%) 25 (64.1%)  19 (37.3%)  35 (48.6%)  0.041 
 History of hypertension   130 (80.3%) 28 (71.2%)  41 (80.4%)  61 (84.7%)  0.263 
 History of diabetes   51 (31.5%) 9 (23.1%)  14 (27.5%)  28 (38.9%)  0.174 
 History of hyperlipidemia   111 (68.5%) 23 (59.0%)  34 (66.7%)  54 (75.0%)  0.209 
 History of peripheral artery disease 20 (12.4%) 2 (5.1%)  5 (9.8%)  13 (18.1%)  0.130 
 Prior myocardial infarction  24 (14.8%) 1 (2.6%)  6 (11.8%)  17 (23.6%)  0.006 
 Prior revascularization   56 (34.6%) 6 (15.4%)  18 (35.3%)  32 (44.4%)   0.009 
Medication use 
 ACE inhibitor use   73 (45.1%) 14 (35.9%)  18 (35.3%)  41 (56.9%)  0.025 
 ARB use     33 (20.4%) 10 (25.6%)  13 (25.5%)  10 (13.9%)  0.187 
 Aspirin use    122 (75.3%) 29 (74.4%)  37 (72.6%)  56 (77.8%)  0.793 
 Beta blocker use    99 (61.1%) 16 (41.0%)  32 (62.8%)  51 (70.8%)   0.009 
 Statin use     123 (75.9%) 27 (69.2%)  39 (76.5%)  57 (79.2%)   0.502 
 Calcium channel blocker use  46 (28.4%) 13 (33.3%)  14 (27.5%)  19 (26.4%)   0.729 
Cardiac catheterization laboratory 
 ACS on presentation   29 (17.9%) 3 (7.7%)  3 (5.9%)  23 (31.9%)   <0.001 
 Presence of collateral   20 (12.4%) 5 (12.8%)  4 (7.8%)  11 (15.3%)  <0.001 
 Stenosis in most severe vessel (%) 50 (80)  0 (0)   40 (25)   90 (15)   <0.001 
ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker. Data presented as mean ± standard deviation, median 
(interquartile range), or count (%). 
One-way ANOVA across CAD extent was performed for continuous variables and Chi-square test or Fisher’s exact test was performed for categorical variables 
as appropriate.  
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Table 2.2 List of all eicosanoid metabolites 
 
Pathway     Analyte  Plasma Concentration (pg/mL) 
AA – CYP epoxides   14,15-EET   299 (139) 
      11,12-EET  163 (86)  
      8,9-EET  197 (94) 
      5,6-EET*  <LLOQ 
AA – sEH diols    14,15-DHET  937 (433) 
      11,12-DHET  594 (322) 
      8,9-DHET   244 (150) 
      5,6-DHET  253 (160)     
AA – CYP hydroxyls   20-HETE  1,188 (762) 
      19-HETE  646 (348) 
AA – LO metabolites   15-HETE  937 (503) 
      12-HETE  63 (42) 
      11-HETE  5,706 (3,600) 
      9,12,13-TriHOME  688 (798) 
      9,10,13-TriHOME  9,150 (12,200) 
      8-HETE  12,628 (6,656) 
      5-HETE  2,243 (1,759) 
AA – COX metabolites   8-iso-PGF2α  29 (12) 
      6-keto-PGF1α  51 (21) 
      PGB2*   <LLOQ 
      PGD2*   <LLOQ 
      PGE2*   <LLOQ 
      PGF2α   238 (712) 
      TXB2*   <LLOQ 
LA – LO metabolites   13-HODE  21,356 (11,200) 
      9-HODE  15,222 (9,844) 
LA – CYP epoxides   12,13-EpOME  1,714 (1,000) 
      9,10-EpOME  4,200 (2,867) 
LA – sEH diols    12,13-DHOME  2,809 (1,881) 
      9,10-DHOME  1,742 (1,274) 
EPA/DHA – CYP/sEH metabolites 19,20-DiHDPA  1,193 (706) 
      17,18-DiHETE  2,794 (1,937) 
      19,20-EpDPE  1,659 (1,019)  
      17,18-EpETE*  <LLOQ 
AA, arachidonic acid; COX, cyclooxygenase; CYP, cytochrome P450; DHA, docosahexaenoic acid; DHET, 
dihydroxyeicosatrienoic acid; DHOME, dihydroxyoctadecaenoic acid; DiHDPA, dihydroxy-docosapentaenoic acid; 
DiHETE, dihydroxytetraenoic acid; EET, epoxyeicosatrienoic acid; EPA; eicosapentaenoic acid; EpDPE, 
epoxydocosapentaenoic acid; EpETE, epoxyeicosatetraenoic acid; EpOME, epoxyoctadecaenoic acid; HETE, 
hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acids; LA, linoleic acid; LO, lipoxygenase; PGB2, 
prostaglandin B2; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGF1α, prostaglandin F1alpha; PGF2α, 
prostaglandin F2alpha; sEH, soluble epoxide hydrolase; TriHOME, trihydroxyoctadecenoic acid; TXB2, 
thromboxane B2.  
Data presented as median (interquartile range). 
*Analyte plasma levels were below lower limit of quantification (LLOQ) and could not be accurately quantified 
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Table 2.3 Comparison of plasma cytochrome P450 (CYP) epoxygenase-derived and soluble epoxide hydrolase (sEH)-derived arachidonic acid 
metabolite biomarkers across coronary artery disease (CAD) extent 
 
Analyte       No apparent CAD  Nonobstructive CAD  Obstructive CAD P a  
                                               (N=39)    (N=51)    (N=72)     
 
AA – CYP epoxides (pg/mL) 
 14,15-EET   368 (170)   295 (170)   286 (117)*†  0.006 
 11,12-EET   192 (89)   171 (99)   152 (85)*†  0.003 
 8,9-EET    235 (125)   205 (112)   189 (87)*†  0.007 
 Sum EETs b   815 (417)   678 (356)   618 (258)*†  0.003 
 
AA – sEH diols (pg/mL) 
 14,15-DHET   1,007 (568)   971 (449)   845 (442)*  0.006 
 11,12-DHET   657 (393)   633 (367)*   563 (257)*  0.005 
 8,9-DHET   300 (193)   229 (206)   217 (110)*  0.039 
 5,6-DHET   290 (145)   244 (198)   229 (122)*  0.028 
 Sum DHETs   2,324 (1305)   2,084 (1605)   1,956 (875)*  0.004 
 
CYP epoxygenase function (pg/mL) 
 Sum EETs + DHETs  3,321 (1,441)   2,737 (1,670)   2,593 (997)*†  0.001 
 
sEH function (ratio) 
 14,15-EET:14,15-DHET  0.35 (0.18)   0.33 (0.22)   0.34 (0.16)  0.693 
 11,12-EET: 11,12-DHET  0.28 (0.19)   0.29 (0.19)   0.27 (0.16)  0.413 
 8,9-EET: 8,9-DHET  0.80 (0.44)   0.81 (0.51)   0.78 (0.31)  0.880 
 Sum EETs: DHETs b  0.37 (0.22)   0.38 (0.22)   0.36 (0.18)  0.649 
DHET, dihydroxyeicosatrienoic acid; EET, epoxyeicosatrienoic acid. Data presented as median (interquartile range) 
aOne-way ANOVA was performed on log-transformed data 
bPlasma concentrations of the 5,6-EET regioisomer were below the limit of quantification and not included in the calculation 
*P<0.05 versus no apparent CAD (Fisher’s LSD). †P<0.05 versus nonobstructive CAD (Fisher’s LSD)
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Table 2.4 Multivariate relationships between clinical factors and plasma epoxyeicosatrienoic acids 
(N=162) 
 
    Parameter SE  Partial R2 P a 
    Estimate 
CAD extent   -0.047   0.017  0.067  0.001 
Female    0.106  0.028  0.049  0.003  
Presence of collaterals  -0.100  0.041  0.032  0.016 
Statin use   0.096  0.033  0.024  0.037 
Beta blocker use  -0.081  0.029  0.036  0.009 
Calcium channel blocker use 0.063  0.030  0.022  0.039 
ACE inhibitor use  -0.050  0.028  0.016  0.077 
 
Full model       0.244  <0.001 
ACE, angiotensin-converting enzyme; CAD, coronary artery disease; SE standard error 
aFactors with P<0.15 in the univariate analysis were included in the multivariate analysis.  
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Table 2.5 Comparison of plasma eicosanoid metabolites across obstructive coronary artery disease 
(CAD) status 
 
Analyte (pg/mL)  No obstructive CAD Obstructive CAD P a  FDR q 
    (n=90)   (n=72) 
AA – CYP epoxides 
 14,15-EET  312 (164)  286 (117)  0.002  0.021 
 11,12-EET  181 (99)  152 (85)  <0.001  0.019 
 8,9-EET   211 (100)  189 (87)  0.002  0.021 
AA – sEH diols 
 14,15-DHET  981 (490)  845 (442)  0.006  0.031 
 11,12-DHET  642 (367)  563 (257)  0.009  0.034 
 8,9-DHET  252 (194)  217 (110)  0.019  0.059 
 5,6-DHET  268 (177)  229 (122)  0.008  0.034 
AA – CYP hydroxyls 
 19-HETE   694 (408)  588 (267)  0.006  0.031 
 20-HETE   1,270 (827)  1,087 (664)  0.076  0.134 
AA – LO metabolites 
 15-HETE   1,021 (620)  847 (382)  0.010  0.036 
 11-HETE   6,361 (3,944)  5,361 (3,222)  0.024  0.066 
 12-HETE   70 (42)   53 (38)   0.047  0.101 
 8-HETE   13,028 (8,100)  12,094 (5,639)  0.068  0.134 
 5-HETE   2,426 (1,707)  2,068 (1,478)  0.076  0.134 
 9,12,13-TriHOME 718 (742)  668 (829)  0.240  0.292 
 9,10,13-TriHOME 9,478 (742)  8,406 (13,552)  0.304  0.340 
LA – CYP epoxides 
 12,13-EpOME  1,786 (918)  1,652 (1,127)  0.083  0.135 
 9,10-EpOME  4,350 (2,562)  3,817 (2,921) *  0.046  0.101 
LA – sEH diols 
 12,13-DHOME  2,911 (1,916)  2,466 (1,929)  0.109  0.170 
 9,10-DHOME  1,961 (1,162)  1,432 (1,158) *  0.046  0.101 
LA – LO metabolites 
 13-HODE  21,839 (10,222)  19,661 (12,561)  0.141  0.208 
 9-HODE   15,489 (8,711)  14,728 (10,611)  0.180  0.230 
EPA/DHA – epoxides/diols 
 19,20-EpDPE  1,666 (1,477)  1,641 (888)  0.253  0.295 
 19,20-DiHDPA  1,206 (741)  1,188 (596)  0.581  0.603 
 17,18-DHET  2,806 (2,184)  2,671 (1,740)  0.181  0.230 
AA – COX metabolites 
 8-iso-PGF2α  29 (11)   28 (12)   0.157  0.220 
 6-keto-PGF1α  51 (20)   50 (21)   0.748  0.748 
 PGF2α   229 (539)  326 (788)  0.379  0.409 
See Table 2.2 for abbreviations. 
Data presented as median (interquartile range) 
aStudent's t-test was performed on log-transformed data followed by FDR calculations for multiple testing 
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Table 2.6 Quantitative enrichment analysis (QEA) results on eicosanoid metabolic pathways 
     Metabolites (N)  Actual Q  Expected Q  P a   FDR q 
AA – CYP epoxides   3   6.14   0.62   0.010   0.010 
AA – sEH diols   4   3.82   0.62   0.050   0.028 
AA – CYP hydroxyls   2   2.87   0.62   0.163   0.070 
AA – LO metabolites   5   2.45   0.62   0.247   0.090 
LA – CYP epoxides   2   2.17   0.62   0.290   0.090 
LA – sEH diols    2   2.14   0.62   0.290   0.090 
LA – LO metabolites   4   0.91   0.62   0.663   0.284 
EPA/DHA – epoxides/diols  3   0.70   0.62   0.663   0.341 
AA – COX metabolites   3   0.51   0.62   0.663   0.374 
AA, arachidonic acid; COX, cyclooxygenase; CYP, cytochrome P450; DHA, docosahexaenoic acid; EPA; eicosapentaenoic acid; FDR, false discovery rate; LA, 
linoleic acid; LO, lipoxygenase; sEH, soluble epoxide hydrolase 
aGlobal test was performed on log-transformed data and p-values (Holm’s corrected) were generated from estimated Q-statistics 
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CHAPTER 3 - THE RELATIONSHIP BETWEEN EPHX2 P.LYS55ARG 
POLYMORPHISM AND SURVIVAL IN PATIENTS FOLLOWING AN ACUTE 
MYOCARDIAL INFARCTION 
 
Introduction 
 
Cardiovascular disease (CVD) has been the leading cause of mortality in the US for over 
a century. Most notably, acute myocardial infarction (AMI) events, complications of CVD, are a 
primary source of the mortality associated with this illness (1). Identification and 
characterization of the key pathways underlying the pathophysiology of post-AMI complications 
will facilitate the development of novel therapeutic strategies that reduce the risk of adverse 
outcomes following AMI. 
Arachidonic acid is metabolized by CYP epoxygenase enzymes to form bioactive EETs 
(2). CYP2J and CYP2C epoxygenases are the primary sources of all four EET regioisomers (5,6-
, 8,9-, 11,12-, and 14,15-EETs) (3). EETs are lipophilic compounds containing highly-reactive 
epoxide functional groups. The predominant fate of EETs is through rapid metabolism by soluble 
epoxide hydrolase (sEH) into diol functional group-containing dihydroxyeicosatrienoic acids 
(DHETs), which generally have less biological activity than their epoxide-containing counterpart 
(4, 5). 
EPHX2 codes for human sEH (6), is located on chromosomal region 8p21-p12 (6), 
contains 19 exons, and has a coding sequence that spans 555 amino acids (7). Furthermore, 
EPHX2 has considerable genetic heterogeneity (8). Many of these SNPs are non-synonymous 
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and alter sEH hydrolysis activity in vitro (8). EPHX2 is also expressed in a multitude of cell 
types and tissues; importantly, it is highly expressed in the cardiovascular system incluing the 
myocardium and blood vessels (9). 
The two most common non-synonymous SNPs in EPHX2 have been found to decrease 
(p.Arg287Gln) or increase (p.Lys55Arg) the activity of sEH in vitro. (8, 10) Specifically, the 
Arg287Gln polymorphism is located at an area of the enzyme responsible for dimerization; its 
presence is thought to reduce the stability of the homodimer (8) which is necessary for hydrolase 
activity (11). The Lys55Arg polymorphism is similarly not located near the catalytic site 
responsible for hydrolase activity (8), but is located in a domain that allows for increased 
stabilization of the dimer (12). Lys55Arg and Arg287Gln are not in linkage disequilibrium (13). 
The allele frequencies for Arg287Gln are approximately 8% and 10% in African 
American and Caucasian populations respectively (14). Lys55Arg has been studied less 
extensively then Arg287Gln, but is the most common functional SNP in the population (15, 16). 
The allele frequencies for Lys55Arg are approximately 22% and 7% in African Americans and 
Caucasians. (14) 
Due to their cardioprotective effects in preclinical models, EETs are a promising 
therapeutic target for AMI. Accumulating preclinical evidence from in vitro, ex vivo, and in vivo 
models of AMI demonstrates that EETs directly protect the myocardium following ischemia via 
a variety of mechanisms (5, 17, 18). Thus, genetic variation in sEH activity may have important 
clinical implications. 
Since pharmacological tools that directly and specifically manipulate sEH to modulate 
EET levels are currently not available for clinical use, investigators have relied on genetic 
observational studies to understand the role of the EET metabolic pathway in human CVD. 
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Associations between functional genetic polymorphisms in EPHX2 and the risk of developing 
CVD have been reported in humans (13, 19-23). The Arg287Gln variant has been linked to 
reduced plasma cholesterol and triglyceride concentrations in patients with familial 
hypercholesterolemia (24), reduced risk of coronary artery calcification in African-Americans 
(20, 21), increased ischemic stroke risk in white Europeans (25), carotid artery calcified plaque 
in Europeans  (26), improved vascular dysfunction in African Americans (27), and increased risk 
of atrial fibrillation recurrence after catheter ablation (28). The Lys55Arg polymorphism is 
associated with higher sEH metabolic function in vivo and is linked to development of CAD in 
Caucasian patients (13), ischemic stroke in Swedish men (23), and vascular dysfunction in 
Caucasian volunteers (22). 
Taken together with the preclinical evidence, these data suggest that the EET metabolic 
pathway may be important in the pathogenesis of CAD in humans and that therapeutic 
interventions that promote the cardioprotective effects of EETs by modulation of sEH offer 
considerable promise as a novel therapeutic strategy to reduce sequelae following AMI; 
however, key questions remain to be addressed prior to translation of EET-promoting strategies 
into successful proof-of-concept phase I and II clinical trials. Evaluation of functional variants in 
EPHX2 and prognosis in AMI patients has not been completed. 
In collaboration with Dr. John Spertus (Mid America Heart Institute) and Dr. Sharon 
Cresci (Washington University School of Medicine), the Craig Lee lab has previously 
investigated the association of both EPHX2 Lys55Arg and EPHX2 Arg287Gln genotype with 5-
year survival in a 2-center cohort of CAD patients hospitalized for an ACS event including 
unstable angina or AMI (INFORM). Compared to noncarriers, EPHX2 Arg55 variant allele 
carriers had a significantly higher risk of death (22.4% vs. 15.3%; HR 1.50, 95% CI 1.02-2.22, 
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P=0.042), however, no association was observed with EPHX2 Arg287Gln (15.2% vs 17.4%; HR 
0.88, 95% CI 0.55-1.41, P=0.597). A race-stratified analysis was conducted to account for the 
potential confounding effects of population stratification. Associations in Caucasians were 
consistent with the overall cohort, and persisted after adjusting for demographic and clinical 
covariates predictive of prognosis. The magnitude of the associations were comparable to 
established prognostic predictors (e.g., diabetes: HR 2.2, 95% CI 1.5-3.2, P<0.01). However, 
associations were not evaluated in African Americans, due to a small sample size (N=124) and 
suboptimal power (29). 
The association between EPHX2 Lys55Arg genotype and survival provide support for 
our hypothesis that CAD patients predisposed to greater EET hydrolysis exhibit poorer prognosis 
post-ACS. However, evaluation of this association specifically in the AMI subpopulation 
remains necessary to determine whether CAD patients predisposed to greater EET hydrolysis 
also exhibit poorer prognosis post-AMI. Furthermore, replication in a larger independent 
population of AMI patients would provide further confirmation to the initial results and facilitate 
race-stratified analyses in African Americans. Finally, elucidation of the underlying mechanisms 
responsible for this association is necessary. Consequently, the objective of the present study was 
to determine the relationship between EPHX2 p.Lys55Arg polymorphism and survival in 
patients recently admitted for an AMI.  
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Materials and methods 
 
Study participants 
INFORM is a prospective, observational study of consecutive ACS patients at 2 US 
hospitals (Kansas City, KS) from March 2001 to October 2002 (30, 31). Only Caucasian and 
African American subjects were included for analyses. Of these subjects, genetic information 
was available in 667 ACS patients including 273 unstable angina patients, 204 NSTEMI patients, 
and 190 STEMI patients. Analyses in the present study were done on the 394 Caucasian and 
African American subjects presenting with an AMI. 
Translational Research Investigating Underlying Disparities in Acute Myocardial 
Infarction Patients' Health Status (TRIUMPH) is a prospective, observational study of 4,340 
consecutive AMI adult patients across 24 US hospitals from April 2005 to December 2008, as 
described (32-34). DNA was available in 2,979 participants. Analyses in the present study were 
conducted on Caucasians and African Americans (n=2712) with genetic information. 
Diagnosis of AMI was based on standard definitions as described earlier above (Chapter 
1: Acute myocardial infarction) and in the literature (35, 36). Briefly, patients who had an 
elevated troponin value in the setting of symptoms or ECG changes during the index 
hospitalization were diagnosed as having an AMI. All participating institutions obtained 
approval from their respective ethics committees and all participants signed an informed consent 
during the initial screening period, as reported previously (32, 37). 
 
Genotyping 
The EPHX2 p.Lys55Arg polymorphism (rs41507953) was genotyped in the TRIUMPH 
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Applied Genomics Core facility using the PSQ 96 HS Pyrosequencer automated genotyping 
system (Biotage AB, Uppsala, Sweden) (38). 
 
Measurement of circulating biomarkers 
Plasma troponin T, high sensitivity C reactive protein (hs-CRP), and pro-B-type 
natriuretic peptide (proBNP) were measured in a subset of TRIUMPH subjects at baseline, 1 
month, and 6 months following index hospitalization (32). For follow-up visits at 1 month and 6 
months, blood was collected by trained medical personnel via an in-home visit or with a kit that 
was mailed to the subject and sent back to the lab for processing for subjects who agreed to 
provide follow-up samples. Data on 24% of subjects for all 3 blood collection periods were 
available. Analysis of blood for biomarker levels were done at the Clinical Reference Laboratory 
(Lenexa, KS). 
 
CV outcomes 
In the current analysis, all-cause mortality was captured as the primary endpoint by query 
of the Social Security Death Masterfile or the Center for Disease Control National Death Index. 
Mortality is reported at 3-month, 6-month, 9-month, 1-year, 2 year, 3-year, 4-year, and 5-year 
time intervals in INFORM. For TRIUMPH, mortality is reported at 1 month and every 6 months 
thereafter (i.e., 7-month, 13-month, etc.) up to 55-month interval. 
 
Statistical analysis 
For baseline characteristics, continuous variables were compared using Student’s T-test 
and categorical variables were compared using chi-square or Fisher’s exact test if >20% of 
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expected cell frequencies were >5. EPHX2 Lys55Arg did not deviate from Hardy-Weinberg 
equilibrium in INFORM or TRIUMPH within Caucasian and African American populations, 
thus further statistical analyses were carried forward in these subsets. Genotype-survival 
associations were evaluated in each cohort using (a) a Cox proportional hazards model 
(unadjusted and adjusted) and (b) the log-rank test to compare Kaplan-Meier survival curves 
across genotypes. In TRIUMPH, two adjustment models were used. Model 1 corrected for age 
sex and race. Model 2 corrected for pre-specified baseline covariates known to predict adverse 
outcomes in AMI patients including age, race, sex, AMI type (STEMI or NSTEMI), diabetes, 
and AMI treatment strategy (medical management or PCI/CABG) (29). In INFORM, only 
unadjusted analyses were conducted since adjusted models had been previously used in the full 
ACS cohort (Chapter 1: The epoxyeicosatrienoic acid metabolic pathway and parallel pathways 
of eicosanoid metabolism) (29). Analyses were completed assuming either an additive mode of 
inheritance or a dominant mode of inheritance. Genotype-survival race-stratified analyses were 
also conducted. For biomarker analysis, continuous variables were compared in a dominant 
mode of inheritance using Student’s t-test. Biomarker analyses were repeated with an additive 
mode of inheritance with the non-parametric Kruskal-Wallis test to lessen the impact of skew 
that occurs with smaller number in each cell. Analyses were performed using SAS 9.2 (SAS 
Institute, Cary, NC). P<0.05 was considered to be statistically significant. Power calculations 
were conducted using Quanto (39). Mortality estimates to derive power were based on 4.5-year 
mortality (36% of patients had 4.5-year mortablity data available) as a conservative estimate 
since 5-year mortality data was not available.  
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Results 
 
INFORM baseline characteristics in ACS population 
In the full ACS population, 79% of participants were Caucasian and 36% were female. 
The 5-year mortality rate in the full population was 17%. Patient characteristics by genotype are 
shown in Table 3.1. No significant differences in baseline characteristics were observed by 
genotype other than African American race which was more prevalent in the Arg55 Carrier 
group warranting race-stratified analyses. The MAF was 11.7% in Caucasians and 21.7% in 
African Americans, consistent with previous literature (14). Of the total INFORM ACS 
population with EPHX2 Lys55Arg data available (n=667), 394 participants were AMI patients. 
Of these, 88% were Caucasian and the total 5-year mortality rate was 17%. 
 
EPHX2 Lys55Arg genotype and mortality in the AMI population from INFORM 
EPHX2 Lys55Arg genotype was significantly associated with survival following an AMI 
in the total INFORM study population where variant carriers had a significantly higher risk of 
death (Figure 3.1a). This association persisted in the Caucasian subset (Figure 3.1b). 
 
TRIUMPH baseline characteristics 
Of the 2712 participants with genetic information, the average age was 59, 76% were 
Caucasian, 32% were female, 44% were suffering from a STEMI, and 76% underwent coronary 
artery vascularization during the index hospitalization (Table 3.2). Patient characteristics by race 
are shown in Table 3.2. There were significant differences in baseline demographics (age and 
sex), ACS classification type, past medical history (smoking, hypertension, diabetes, 
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hyperlipidemia, heart failure, MI), cholesterol (high density lipoprotein [HDL], triglycerides), 
treatment strategy, and beta blocker use between Caucasians and African Americans, warranting 
race-stratified genetic analyses. The MAF was 11.2% in Caucasians and 22.4% in African 
Americans, consistent with prior reports (14). Patient characteristics by genotype for the total 
population, Caucasians, and African Americans are shown in Tables 3.3-3.5. In the total 
population, variant allele carriers were less likely to be admitted for a STEMI and more likely to 
be using beta blocker medication. Within the Caucasian subset, there were no significant 
differences in baseline characteristics. In African Americans, variant carriers had higher LDL, 
higher cholesterol levels, higher beta-blocker use, and lower aspirin use. 
 
EPHX2 Lys55Arg genotype and mortality in TRIUMPH 
Follow-up data were not available in the full population as shown (Table 3.6). Complete 
follow-up data at 3 years was available in 75% of the population. The observed 3-year mortality 
rate was 12.1% overall (327 deaths), 10.1% in Caucasiancs (206 deaths), and 18.3% in African 
Americans (121 deaths). 
EPHX2 Lys55Arg genotype was not significantly associated with survival following an 
AMI in the total TRIUMPH study population (Log-rank P=0.144; Figure 3.2a). Based on 
mortality estimates generated from the subset of participants with full 3-year mortality data, 
genotype was not significantly associated with 3-year mortality (All Subjects: HR 1.19 95% CI 
0.94-1.51, P=0.156; Figure 3.2a). Furthermore, there was no association between genotype and 
survival in race-stratified analyses (Caucasians: log-rank P=0.742; Figure 3.2b-c; African 
Americans: log-rank P=0.269; Figure 3.2b-c).  Genotype was not significantly associated with 3-
year mortality (Caucasians: HR 0.96 95% CI 0.68-1.36, P=0.831; African Americans: HR 0.84 
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95% CI 0.61-1.17, P=0.303; Figure 3.2b-c). The association remained non-significant after 
adjusting for demographic and clinical covariates (Table 3.7). 
Using an additive mode of inheritance (unadjusted analyses) in the combined Caucasian 
and African American population, Arg/Arg subjects (n=75) had a HR of 1.62-fold greater risk of 
projected 3-year mortality relative to Lys/Lys patients following AMI, however this did not meet 
the threshold of significance (95% 0.88-2.96, P=0.194). No significant differences across 
genotype were observed using an additive mode of inheritance in unadjusted analyses for 
projected 3-year mortality data (Caucasians: P=0.675; African Americans: P=0.758; Figure 3.3, 
Table 3.8). 
 
EPHX2 Lys55Arg genotype and cardiac biomarkers in TRIUMPH 
To provide mechanistic insight into the genotype-prognosis association, Troponin T 
(myocardial injury), hs-CRP (inflammation), and proBNP (myocardial stretch) were measured in 
a subset of subjects. There was no significant difference between troponin T levels in Arg55 
variant carriers compared to wildtype individuals at baseline (P=0.656), 1 month (P=0.057), and 
6 months (P=0.215) following AMI (Table 3.9). Similarly no differences in hs-CRP were 
observed at baseline, 1 month, and 6 months (P=0.899, P=0.059, P=0.931, respectively). No 
differences were observed in proBNP between Lys/Lys and Arg55 carriers. Using the additive 
mode of inheritance, genotype was not associated with Troponin T at baseline (P=0.563) or 6 
months (P=0.225). However, Troponin T levels were significantly associated with genotype at 1 
month across Lys/Lys (0.02 ± 0.02 mg/dL), Lys/Arg (0.02 ± 0.03), and Arg/Arg patients (0.25 ± 
0.96 mg/dL). No differences were observed in hs-CRP and proBNP levels across genotype using 
the additive mode of inheritance at baseline, 1 month, and 6 months following AMI. 
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Discussion 
Our group has previously observed an association between EPHX2 p.Lys55Arg genotype 
with 5-year survival in a cohort of ACS patients (INFORM) (29), where EPHX2 Arg55 variant 
allele carriers had a significantly higher risk of death. The objective of the present study was to 
determine the relationship between EPHX2 Lys55Arg polymorphism and survival in patients 
recently admitted for an AMI. Using the AMI subpopulation of INFORM as well as a larger 
cohort of AMI patients (TRIUMPH), we determined that EPHX2 Lys55Arg was significantly 
associated with mortality in AMI patients from INFORM, but that this association was not 
validated in the larger population of AMI patients from TRIUMPH. 
Although TRIUMPH has a larger sample size compared to INFORM and thus should 
have more power to detect differences, it is important to reiterate that full mortality data was not 
available for analysis in this cohort. Whereas INFORM data had 5-year mortality data in all 
patients available for analysis, no patients in TRIUMPH had 5-year mortality data available and 
only 36% had full 4.5 year data. Thus, power to validate a genotype-survival association in 
TRIUMPH was limited. Based on the available mortality data at 3 years, we had 74% power to 
detect an association assuming a hazard ratio (HR) of 1.4 in a dominant model. With full 4.5-
year mortality, we anticipate 80% power (Table 3.10). Additionally, it is qualitatively evident in 
the results of the INFORM AMI patients that survival curves don’t begin to separate until 3 years 
post-AMI. Thus, although speculative in nature, it is plausible that a similar pattern could occur 
in TRIUMPH with complete mortality data. A final analysis when full 5-year mortality data are 
available is necessary to rule out the possibility that lack of sufficient power prevented the 
positive INFORM results from being replicated in TRIUMPH. Full 4-year mortality data will be 
available in summer 2015 and 5-year data is anticipated to be available within a year thereafter. 
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Biologically, separation of survival curves at 3 years indicates that the EET metabolic pathway 
may play an important role in the chronic period after AMI (rather than the acute period), further 
justifying the need for longer term mortality follow-up in TRIUMPH. 
Considering the well-established cardioprotective/anti-inflammatory effects of EETs in 
preclinical studies (4) and to gain more insight into a potential association between genotype and 
survival, we explored the impact of EPHX2 Lys55Arg on established plasma biomarkers of 
myocardial injury, inflammation, and remodeling in TRIUMPH subjects at baseline, 1 month, 
and 6 months following AMI. In the overall population, we determined that for the majority of 
biomarkers and time points, genotype was not associated with levels. However, we observed that 
EPHX2 Lys55Arg genotype was associated with plasma troponin T at 1 month using an additive 
mode of inheritance (P=0.038), where mean levels in Arg/Arg patients were 12.5-fold higher 
than levels in Lys/Lys and Lys/Arg. Using a dominant mode of inheritance, mean plasma 
troponin T levels in Arg55 carriers were 2-fold greater than mean levels in noncarriers 
(P=0.057). These associations are in the direction hypothesized since we would predict that 
enhanced sEH-derived hydrolysis would have a deleterious effect and suggest that Arg/Arg 
subjects may have evidence of increased myocardial infarct size following AMI compared to 
Lys/Lys and Lys/Arg participants. It is important to note, however, that clinical guidelines 
recommend measuring troponin levels within hours of symptom onset for AMI diagnosis and 
potentially once on day 3 or 4 after symptom onset for post-AMI prognosis. Furthermore, the 
rise and falling pattern of troponin levels is similarly important for prognosis following AMI as 
the levels themselves (40). Thus the clinical relevance of an association between genotype and a 
single 1-month troponin level is unknown. Nevertheless, troponin levels have been found to 
predict survival in CVD patients not suffering from an AMI (41). Overall, results of this 
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exploratory analysis must be interpreted with caution due to small numbers in the Arg/Arg group 
(n=19) from loss to follow-up in biomarker sample collection (Kruskal-Wallis non-parametric 
analyses were conducted to alleviate the effects of skewed biomarker data which are inflated 
with small data). Additionally, these results underscore the need for follow-up TRIUMPH 
analysis with full 5-year mortality data to determine if the relationship between genotype and 
troponin T following AMI contributes to an association between genotype and survival. 
As mentioned, insufficient power may be the reason why there was a lack of genotype-
survival association. However, if current findings in the TRIUMPH cohort hold when full 
mortality data are available, this would be discordant with several previous studies that have 
shown that EPHX2 Lys55Arg polymorphism is associated with the risk of cardiovascular disease 
(13, 22, 23). Nevertheless, several key studies reported a lack of association between Lys55Arg 
and the incidence of CVD. There was no relationship between EPHX2 Lys55Arg genotype and 
restenosis in a population of CAD patients following PCI (42). EPHX2 Arg287Gln, but not 
Lys55Arg was found to be associated with the incidence of atrial fibrillation following catheter 
ablation (28). Likewise, EPHX2 Arg287Gln, but not Lys55Arg was associated with the 
occurrence of ischemic stroke in Caucasians with multiple risk factors for CVD (43). 
Interestingly, although in vitro  transfection of the Arg287Gln polymorphism into cell lines has 
been found to reduce cell death compared to non-transfected cells in both cardiomyocytes (44) 
and neuronal cells (10) undergoing ischemic injury, transfection with Lys55Arg in the same 
respective models did not cause any significant change in the rate of cell death. Although our lab 
previously did not find an association between EPHX2 Arg287Gln and mortality following ACS 
in the full INFORM cohort, further analysis investigating the association between EPHX2 
Arg287Gln and survival following AMI is needed to better understand the role of EPHX2 
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genetic variation in prognosis following CVD. 
The aforementioned lack of consistent findings across studies suggests that the 
relationship between genetic markers and CVD is highly complex and may involve other factors. 
Indeed, associations between CAD and EPHX2 variation are more pronounced in cigarette 
smokers (13, 21). We recently reported that multiple clinical factors were associated with low 
EET levels in patients with established CAD (45), suggesting that quantifying EET metabolite 
levels may provide insight into factors associated with inter-individual variation in EET 
biosynthesis and EET hydrolysis (beyond genetic polymorphisms). The quantification of EET 
levels in humans would provide further insight into this association; circulating levels of EETs 
was not obtained sample from the TRIUMPH or INFORM cohort. Prior evidence, however, 
functionally links EPHX2 Lys55Arg genotype to sEH activity and suggests that eicosanoids are 
altered by this polymorphism in humans (8, 13). Furthermore, we reported that EET levels were 
associated with the extent of CAD in the largest observational human study to date that 
quantifies EET levels in humans with CVD (Chapter 2: Figure 1). We also showed in 
exploratory analyses that baseline EETs may predict the risk of CV events in obstructive CAD 
patients (Chapter 2: Figure 3). Investigation of the relationship between baseline EET levels and 
survival in a large cohort of AMI patients would provide further insight into a genotype-
prognosis association (or lack thereof) with EPHX2 Lys55Arg genotype following AMI. 
There are some limitations to this study. First, mortality rates were determined using the 
full sample size as the denominator (for all analyses including the power calculations), thus they 
underestimate the actual mortality rate. However, using sample size based on the proportion of 
patients with full mortality data available as the denominator grossly overestimates the sample 
size (i.e., 40% mortality rate at 4.5 years in total population), because this approach assumes 
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incorrectly that patients who did not survive would have had full follow-up data 5 years had they 
not died during this time interval. In the absence of full mortality data, future interim analyses 
should include a projected/estimated mortality calculation for a more accurate estimation of the 
mortality rate. Second, even with full mortality data available, power calculations reveal that we 
are underpowered to detect associations in the African American subset (Table 3.10). However, 
it is well established that African Americans are poorly represented in clinical trials despite 
having a greater risk of CVD. TRIUMPH is one of the largest registries to provide detailed 
information on clinical, genetic, and metabolic characteristics in a racially-diverse population. 
Indeed, one of the goals of TRIUMPH was to investigate racial disparities in post-AMI 
outcomes. Consequently, 16 of the 24 recruitment sites were located in large urban centers to 
enable enrollment of a racially diverse population (32). When full mortality data are available, 
the relatively large sample size of African Americans in TRIUMPH provides more power to 
detect associations in this subpopulation, which was one of the limitations of the INFORM 
cohort. Low MAF and small numbers in TRIUMPH preclude analysis in populations who are not 
African American or Caucasian. The association between variants in EPHX2 and CVD in Asian 
and Hispanic population has not been investigated and is a potential future direction. Third, 
smaller effect sizes than anticipated (HR<1.5) would limit power to detect significant 
associations even in Caucasians when full mortality data are available. Nevertheless, 80% power 
exists to detect an HR of 1.4 in the overall population when full mortality data are available. 
Furthermore, HR (95% CI) was 2.33 (1.43-3.79) and 2.42 (1.40-4.19) in INFORM total 
population and Caucasian cohorts, respectively. This indicates that assuming a HR of 1.4 or 1.5 
(along with using 4.5-year mortality rates) to estimate power is conservatively low for the 
incoming 5-year mortality data. Moreover, effect sizes may be larger in the presence of an 
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environmental exposure such as current cigarette smoker or other clinically distinct high-risk 
subset such as hs-CRP >2 g/dL (46). Our group and others have shown that associations between 
EPHX2 and CAD risk are most pronounced in cigarette smokers (47). Evaluation of such 
interactions is an important area of further investigation.  
In conclusion, we observed that EPHX2 Lys55Arg was associated with 5-year mortality 
following AMI, but we were not able to replicate this in an independent cohort of AMI patients. 
Future analysis with full 5-year mortality data is needed as a follow-up to this interim analysis to 
validate the association with adequate power.  
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Figures 
 
  
 
Figure 3.1 Mortality in acute myocardial infarction (AMI) patients from the INFORM 
cohort by genotype using a dominant mode of inheritance. A comparison of Kaplan-Meier 
curves and a comparison of 5-year mortality rates between noncarriers and EPHX2 Lys55Arg 
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carriers in (a) Caucasian + African American (n=394) and (b) Caucasian (n=345) subjects. Log-
rank P-values and hazard ratio (HR) for each population are unadjusted.  
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Figure 3.2 Mortality in acute myocardial infarction (AMI) patients from the TRIUMPH 
cohort by genotype using a dominant mode of inheritance. A comparison of Kaplan-Meier 
curves and a comparison of observed 3-year mortality rates between noncarriers and EPHX2 
Lys55Arg carriers in (a) Caucasian + African American (n=2712) , (b) Caucasian (n=2049), and 
(c) African American (n=663) subjects. Log-rank P-values and hazard ratio (HR) for each 
population are unadjusted.  
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Figure 3.3 Mortality in acute myocardial infarction (AMI) patients from the TRIUMPH 
cohort by genotype using an additive mode of inheritance. A comparison of Kaplan-Meier 
curves and a comparison of projected 3-year mortality rates between noncarriers and EPHX2 
Lys55Arg carriers in (a) Caucasian + African American (n=2712) , (b) Caucasian (n=2049), and 
(c) African American (n=663) subjects. Log-rank P-values and hazard ratio (HR) for each 
population are unadjusted.  
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Tables 
 
Table 3.1 Characteristics of the acute coronary syndrome (ACS) study population from the INFORM 
cohort by genotype 
 
Characteristic    Lys/Lys  Arg55 Carrier   P 
     (n=502)  (n=165) 
Age (years)    60.4 ± 12.4  60.8 ± 12.8   0.69 
Female     177 (35.3%)   64 (38.8%)    0.413 
African-American race   76 (15.1%)   46 (27.9%)    <0.001 
ACS Classification Type         0.064 
 ST elevation MI/LBBB   154 (30.7%)   36 (21.8%) 
 Non ST elevation MI   152 (30.3%)   52 (31.5%) 
 Unstable angina    196 (39.0%)   77 (46.7%) 
Past medical history 
 History of hypertension   324 (64.5%)   113 (68.5%)    0.355 
 History of diabetes  136 (27.1%)   51 (30.9%)    0.344 
 History of hyperlipidemia  295 (58.8%)   109 (66.1%)   0.096 
 Current heart failure   38 (7.6%)   14 (8.5%)   0.704 
 Prior MI    159 (31.7%)   58 (35.2%)    0.408 
Smoking Status           0.869 
 Current     183 (36.5%)   57 (34.5%) 
 Former     178 (35.5%)   62 (37.6%) 
 Never     140 (27.9%)   46 (27.9%) 
BMI (kg/m2) *     29.6 ± 6.3   30.2 ± 6.7    0.282 
Total cholesterol (mg/dL) #   178.4 ± 39.6 [65]  181.6 ± 49.1 [14]   0.436 
LDL (mg/dL) #    103.5 ± 34.5 [91] 102.3 ± 44.2 [24]  0.757 
HDL (mg/dL) #    41.6 ± 14.7 [71] 43.6 ± 17.9 [17]  0.183 
Triglycerides (mg/dL) #   176.4 ± 117.8 [70] 181.2 ± 144.9 [17]  0.698 
Treatment Strategy           0.252 
 Medical Management   182 (36.3%)   68 (41.2%) 
 PCI     299 (59.6%)   87 (52.7%) 
 CABG     21 (4.2%)   10 (6.1%) 
Discharge Medications 
 Beta-blocker    412 (82.2%)   124 (75.6%)    0.063 
 Statin     382 (76.1%)   121 (73.3%)    0.475 
 Aspirin     463 (92.4%)   157 (95.7%)    0.142 
BMI, body mass index; CABG, coronary artery bypass graft; HDL, high density lipoprotein; LBBB, left bundle 
branch block; LDL, low density lipoprotein; MAF, minor allele frequency; MI, myocardial infarction; PCI, 
percutaneous coronary intervention. Data presented as mean ± standard deviation or count (%). Number of 
participants with missing values is in brackets 
Student’s t-test was performed for continuous variables and chi-squared test or Fisher’s exact test was performed for 
categorical variables as appropriate. 
* Measured at admission # Measured at discharge  
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Table 3.2 Characteristics of the TRIUMPH cohort overall and by race 
 
Characteristic    Total   Caucasian  African American P 
     (n=2712)  (n=2049)  (n=663) 
Age (years)    59.2 ± 12.2  59.8 ± 12.1  57.4 ± 12.2  <0.001  
Sex               <0.001 
 Male    1855 (68.4%)  1483 (72.4%)  372 (56.1%) 
 Female    857 (31.6%)   566 (27.6%)   291 (43.9%)   
AMI Classification Type           <0.001 
 ST elevation MI    1186 (43.7%)   985 (48.1%)  201 (30.3%)  
 Non ST elevation MI   1526 (56.3%)   1064 (51.9%)  462 (60.7%) 
Past medical history 
 Current smoker   1062 (39.5%) [21] 760 (37.3%) [14] 302 (46.0%) [7]  <0.001 
 Obese (BMI ≥30 kg/m2)  1105 (42.6%) [118] 844 (42.1%) [42] 261 (44.5%) [76] 0.299 
 History of hypertension   1775 (65.4%)  1256 (61.3%)  519 (78.3%)  <0.001 
 History of diabetes  795 (29.3%)  532 (26.0%)  263 (39.7%)  <0.001 
 History of hyperlipidemia  1326 (48.9%)  1037 (50.6%)  289 (43.6%)  0.002 
 Current heart failure   217 (8.0%)  112 (5.5%)  105 (15.8%)  <0.001 
 Prior myocardial infarction 532 (19.6%)  379 (18.5%)  153 (23.1%)  0.010 
Total cholesterol (mg/dL) *   156.1 ± 38.0 [592] 155.3 ± 37.3 [479] 158.6 ± 39.7 [113] 0.076 
LDL (mg/dL) *    95.5 ± 31.9 [592] 95.3 ± 31.1 [479] 96.1 ± 33.8 [113] 0.583 
HDL (mg/dL) *    40.0 ± 10.6 [592] 38.7 ± 9.8 [479] 43.6 ± 12.0 [113] <0.001 
Triglycerides (mg/dL) *   154.0 ± 102.7 [592] 162.0 ± 108.1 [479] 131.3 ± 81.2 [113] <0.001 
Treatment Strategy 
 PCI/CABG during index visit 2056 (75.8%)  1665 (81.3%)  391 (59.0%)  <0.001 
Discharge Medications 
 Beta-blocker    2459 (90.7%)  1878 (91.7%)  581 (87.6%)   0.002 
 Statin     2398 (88.4%)  1824 (89.0%)  574 (86.6%)    0.087 
 Aspirin    2579 (95.1%)  1958 (95.6%)  621 (93.7%)  0.050 
EPHX2 Lys55Arg MAF  13.9%   11.2%   22.4%    
BMI, body mass index; CABG, coronary artery bypass graft; HDL, high density lipoprotein; LDL, low density lipoprotein; MAF, minor allele frequency; MI, 
myocardial infarction; PCI, percutaneous coronary intervention. Data presented as mean ± standard deviation or count (%). Number of participants with missing 
values is in brackets 
Student’s t-test was performed for continuous variables and chi-squared test or Fisher’s exact test was performed for categorical variables as appropriate. 
* Measured at admission
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Table 3.3 Characteristics of the TRIUMPH cohort overall and by genotype using a dominant mode of inheritance 
 
Characteristic    Total   Lys/Lys  Arg55 Carrier  P 
     (n=2712)  (n=2020)  (n=692) 
Age (years)    59.2 ± 12.2  59.2 ± 12.2  59.1 ± 12.2  0.879 
Sex               0.488 
 Male    1855 (68.4%)  1389 (68.8%)  466 (67.3%) 
 Female    857 (31.6%)   631 (31.2%)  226 (32.7%)   
AMI Classification Type           0.005 
 ST elevation MI    1186 (43.7%)   915 (45.3%)  271 (39.2%)  
 Non ST elevation MI   1526 (56.3%)   1105 (54.7%)  421 (60.8%) 
Past medical history 
 Current smoker    1062 (39.5%) [21] 803 (40.0%) [10] 259 (38.0%) [11] 0.376 
 Obese (BMI ≥30 kg/m2)  1105 (42.6%) [118] 822 (42.4%) [82] 283 (43.1%) [36] 0.745 
 History of hypertension   1775 (65.4%)  1306 (64.7%)  469 (67.8%)  0.136 
 History of diabetes  795 (29.3%)  576 (28.5%)  219 (31.6%)  0.118 
 History of hyperlipidemia  1326 (48.9%)  980 (48.5%)  346 (50.0%)  0.500 
 Current heart failure   217 (8.0%)  152 (7.5%)  65 (9.4%)  0.118 
 Prior myocardial infarction 532 (19.6%)  395 (19.6%)  137 (19.8%)  0.889 
Total cholesterol (mg/dL) *   156.1 ± 38.0 [592] 155.9 ± 37.3 [451] 156.7 ± 39.8 [141] 0.671 
LDL (mg/dL) *    95.5 ± 31.9 [592] 95.4 ± 31.3 [451] 95.8 ± 33.5 [141] 0.817 
HDL (mg/dL) *    40.0 ± 10.6 [592] 39.7 ± 10.2 [451] 40.6 ± 11.6 [141] 0.096 
Triglycerides (mg/dL) *   154.0 ± 102.7 [592] 156.2 ± 107.4 [451] 147.6 ± 87.4 [141] 0.088 
Treatment Strategy 
 PCI/CABG during index visit 2056 (75.8%)  1547 (76.6%)  509 (73.6%)  0.108 
Discharge Medications 
 Beta-blocker    2459 (90.7%)  1814 (89.8%)  645 (93.2%)   0.008 
 Statin     2398 (88.4%)  1782 (88.2%)  616 (89.0%)    0.571 
 Aspirin    2579 (95.1%)  1918 (95.0%)  661 (95.5%)  0.549 
BMI, body mass index; CABG, coronary artery bypass graft; HDL, high density lipoprotein; LDL, low density lipoprotein; MI, myocardial infarction; PCI, 
percutaneous coronary intervention. Data presented as mean ± standard deviation or count (%). Number of participants with missing values is in brackets 
Student’s t-test was performed for continuous variables and chi-squared test or Fisher’s exact test was performed for categorical variables as appropriate. 
* Measured at admission  
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Table 3.4 Characteristics of the TRIUMPH cohort overall and by genotype using a dominant mode of inheritance in Caucasian patients only 
 
Characteristic    Total   Lys/Lys  Arg55 Carrier  P 
     (n=2049)  (n=1620)  (n=429) 
Age (years)    59.8 ± 12.1  59.8 ± 12.0  59.2 ± 12.2  0.989 
Sex               0.248 
 Male    1483 (72.4%)  1163 (71.8%)  320 (74.6%) 
 Female    566 (27.6%)  457 (28.2%)  109 (25.4%)   
AMI Classification Type           0.498 
 ST elevation MI    985 (48.1%)  785 (48.5%)  200 (46.6%)  
 Non ST elevation MI   1064 (51.9%)  835 (51.5%)  229 (53.4%) 
Past medical history 
 Current smoker   760 (37.3%) [14] 610 (37.8%) [8]  150 (35.5%) [6]  0.368 
 Obese (BMI ≥30 kg/m2)  844 (42.1%) [42] 664 (41.9%) [34] 180 (42.8%) [8]  0.743 
 History of hypertension   1256 (61.3%)  990 (61.1%)  266 (62.0%)  0.735 
 History of diabetes  532 (26.0%)  414 (25.6%)  118 (27.5%)  0.413 
 History of hyperlipidemia  1037 (50.6%)  809 (49.9%)  228 (53.1%)  0.237 
 Current heart failure   112 (5.5%)  88 (5.4%)  24 (5.6%)  0.895 
 Prior myocardial infarction 379 (18.5%)  297 (18.3%)  82 (19.1%)  0.711 
Total cholesterol (mg/dL) *   155.3 ± 37.3 [479] 156.0 ± 37.7 [382] 152.5 ± 35.9 [97] 0.124 
LDL (mg/dL) *    95.3 ± 31.1 [479] 95.9 ± 31.3 [382] 93.0 ± 30.5 [97] 0.140 
HDL (mg/dL) *    38.7 ± 9.8 [479] 38.7 ± 9.6 [382] 38.6 ± 10.4 [97] 0.808 
Triglycerides (mg/dL) *   162.0 ± 108.1 [479] 163.1 ± 110.8 [382] 157.5 ± 97.3 [97] 0.400 
Treatment Strategy 
 PCI/CABG during index visit 1665 (81.3%)  1320 (81.5%)  345 (80.4%)  0.616 
Discharge Medications 
 Beta-blocker    1878 (91.7%)  1476 (91.1%)  402 (93.7%)   0.084 
 Statin     1824 (89.0%)  1437 (88.7%)  387 (90.2%)    0.375 
 Aspirin    1958 (95.6%)  416 (97.0%)  1542 (95.2%)  0.111 
BMI, body mass index; CABG, coronary artery bypass graft; HDL, high density lipoprotein; LDL, low density lipoprotein; MI, myocardial infarction; PCI, 
percutaneous coronary intervention. Data presented as mean ± standard deviation or count (%). Number of participants with missing values is in brackets 
Student’s t-test was performed for continuous variables and chi-squared test or Fisher’s exact test was performed for categorical variables as appropriate. 
* Measured at admission   
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Table 3.5 Characteristics of the TRIUMPH cohort overall and by genotype using a dominant mode of inheritance in African American patients 
only 
 
Characteristic    Total   Lys/Lys  Arg55 Carrier  P 
     (n=663)  (n=400)  (n=263) 
Age (years)    57.4 ± 12.2  56.9 ± 12.0  58.0 ± 12.4  0.238 
Sex               0.802 
 Male    372 (56.1%)  226 (56.5%)  146 (55.5%) 
 Female    291 (43.9%)  174 (43.5%)  117 (44.5%)   
AMI Classification Type           0.131 
 ST elevation MI    201 (30.3%)  130 (32.5%)  71 (27.0%)  
 Non ST elevation MI   462 (69.7%)  270 (67.5%)  192 (73.0%) 
Past medical history 
 Current smoker    302 (46.0%) [7]  193 (48.5%) [5]  109 (42.2%) [2]  0.117 
 Obese (BMI ≥30 kg/m2)  261 (44.5%) [76] 158 (44.9%) [48] 103 (43.8%) [28] 0.801 
 History of hypertension   519 (78.3%)  316 (79.0%)  203 (77.2%)  0.580 
 History of diabetes  263 (39.7%)  162 (40.5%)  101 (38.4%)  0.589 
 History of hyperlipidemia  289 (43.6%)  171 (42.8%)  118 (44.9%)  0.591 
 Current heart failure   105 (15.8%)  64 (16.0%)  41 (15.6%)  0.887 
 Prior myocardial infarction 153 (23.1%)  98 (24.5%)  55 (20.9%)  0.283 
Total cholesterol (mg/dL) *   158.6 ± 39.7 [113] 155.6 ± 36.1 [69] 163.2 ± 44.3 [44] 0.028 
LDL (mg/dL) *    96.1 ± 33.8 [113] 93.6 ± 31.2 [69] 99.9 ± 37.1 [44] 0.033 
HDL (mg/dL) *    43.6 ± 12.0 [113] 43.7 ± 12.7 [69] 43.5 ± 11.5 [44] 0.878 
Triglycerides (mg/dL) *   131.3 ± 81.2 [113] 130.4 ± 89.2 [69] 132.5 ± 67.4 [44] 0.772 
Treatment Strategy 
 PCI/CABG during index visit 391 (59.0%)  227 (56.8%)  164 (62.4%)  0.151 
Discharge Medications 
 Beta-blocker    581 (87.6%)  338 (84.5%)  243 (92.4%)   0.003 
 Statin     574 (86.6%)  345 (86.3%)  229 (87.1%)    0.761 
 Aspirin    515 (77.7%)  329 (82.3%)  186 (70.7%)  <0.001 
BMI, body mass index; CABG, coronary artery bypass graft; HDL, high density lipoprotein; LDL, low density lipoprotein; MI, myocardial infarction; PCI, 
percutaneous coronary intervention. Data presented as mean ± standard deviation or count (%). Number of participants with missing values is in brackets 
Student’s t-test was performed for continuous variables and chi-squared test or Fisher’s exact test was performed for categorical variables as appropriate. 
* Measured at admission
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 Table 3.6 Mortality follow-up status in TRIUMPH 
 
Interval  Evaluable *  Mortality rate (deaths) † 
2-year  2654 (98%)  9.6% (259 deaths) 
3-year  2024 (75%)  12.1% (327 deaths) 
4-year  1298 (48%)  14.1% (382 deaths) 
4.5-year 981 (36%)  14.4% (391 deaths) 
5-year  0 (0%)   N/A  
* Total population with evaluable mortality data (%) 
† Overall mortality rate based on data available
  
102 
Table 3.7 Hazard ratios between EPHX2 Lys55Arg and 3-year mortality using a dominant mode of 
inheritance 
 
     HR (95% CI)  P 
All subjects    
 Arg55 carrier vs Lys/Lys  
  Unadjusted   1.19 (0.94-1.51) 0.156   
  Model 1   1.02 (0.80-1.30) 0.889  
  Model 2   1.00 (0.78-1.28) 0.999  
 
Caucasians 
 Arg55 carrier vs Lys/Lys      
  Unadjusted   0.96 (0.68-1.36) 0.831   
  Model 1   0.98 (0.69-1.38) 0.889  
  Model 2   0.90 (0.64-1.27) 0.564  
 
African Americans 
 Arg55 carrier vs Lys/Lys   
  Unadjusted   1.14 (0.80-1.64) 0.473  
  Model 1   1.08 (0.75-1.55) 0.688  
  Model 2   1.11 (0.77-1.59) 0.591  
Model 1: adjusted for age, sex, and race (age and sex in race-stratified analyses) 
Model 2: adjusted for age, sex, race, AMI type (STEMI, NSTEMI), diabetes, treatment strategy (medical 
management, PCI, CABG) 
CI=confidence interval, HR=hazard ratio
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Table 3.8 Hazard ratios between EPHX2 Lys55Arg and 3-year mortality using an additive mode of inheritance 
 
   Unadjusted)    Model 1    Model 2    
   HR (95% CI)  P  HR (95% CI)  P  HR (95% CI)  P 
All subjects    
       0.194     0.954     0.840 
  Lys/Lys  Reference    Reference    Reference 
  Lys/Arg  1.15 (0.89-1.48)   1.01 (0.78-1.30)    0.98 (0.76-1.27) 
  Arg/Arg 1.62 (0.88-2.96)   1.10 (0.60-2.03)    1.19 (0.64-2.19) 
 
Caucasians 
       0.675     0.812     0.484 
  Lys/Lys  Reference    Reference    Reference 
  Lys/Arg  0.93 (0.65-1.33)   0.95 (0.66-1.36)   0.87 (0.61-1.24) 
  Arg/Arg 1.47 (0.54-3.96)   1.33 (0.49-3.57)   1.54 (0.57-4.16) 
 
African Americans 
       0.758     0.921     0.865 
  Lys/Lys  Reference    Reference    Reference 
  Lys/Arg  1.13 (0.78-1.64)   1.08 (0.74-1.57)   1.11 (0.76-1.61) 
  Arg/Arg 1.22 (0.56-2.66)   1.06 (0.48-2.31)   1.10 (0.50-2.42) 
Model 1: adjusted for age, sex, and race (age and sex in race stratified-analyses) 
Model 2: adjusted for age, sex, race, AMI type (STEMI, NSTEMI), diabetes, treatment strategy (medical management, PCI, CABG) 
CI=confidence interval, HR=hazard ratio  
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Table 3.9 Relationship between EPHX2 Lys55Arg and biomarkers of myocardial injury, inflammation, and ventricular remodeling 
 
Dominant     Overall   Lys/Lys  Arg55 carrier  P   
Baseline   
 Troponin T (mg/L)   1.57 ± 2.14 [684] 1.55 ± 2.11 [516] 1.60 ± 2.23 [168] 0.656   
 hs-CRP (mg/L)    3.64 ± 4.79 [558] 3.63 ± 4.80 [424] 3.66 ± 4.76 [134] 0.899 
 proBNP (g/L)    2.94 ± 8.13 [568] 2.82 ± 7.95 [434] 3.25 ± 8.64 [134] 0.284 
 
1 month 
 Troponin T (mg/L)   0.02 ± 0.14 [1796] 0.02 ± 0.02 [1341] 0.04 ± 0.28 [455] 0.057   
 hs-CRP (mg/L)    0.55 ± 1.16 [1789] 0.50 ± 0.88 [1339] 0.67 ± 1.73 [450] 0.059 
 proBNP (g/L)    1.67 ± 9.93 [1789] 1.78 ± 11.36 [1337] 1.36 ± 3.44 [452] 0.568 
 
6 months 
 Troponin T (mg/L)   0.02 ± 0.03 [2070] 0.01 ± 0.03 [1537] 0.02 ± 0.04 [533] 0.215  
 hs-CRP (mg/L)    0.39 ± 0.63 [2062] 0.39 ± 0.63 [1530] 0.38 ± 0.66 [532] 0.931 
 proBNP (g/L)    1.00 ± 5.15 [2061] 1.09 ± 5.61 [1530] 0.71 ± 3.42 [531] 0.413 
 
Additive     Lys/Lys  Lys/Arg  Arg/Arg  P 
Baseline   
 Troponin T (mg/L)   1.55 ± 2.11 [516] 1.63 ± 2.31 [151] 1.31 ± 1.14 [17] 0.997 
 hs-CRP (mg/L)    3.63 ± 4.80 [424] 3.60 ± 4.64 [120] 4.29 ± 5.85 [14] 0.878 
 proBNP (g/L)    2.82 ± 7.95 [434] 3.25 ± 8.82 [120] 3.27 ± 6.65 [14] 0.655 
 
1 month 
 Troponin T (mg/L)   0.02 ± 0.02 [1341] 0.02 ± 0.03 [411] 0.25 ± 0.96 [44] 0.038   
 hs-CRP (mg/L)    0.50 ± 0.88 [1339] 0.66 ± 1.78 [407] 0.78 ± 1.02 [43] 0.523 
 proBNP (g/L)    1.78 ± 11.36 [1337] 1.20 ± 2.98 [408] 3.14 ± 6.72 [44] 0.403 
 
6 months 
 Troponin T (mg/L)   0.01 ± 0.03 [1537] 0.02 ± 0.04 [485] 0.03 ± 0.06 [48] 0.780  
 hs-CRP (mg/L)    0.39 ± 0.63 [1530] 0.39 ± 0.68 [484] 0.26 ± 0.31 [48] 0.295 
 proBNP (g/L)    1.09 ± 5.61 [1530] 0.74 ± 3.6 [483] 0.37 ± 0.34 [48] 0.690 
proBNP, pro-B-type natriuretic peptide; hs-CRP, high sensitivity C reactive protein. Data presented as mean ± standard deviation. Number of participants with 
missing values is in brackets 
One-way ANOVA was performed for dominant mode of inheritance data and Kruskal-Wallis test was performed for additive mode of inheritance data 
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Table 3.10 Power calculations 
 
Population    Power 
                                   Current analysis  Projected full analysis 
    HR=1.4 HR=1.5 HR=1.4 HR=1.5 
Total population   74%  88%  80%  92% 
Caucasians only   50%  66%  57%  74% 
African Americans only   38%  51%  41%  55% 
Power calculations to detect a hazard of 1.4 or 1.5 between EPHX2 Lys55Arg genotype (dominant model) and 
mortality based on the current 3-year mortality data available and if full 4.5 year mortality data was available 
Power calculations of the current analysis were based on the 3-year mortality rates in the current report (total 
population: 12.1%, Caucasians: 10.1%, and African Americans: 18.3%) 
Power calculations of the projected full analysis were based on the 4.5-year mortality rates in the current report 
(total population: 14.4%, Caucasians: 12.5%, and African Americans: 20.4%) and assuming that all patients had full 
mortality data at 4.5 years
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CHAPTER 4 - CHARACTERIZATION OF MALADAPTIVE VENTRICULAR 
REMODELING IN AN IN VIVO MOUSE MODEL OF MYOCARDIAL ISCHEMIA 
REPERFUSION INJURY 
 
Introduction 
 
A key consequence of CAD is heart failure, which afflicts almost 6 million Americans 
and is predicted to increase by an additional 46% by 2030. Patients who survive an AMI are at 
especially increased risk of developing heart failure. Consistent with the overall heart failure 
incidence, the incidence of post-AMI heart failure has also increased in recent decades (1). This 
devastating disease is a major reason why CVD as a whole remains the leading cause of 
morbidity and mortality worldwide (2). 
Heart failure is a clinical syndrome that manifests in patients as dyspnea (shortness of 
breath) and/or fluid retention (edema). Symptoms of heart failure result primarily from structural 
or functional deficits that lead to a reduced ability in ventricular filling (diastolic dysfunction) or 
ejection of blood (systolic dysfunction). It is important to reiterate that structural abnormalities in 
heart failure patients range from having no changes at all to having marked ventricular dilation. 
Likewise, functional impairment may or may not coexist with structural changes and range from 
having HFpEF to having HFrEF (Chapter 1: Introduction). 
Post-AMI heart failure is preceded by myocardial cell death, inflammation, and 
maladaptive ventricular remodeling which are integral to its pathogenesis and progression. The 
initial injury caused by prolonged ischemia and subsequent reperfusion ultimately leads to 
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cardiomyocyte necrosis (uncontrolled cell death) and apoptosis (programmed cell death), each of 
which independently contribute to the resulting infarct (3). Troponin is a cardiac enzyme that is 
highly specific to myocardial damage and is released primarily by necrosed cardiomyocytes (4). 
Changes in the myocardial expression of the anti-apoptotic Bcl-2 and the pro-apoptotic Bax 
regulate activation of the caspase family, which is primarily pro-apoptotic. 
Necrosis but not apoptosis is recognized as the primary mediator of the acute 
inflammatory response (3). Inflammatory-mediated induction of a class of chemoattractants 
called chemokines promotes leukocyte recruitment to the site of injury. Notably, MCP-1 and 
MIP-2α, which are chemotactic for monocytes and neutrophils, respectively, are induced by 
myocardial necrosis (5). Recruited leukocytes subsequently initiate the cytokine cascade 
including the synthesis of IL-6 in leukocytes and cardiomyocytes. Cytokines induce the 
myocardial expression of adhesion molecules such as ICAM-1, which specifically aid in the 
recruitment of further neutrophils to the site of infarct and mediate neutrophil-derived 
cytotoxicity. This marked inflammatory response is followed by maladaptive ventricular 
remodeling. 
Mediators involved in the resolution of the inflamed myocardium initiate a maladaptive 
ventricular remodeling response including scar tissue formation, structural changes to 
cardiomyocytes, and cardiac dysfunction (6). Fibrosis is initiated following the early 
inflammatory phase of AMI when circulating and resident fibroblasts infiltrate the myocardium 
in the infarct zone (Figure 1.2). In tandem, these fibroblasts undergo rapid proliferation 
(mediated by FGF-2) followed by activation into myofibroblasts (a process largely mediated by 
transforming growth factor TGF-β). Subsequently, activated myofibroblasts, distinguished from 
their quiescent precursors via the expression of TGF-β/Smad3 pathway-induced α-smooth 
 113 
muscle actin SMA, function to produce extracellular matrix ECM proteins that ultimately cause 
scar formation (7). The ECM proteins including the structural proteins collagens, glycoproteins, 
proteoglycans, glycosaminoglycans, and matricellular proteins are induced post-AMI 
contributing to dynamic changes in ECM structure. The ECM proteins also include proteases that 
are involved in the degradation of these structural components, further contributing to dynamic 
changes post-AMI. In addition to myofibroblasts which are the most abundant source of ECM 
proteins post-AMI, endothelial cells, neutrophils, mast cells, lymphocytes, and macrophages are 
other major sources of ECM proteins. Collagens are considered the structural backbones of the 
ECM and are present at low levels in the normal, non-infarcted heart. Post-AMI, collagen 
expression increases in all regions of the heart, with the greatest magnitude of expression in the 
infarct zone (8). Only myofibroblasts synthesize collagen. LOX mediates the maturation of scar 
tissue by cross-linking collagen fibrils. Following this process, myofibroblasts halt production of 
further profibrotic mediators and become less abundant in the myocardium, potentially through 
apoptosis (7).  
The development of fibrosis is often accompanied by activation of the fetal gene 
program, which results in the dysregulation of a set of genes associated with maladaptive 
ventricular remodeling. Increased BNP expression and a “switch” from expression of the adult α-
myosin heavy chain MHC to the fetal β-MHC are biomarkers of this process (9). BNP promotes 
compensatory vasodilator and natriuretic responses that indicate that myocardial strain (i.e. an 
abnormal structural change) is occurring (10). Fetal gene activation begins early and is thought 
to be promoted at least partially by initial mechanical stretch-induced activation of EGR-1 (11). 
It is evident that the induction of these mediators during the acute phase following IR activates 
responses that promote ventricular remodeling during the early chronic and late chronic stages. 
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Established and emerging biomarkers of these ventricular remodeling processes have been found 
to have prognostic and therapeutic utility in patients (10). 
The extracellular matrix governs not only the structure of the heart, but also the 
connections between heart muscle bundles that regulate the ability of the heart to contract (12). 
Thus fibrosis development can cause abnormalities in cardiac function. In addition to the 
aforementioned molecular changes, the neurohormonal system including the renin–angiotensin–
aldosterone system (RAAS) and the sympathetic nervous system is activated. These systems 
cause vasoconstriction and increased cardiac output in order to compensate further for the loss of 
cardiomyocytes from the IR injury (12). When overcompensation occurs, these processes in 
tandem with advanced structural changes including severe wall thinning progresses to systolic 
and/or diastolic dysfunction ultimately leading to the first signs and symptoms of heart failure 
(6). Importantly, progression can occur quickly (13) and clinical trial data shows that the 
development of heart failure in AMI patients with no previous history of AMI or heart failure 
can occur within a week (14). Indeed, early treatment post-AMI has been found to reduce the 
occurrence of heart failure (15, 16), likely due to attenuation of the early maladaptive ventricular 
remodeling response. It is clear that early and aggressive therapy well before the manifestation of 
symptomatic heart failure improves outcomes. 
For decades, the cornerstone therapies for AMI have consisted of antiplatelet agents, beta 
blockers, statins, and renin-angiotensin aldosterone system inhibitors post-AMI (17-19). 
Considering the aforementioned projections of heart failure, novel therapeutic strategies are 
necessary to attenuate this rising burden. Preclinical models of post-AMI myocardial remodeling 
are critical tools to screen/develop novel therapeutic strategies (20). 
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Induction of AMI in rodents in vivo is feasible and produces injury comparable to the 
more established large animal models of AMI. Mice in particular are more amenable to genetic 
manipulation compared to other rodents, enabling the evaluation of key biological pathways that 
mediate AMI evoked maladaptive cardiac remodeling and the development of heart failure and 
discovery of new therapeutic targets (21, 22). The LAD coronary artery is the artery most 
commonly manipulated in these models compared to other regions of the coronary anatomy (23). 
Clinically, it also usually supplies the largest amount of blood to the myocardium among the 
three major non-left main epicardial branches (24). Surgical ligation is the most common 
technique to evoke myocardial IR (25). Multiple mouse models of LAD coronary artery ligation 
each offer specific advantages depending on the objective of the experiment. Permanent 
occlusion (PO) of the LAD induces a great degree of damage which improves the ability to 
measure the impact of protective interventions. The in vivo model of myocardial IR is a more 
clinically relevant approach to understanding the pathophysiology of AMI; unlike PO, AMI 
patient undergo reperfusion procedures through coronary artery revascularization. Furthermore, 
it allows for the study of maladaptive ventricular remodeling without causing the overt dilated 
cardiomyopathy phenotype that permanent ligation causes (23). Thus, mouse myocardial IR can 
be considered a model of early ventricular remodeling before the onset of symptomatic heart 
failure. Moreover, since experimental transient myocardial ischemia produces injury of less 
magnitude than permanent ischemia, this approach may be better suited for experimental 
interventions hypothesized to enhance myocardial injury and/or remodeling. Surprisingly, the 
acute and chronic impact of this model on parameters of ventricular remodeling has not been 
fully characterized in the literature and requires further investigation. A more thorough 
understanding of the pathophysiology of myocardial remodeling following IR in mice will 
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facilitate the design of experimental studies that elucidate the role of therapeutic pathways in the 
disease. As an initial means to design a future mouse study characterizing the role of the EET 
metabolic pathway in post-IR ventricular remodeling, the objective of the present study was to 
systematically characterize a time course of the molecular, structural, functional, and histological 
alterations that occur in the mouse myocardium in vivo at time points widely considered to be 
acute (<1 week) and chronic (1-3 weeks) following IR (26, 27).  
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Materials and Methods 
 
Mice 
All mice used to complete these experiments were adult, male, and wild-type on a 
C57BL/6 background. Mice were acquired from Taconic Laboratories (Hudson, NY), from 
Charles River Laboratories (Wilmington, MA), or the NIEHS/NIH (Research Triangle Park, 
NC). Mice derived from the NIEHS/NIH were kindly provided by Dr. Darryl Zeldin. Mice were 
2-5 months of age at the time of ligation. All mice had free access to food and water, and were 
housed in controlled conditions for temperature and humidity using a 12-h light/dark cycle. All 
experiments were completed in accordance with the US National Institutes of Health (NIH) 
Guide for the Care and Use of Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill and the 
National Institute of Environmental Health Sciences. 
 
Myocardial IR injury model 
The LAD coronary artery ligation model was utilized to evaluate the impact of 
myocardial IR on myocardial injury, inflammatory responses, myocardial fibrosis, and cardiac 
function. Surgeries were conducted by the UNC McAllister Heart Institute Mouse 
Cardiovascular Models Core laboratory under the direction of Dr. Mauricio Rojas. 
Briefly, the mice were anesthetized with pentobarbital (45 mg/kg). Under direct 
visualization of the trachea, an endotracheal tube was inserted and connected to a Harvard rodent 
volume-cycle ventilator. The chest cavity was opened by a 0.5 cm incision of the left third 
intercostal space, the pericardial sac was opened, and the LAD artery was visualized. Ligation 
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was performed with an 8-0 silk suture passed with a tapered needle underneath the LAD artery 
about 1 mm lower than the tip of the left auricle. The artery was compressed by tightening the 
ligature, producing myocardial blanching and electrocardiographic S-T segment elevation 
(indicative of ischemia). After occlusion of the desired time (30 minutes), blood flow was 
restored by removing the ligature to produce an IR response similar to that produced in humans 
undergoing a revascularization procedure. Lidocaine (6 mg/kg) was administered as needed to 
prevent lethal ventricular arrhythmias and atropine (0.04-0.1 mg/kg) was administered as 
necessary to combat bradycardia. The chest wall was then closed with a prolene or silk suture. 
Sham surgery mice (control) underwent an identical procedure except there was no tightening of 
ligature and therefore no IR.  A subset of mice also underwent an identical procedure except the 
ligature was not removed to determine the impact of permanent LAD occlusion. Post-
operatively, each mouse was kept on rodent warming pads until they regained consciousness, 
after which they are housed in their respective cages and observed until they have recovered to 
normal activity. Mice were euthanized by CO2 or isoflurane inhalation at short-term (2 hours, 24 
hours) or long term (2 weeks) time points following IR. Blood was collected through the inferior 
vena cava, and plasma was separated by centrifugation, aliquoted and stored at -80°C. Whole 
hearts were extracted, blotted dry, and, weighed. Hearts that were reserved for histological 
analysis were fixed in 4% paraformaldehyde (24-48 hours). A subset of hearts was flash frozen 
in liquid nitrogen and stored at -80°C for subsequent molecular phenotyping after being 
dissected into LV, right ventricle, and atria upon extraction. 
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Quantitative real-time PCR 
RNA was isolated from frozen LV and right ventricle tissue using the RNeasy Mini Kit 
(Qiagen, Valencia, CA) and reverse transcribed to complementary (cDNA) using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). 
Quantitative real-time PCR (qPCR) analysis was performed in triplicate using the 7300 Real-
Time PCR system (Applied Biosystems), as described (28). Expression of myocardial α-MHC 
(Myh6), β-MHC (Myh7), Bax (Bax), Bcl-2 (Bcl2), BNP (Nppb), EGR-1 (Egr1), ICAM-1 
(Icam1), IL-6 (Il6), LOX (Lox), MCP-1 (Mcp1), MIP-2α (Cxcl2), and TGF-β (Tgfb) mRNA 
levels were quantified using Taqman Assays on Demand (Applied Biosystems). Data was 
normalized to Gapdh (endogenous reference) and expressed relative to a designated 
experimental control group using the 2-ΔΔCt method (29). Only mouse hearts from experiments 
(sham and IR procedure) evaluating the impact of IR underwent analysis form gene expression at 
acute time points. Mouse hearts from experiments evaluating the impact of PO were not 
analyzed for gene expression at acute time points. 
 
Myocardial necrosis 
Twenty-four hour plasma cardiac troponin levels were measured by ELISA (Life 
Diagnostics, West Chester, PA), according to the manufacturer instructions, as a biomarker of 
cardiomyocyte necrosis and an early index of infarct size (30). 
 
Cardiac structure and function 
Echocardiography on conscious mice was performed over the course of 2 weeks 
(baseline, 24 hours, 72 hours, 1 week, 2 weeks) following IR using a Vevo 2100 Imaging System 
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(VisualSonics, Toronto, ON). M-mode images were traced to measure direct parameters of 
cardiac structure at diastole and systole of the cardiac cycle during all 5 of the aforementioned 
time points. Direct parameters of structure from M-mode images included ventricle wall 
thickness and chamber size. Wall thickness parameters were inter ventricular septum at systole 
(IVSs), inter ventricular septum at diastole (IVSd), left ventricular posterior wall at systole 
(LVPWs), and left ventricular posterior wall at diastole (LVPWd). Chamber size parameters 
were left ventricular internal diameter at systole (LVIDs) and left ventricular internal diameter at 
diastole (LVIDd). The calculated parameters of structure (LV Mass) and systolic function 
(fractional shortening [FS], EF) were derived from the direct parameters of structure as well as 
from LV volume at systole (Vols) and LV volume at diastole (Vold) as follows: 
EF (%) = 100 * ((LV Vold – LV Vols) / LV Vold) 
LV Vold (µL) = ((7.0 / (2.4 + LVIDd)) * LVIDd3) 
LV Vols (µL) = ((7.0 / (2.4 + LVIDs)) * LVIDs3) 
FS (%) = 100 * ((LVIDd – LVIDs) / LVIDd) 
LV Mass (corrected) (mg) = 0.8424 * ((LVIDd + LVPWd + IVSd)3 – LVIDd3) 
Pulsed wave Doppler on mitral valve images were traced to measure direct parameters of 
diastolic function and systolic function at baseline and 2 weeks following IR. Direct parameters 
of diastolic function from Doppler images included early (E)-peak velocity, atrial (A)-peak 
velocity, isovolumic relaxation time (IVRT), deceleration rate (Dr), and deceleration time (Dt). 
Direct parameters of systolic function included isovolumic contraction time (IVCT) and aortic 
ejection time (AET). Each calculated parameter of diastolic dysfunction (E/A ratio) and global 
function (myocardial performance index [MPI]) was derived from direct parameters of diastolic 
dysfunction and systolic function as follows: 
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E/A ratio = E-peak velocity / A-peak velocity 
MPI (ratio) = (IVRT + IVCT) / AET 
At each time point for each mouse, all direct echocardiography parameters were averaged 
across a series of ≥3 sets of ≥3 consecutive beats. Heart weight/tibial length ratio at 2 weeks was 
measured as a secondary parameter of non-echocardiography cardiac structure. 
 
Histology 
Fixed hearts were embedded in paraffin, and cut into 5μm transverse sections to measure 
evidence of fibrosis. Specifically, serial interrupted sectioning was performed to the hearts. 
Starting from the apex, the most inferior distance where sections were collected occurred where 
both the left and right ventricle could be visualized. A series of sections (4-6) were collected at 
this distance. The next series of sections were collected at a distance 200 microns superior to the 
previous distance. This was repeated for several distances to cover a large portion of the heart 
where injury was anticipated to occur. For hearts of mice undergoing IR, sections from 8 
distances (spanning 1800 microns from the most inferior distance) were collected per sample 
(note: only 4 distances were collected from an IR experiment described later where sections were 
stained with both Masson’s Trichrome and Picrosirius Red stain). Sections from 5 distances 
(spanning 1000 microns) were collected per sample for hearts of mice undergoing permanent 
ischemia. For each sample, a slide contained a section from each distance where sections were 
collected. The result was that each slide contained serial sections with each section representing 
a specific distance from the apex of the heart. Our group believed that this technique was 
advantageous over the traditional approach of analyzing an isolated section from each sample. 
Furthermore, each heart sample had multiple slides which allowed for multiple stains to be done 
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at each specific distance from the heart’s apex. Embedding and processing of samples were 
completed in the Cell Services & Histology Core within the UNC Center for Gastrointestinal 
Biology and Disease. Sectioning and staining by was done in the Histology Research Core 
within the Department of Cell Biology and Physiology under the direction of Kirk McNaughton. 
Sections were stained with Picrosirius Red (collagen) or Masson’s Trichrome (connective 
tissue including collagen and proteoglycans) for image analysis. 
All images were digitally scanned with the ScanScope CS System (Aperio Technologies, 
Vista, CA). From the digital scans, one 1x zoom image was taken per section of each sample, 
which allowed for the coverage of the entire heart cross-section. The area of fibrosis was 
measured with NIH ImageJ (31). Specifically, two sets of color thresholding minimums and 
maximums for red, green, and blue colors were generated to capture the area of the stain and the 
area of the total ventricle cross-section. These thresholding ranges were generated from three 
randomly-selected representative images. The same ranges for stain and total cross-section were 
applied to all sections used in the study without regards to treatment groups to minimize observer 
bias. The surface area of staining was normalized to the surface area of total myocardial tissue 
for each section. The resulting % stained value averaged over the total amount of serial sections 
used for each sample (sections from 4-8 distances) generated a single value per mouse that 
reflected the average staining throughout the infarcted region. All quantification was averaged 
over multiple sections per heart sample using NIH ImageJ. 
 
Statistical analysis 
Data are expressed as mean± standard error of the mean (SEM) unless stated otherwise. 
All analyses were conducted on log-transformed data. Gene expression and troponin data were 
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compared across experimental groups with Student’s t-test at every given time point. For M-
mode-derived echocardiography analysis in mice from IR experiments, data from 3 different 
experiments that used different time points were merged together for graphical purposes but 
were analyzed as 3 separate data sets statistically to compare parameters between experimental 
groups. Echocardiography data at 1 and 3 days were each analyzed with ANCOVA with baseline 
as a covariate followed by Fisher’s LSD post hoc tests (if overall ANCOVA was significant). 
Echocardiography data at 7 and 14 days were from the same experiment and analyzed together 
using repeated measures ANOVA with baseline as a covariate followed by Fisher’s LSD post 
hoc tests (if overall repeated measures ANOVA was significant). For Pulse Wave Doppler-
derived echocardiography analysis, data were compared across experimental groups using 
ANCOVA at 2 weeks with baseline as a covariate followed by Fisher’s LSD post hoc tests (if 
overall ANCOVA was significant). For M-mode-derived echocardiography analysis in mice 
from PO experiments, data at 7 and 14 days were from the same experiment and analyzed 
together across experimental groups together using repeated measures ANOVA with baseline 
values as a covariate followed by Fisher’s LSD post hoc tests (if overall ANCOVA was 
significant). For histology data analyzed across two experimental groups, comparisons were 
performed with Student’s t-test at 2 weeks. For histology data comparing staining methods, 
linear regression analysis was conducted and Pearson's correlation coefficient was calculated. 
P<0.05 was considered to be statistically significant. Statistical analyses were performed using 
SAS 9.2 (SAS Institute, Cary, NC).  
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Results 
 
Acute biomarkers of myocardial injury, inflammation, and remodeling following ischemia 
reperfusion 
Myocardial ischemia for 30 minutes significantly increased biomarkers of cardiomyocyte 
necrosis and apoptosis compared to sham treatment. In particular, IR increased plasma troponin 
levels after 2 and 24 hours of reperfusion (Figure 4.1a) and myocardial Bax:Bcl-2 ratio mRNA 
levels at 24 hours of reperfusion compared to sham-treated mice (Figure 4.1b). Similarly, IR 
increased myocardial inflammatory gene expression compared to sham-treated mice at 2 hours, 
24 hours, or 2 and 24 hours of reperfusion (Figure 4.2). LV Il6 expression was significantly 
increased by IR at 2 and 24 hours following IR (Figure 4.2a). Right ventricle Il6 expression was 
significantly increased in IR-treated mice at 24 hours following IR (Figure 4.2b). Importantly, 
the magnitude of induction in the right ventricle was less pronounced than in the LV. Expression 
of subsequent markers is only reported in the LV. LV Mcp1 expression was significantly greater 
in IR-treated hearts compared to sham at 2 hours following IR (Figure 4.2c), demonstrating IR-
induced upregulation of monocyte expression. Expression of Cxcl2 in the LV was significantly 
increased by IR at 2 and 24 hours following IR (Figure 4.2d). Expression of Icam1 in the LV was 
greater in IR-treated hearts compared to sham-treated hearts at 2 hours following IR (Figure 
4.2e). 
IR also increased the myocardial mRNA levels of a majority of the markers associated 
with ventricular remodeling at acute time points following initial injury (Figure 4.3). IR 
induction of Egr1 expression was significantly pronounced 2 hours following IR (Figure 4.3a). 
Expression of LV Tgfb was not significantly increased by IR injury at 2 hours (P=0.68) or 24 
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hours (P=0.25) of reperfusion (Figure 4.3b). However, Lox expression was significantly 
increased at 2 and 24 hours of reperfusion in IR-treated mice compared to sham-treated mice 
(Figure 4.3c). Expression of LV Myh7:Myh6 was significantly increased by IR at 24 hours 
following IR injury (Figure 4.3d). LV atrial natriuretic factor (ANF) expression was not 
significantly induced by IR at 2 hours (P=0.91) or 24 hours (P=0.22) of reperfusion (Figure 
4.3e). In contrast, BNP gene expression in the LV was significantly greater in IR-treated mouse 
hearts compared to sham-treated hearts at 2 hours following IR (Figure 4.3f). BNP expression 
was not statistically significant at 24 hours following IR (P=0.14). 
 
Systolic function 
IR did not significantly alter EF over time compared to sham treatment (Analysis A [1 
day] P=0.070, Analysis B [3 days] P=0.202, Analysis C [7 and 14 days] P=0.460; Figure 4.4a). 
Likewise, IR did not significantly alter FS over time compared to sham treatment (Analysis A [1 
day] P=0.113, Analysis B [3 days] P=0.172, Analysis C [7 and 14 days] P=0.539; Figure 4.4b). 
EF and FS were lower in IR-treated mice compared to sham-treated mice at 2 weeks; however, 
the difference was not statistically significant and should be interpreted with caution (EF: overall 
repeated measures ANOVA P=0.460, Fisher’s post-hoc P=0.048; FS: overall repeated measures 
ANOVA P=0.539, Fisher’s post-hoc P=0.054). 
Similar results were seen with Pulse Wave Doppler image-derived parameters of systolic 
function Table 4.1). IVCT was not impacted by IR-treatment compared to sham treatment at 2 
weeks (P=0.41). AET was not affected by IR compared to sham (P=0.14). 
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Diastolic function 
Diastolic dysfunction indicated by a reduction in E/A ratio, was unchanged between 
sham and IR at 2 weeks following IR (P=0.678; Figure 4.5a). Likewise, IVRT was not affected 
by IR treatment compared to sham treatment at 2 weeks of reperfusion (P=0.951; Figure 4.5b). 
This was confirmed in all other parameters of diastolic dysfunction (P>0.05 for all parameters, 
Analyses A-C Table 4.1). 
 
Cardiac structure 
Mean echocardiography-derived parameters of cardiac structure over 2 weeks for sham 
and IR mice are summarized in Table 4.2. IR did not significantly alter any of these indices over 
time compared to sham treatment (P>0.05 for all parameters in Analyses A-C). Likewise, there 
was no difference in heart weight/tibial length between IR and sham (5.82 ± 0.35 versus 6.18 ± 
0.24 mg/mm, respectively, P=0.486). 
 
Myocardial fibrosis 
Given the early induction of LOX in myocardial tissue acutely following IR, heart 
sections were stained for evidence of collagen deposition. Histological stains of collagen were 
examined using two different staining approaches. Collagen deposition as measured by 
Picrosirius Red was significantly correlated with connective tissue deposition from Masson’s 
trichrome staining (Figure 4.6) at 2 weeks following IR. Following the confirmation of a 
correlation between the stains, further analysis was conducted with Picrosirius Red stained slides 
only since thresholding was more time-efficient thresholding compared to Masson’s Trichrome 
(2-color stain vs 3-color stain). An independent experiment was conducted to determine the 
 127 
impact of IR on collagen deposition. Although sham-treated hearts did show evidence of 
collagen at 2 weeks, induction of collagen was significantly increased in the IR-treated mice 
(Figure 4.7a-b) with a mean % collagen deposition of 3.43 ± 0.64%. 
 
Impact of permanent occlusion 
A subset of mice were subjected to permanent LAD ligation surgery (2 weeks of 
ischemia) for comparison with the above results in IR-treated mice as a means to further 
characterize the impact of IR on ventricular remodeling. PO did not significantly alter LVIDs 
(Figure 4.8a) or EF (Figure 4.8b). In particular, at 1 and 2 weeks following PO, LVIDs was non-
significantly increased by 1.93-fold and 2.07-fold induction, respectively, by PO compared to 
sham. EF in PO-treated mice was 0.62-fold and 0.59-fold the value of sham-treated mice at 1 and 
2 weeks, respectively. Similar results were observed with other parameters of cardiac structure 
that showed a lack of effect (LVIDd: Repeated measures ANOVA P=0.096) and function (FS: 
Repeated measures ANOVA P=0.510). In contrast, PO enhanced fibrosis extensively with a 
mean % connective tissue deposition of 29.07 ± 4.93% (Figure 4.8c-d). Myocardial structural 
changes (including ventricular wall thinning) were qualitatively evident in the majority of heart 
from mice that underwent permanent ischemia (Figure 4.8c), but not appreciable following IR 
(Figure 4.7b).  
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Discussion 
 
Preclinical models of post-AMI myocardial remodeling are critical tools that aid in the 
discovery and development of novel therapeutic strategies (20), but they can only facilitate 
translation of novel strategies if they truly mimic the pathophysiology of AMI in humans. There 
are few reports in the literature fully dedicated to the characterization of pathological responses 
in mice following myocardial IR. Consequently, using molecular, echocardiography, and 
histological approaches, we determined that a 30-minute mouse model of myocardial ischemia 
followed by reperfusion caused time-dependent responses associated with ventricular 
remodeling. In particular, IR induced myocardial cell death and inflammation acutely following 
ischemia and generated substantial fibrosis at an early chronic time point, but did not cause 
significant changes in myocardial structure or function. 
The acute myocardial cell death and inflammatory response in the current study peaked at 
2 hours and dropped by 24 hours, though the drop was not to the level of sham-treated mice; this 
demonstrates the transient but marked acute response that occurs in the myocardium following 
IR. These effects were most pronounced in the left ventricule. Importantly, they were also 
present in the right ventricle (to a lesser degree), despite the fact that the LAD does not supply 
the right ventricle. These acute myocardial necrotic and inflammatory responses mirror what has 
been shown by others. It has been previously shown that IR in mice causes acute increases in 
troponin levels that are low in sham-operated mice (32). An investigation of the time course of 
myocardial inflammatory gene expression showed that IR induced IL-6 expression markedly at 3 
hours of reperfusion. This increase in cytokine expression had largely dissipated after 24 hours 
of reperfusion, but levels remained significantly elevated compared to sham (33). 
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Fibrosis is a key component of ventricular remodeling and biomarkers of fibrosis are 
independent predictors of poor prognosis in patients with ventricular remodeling on top of 
established risk factors (34, 35). In the current study, myocardial fibrosis formation was the most 
altered phenotype during the early chronic phase following IR. IR promoted the deposition of 
collagen into the myocardial tissue. This finding was supported by the foreboding induction of 
myocardial LOX gene expression, a key mediator of collagen maturation, during the acute phase 
following IR. The induction of left ventricular TGF-β expression by IR was not statistically 
significant; however, evidence exists that this important fibrosis mediator may reach its peak at 
72 hours following IR in C57BL/6 mice (36). Furthermore, a greater than 2-fold change at 24 
hours suggests that this lack of a statistically significant difference was due, at least partially, to 
low power (n=3, coefficient of variation at 24 hours in IR-treated mice=52.11%). Moreover, 
Gapdh may not be the most stable housekeeping gene in the AMI model and may have increased 
variability within experimental groups (37). Thus further exploration including validation with a 
larger n, follow-up with myocardial protein expression analysis, the inclusion of an additional 
‘subacute’ time point (3 days following IR), and confirmation with a second housekeeping gene 
is necessary to address limitations with the evaluation of mRNA expression data in this study. 
In contrast to induction of myocardial fibrosis, IR did not produce significant changes in 
cardiac structure demonstrating that there was no evidence of ventricular wall thinning or 
hypertrophy. Furthermore, IR did not produce significant changes in either systolic or diastolic 
function during the acute (24 hours), subacute (3 days) and early chronic (7, 14 days) time 
points. This discrepancy between the induction of myocardial fibrosis and structural/functional 
changes was unexpected. One possible explanation for this finding is that changes in cardiac 
function actually occurred, but echocardiography was not sensitive enough to pick up these 
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changes. The use of alternate tools that may be more sensitive in detecting cardiac function 
changes (i.e., catheter-based invasive analyses (38)) would provide more insight as to whether 
technical difficulties contributed to the lack of association between fibrosis and cardiac 
dysfunction. Another plausible explanation for these findings is that perhaps the fibrosis changes 
truly did not correlate with cardiac function. Indeed, these findings agree with clinical data 
showing that fibrosis does not correlate with ejection fraction. In heart failure participants from 
the Cardiovascular Health Study, circulating BNP levels, but not markers of collagen deposition 
discriminated heart failure patients with preserved ejection fraction from those with reduced 
ejection fraction even after adjustment for covariates (39). This is further corroborated in another 
clinical study in which no association was found between a marker of collagen deposition and 
either structural or functional cardiac dysfunction (40). In line with this explanation, it is possible 
that enhanced fibrosis compensated for and thus masked any worsening of IR-induced systolic 
dysfunction by replacing dead myocardial cells and preserving the structural integrity of the 
ventricle. This is supported by our data which shows an early increase in expression of fetal gene 
activation mediators, demonstrating that mediators of cardiac dysfunction had been, at least 
transiently, activated. Furthermore, we do not differentiate between adaptive and maladaptive 
fibrosis which would provide insight as to if the increased fibrosis compensated for changes in 
dysfunction. However, few studies investigating fibrosis address this issue because techniques 
that delineate protective and harmful fibrosis have not been developed (41). This is an important 
future area of investigation because novel therapies that attenuate adaptive fibrosis would be 
deleterious. New approaches are needed to better discriminate between adaptive and maladaptive 
fibrosis as well as the relationship between these processes and cardiac function/structure in this 
mouse model of AMI. 
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Any subtle differences in systolic function that did occur were observed at the earliest (24 
hours) and latest (2 weeks) measured time points following IR. This biphasic pattern of 
dysfunction likely derives from two independent sources of tissue damage with the initial hit 
being related to infarct size and the second drop occurring in latter stages when fleeting attempts 
to recover from the acute injury causes overcompensating, maladaptive ventricular remodeling. 
Considering the lack of a statistical significance in cardiac dysfunction at these two time points, 
these data must be interpreted with major caution. However, this postulation is supported by 
clinical evidence that recovery of initial systolic dysfunction is a common clinical occurrence 
(42). Furthermore, evidence exists in C57BL/6 mice that the most pronounced drop in EF may 
occur at about 7 weeks of reperfusion following IR (43), shining light on the possibility of a 
triphasic pattern of systolic dysfunction in this strain of mice. Moreover, structural changes 
related to dilated cardiomyopathy (increased end diastolic volume and reduced ventricular wall 
thickness) have been found to peak after 7 weeks of reperfusion following IR (43). A future 
investigation evaluating the impact of 30-minute myocardial IR in mice on cardiac structure and 
function at prolonged reperfusion time points is warranted (late chronic phase: >7 weeks post-
IR). 
Thus, the in vivo mouse model of 30-minute ischemia followed by 2 weeks of reperfusion 
is best suited for investigating the impact of intervention on inflammatory and fibrotic responses 
independent of cardiac structure or function. On the other hand, we found that an in vivo mouse 
model of permanent LAD coronary artery ligation for 2 weeks caused gross histological 
evidence of ventricular dilation, myocardial wall thinning, and myocardial fibrosis.  This agrees 
with previous data showing structural changes as early as 1 week following surgery (23). 
Furthermore, an acute inflammatory response is blunted in the permanent ischemia model (23, 
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33), which precludes the investigation of acute inflammatory response with that model. PO did 
not significantly alter systolic and diastolic function at 2 weeks of ischemia. Considering the 
large absolute decline in EF (0.59 fold at 2 weeks) and increase in LVIDs (2.07-fold at 2 weeks) 
which are indicative of reduced systolic function and dilated cardiomyopathy, respectively, as 
well as the aforementioned PO-induced histological alterations of ventricular remodeling, 
statistical power may have played a role, at least partially, in the non-significant findings 
(coefficient of variation in EF at 2 weeks in IR-treated mice=61.40%). Although conscious 
echocardiography measurements offer the advantage of deriving physiological parameters, they 
also may increase variability due to varying levels of excitement and sympathetic activation from 
being manipulated (25); this may potentially reduce power. This hypothesis needs confirmation 
in future studies with a larger sample size or with echocardiography using anesthetized mice. 
There are limitations in this study. The reproducibility of the extent of injury varies since 
placement of the ligature influences the size of the infarct. Sources of this problem include the 
small size of the mouse heart and variation in coronary branching pattern even among inbred 
mice, but technology to improve the consistency of mouse infarcts within experiments are 
improving (32). Moreover, results may not translate to humans for a variety of reasons. Firstly, 
this model of IR does not entirely replicate revascularization following an AMI in humans 
because our mice do not have underlying atherosclerotic cardiovascular disease at the time of 
surgery. Efforts have begun to utilize mice with comorbid conditions in models of AMI (44). 
Secondly, suture ligation does not mimic the etiology of AMI, which most commonly involves 
the disruption and occlusion of an atheromatous plaque in the coronary artery. Preclinical models 
of thrombosis-induced AMI are in the infancy phases in large animals and rodents and are not 
yet routinely used as established methods (45, 46). Thirdly, results are only from C57BL/6 mice, 
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though myocardial IR injury in mice varies by strain (43, 47). The Collaborative Cross is a large 
panel of novel inbred mouse strains that simulate genetic diversity in humans (48). Application 
of this tool to AMI is a potential avenue for further investigation that could increase the 
generalizability of results. Altogether, scarce data exist in the literature that utilize IR models 
more closely resembling AMI in clinical practice, thus these are issues that have not been 
adequately addressed by the scientific community and warrant further investigation. 
In conclusion, the present study demonstrates that myocardial IR injury induces 
myocardial cell death, inflammation, and collagen deposition. As a whole, these results provide a 
better understanding of the pathology that occurs after AMI and facilitate the design and 
interpretation of future studies that investigate the role of pathways as novel therapeutic targets 
in mouse models of AMI. For our research group, these findings lay the foundation for the 
evaluation of the contribution of cardiomyocyte sEH to maladaptive ventricular remodeling in 
mice post-AMI in vivo.  
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Figures 
 
 
 
Figure 4.1 Impact of myocardial ischemia reperfusion (IR) on myocardial cell death. Time 
course of myocardial IR-induced (a) necrosis and (b) apoptosis. Reference group for relative 
mRNA levels: sham levels at 24 hours. Sham: n = 3-5 per group. IR: n = 4-8 per group. * P < 
0.05 for sham vs IR at each time point. Bax, bcl-2-like protein 4; Bcl-2, B-cell lymphoma 2. 
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Figure 4.2 Impact of myocardial ischemia reperfusion (IR) on acute inflammatory 
responses. Time course of myocardial IR-induced (a-b) cytokine, (c-d) chemokine, and (e) 
cellular adhesion molecule expression in the left ventricle (LV) or right ventricle. Reference 
group for relative mRNA levels: sham levels at 24 hours. Sham: n = 3 per group. IR: n = 4-5 per 
group. * P < 0.05 for sham vs IR at each time point. ICAM-1, intercellular adhesion molecule 1; 
IL-6, interleukin 6; MCP-1, monocyte chemoattractant protein-1; MIP-2α, macrophage 
inflammatory protein 2-alpha.  
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Figure 4.3 Impact of myocardial ischemia reperfusion (IR) on early maladaptive 
ventricular remodeling. Time course of myocardial IR-induced (a) early response, (b-c) 
fibrosis, and (d-f) fetal gene activation expression. Reference group for relative mRNA levels: 
sham levels at 24 hours. Sham: n = 3 per group. IR: n = 3-5 per group. * P < 0.05 for sham vs IR 
at each time point. ANF, atrial natriuretic factor; BNP, brain natriuretic peptide; EGR-1, early 
growth response protein 1; LOX, lysyl oxidase; MHC, myosin heavy chain; TGF-β, transforming 
growth factor beta  
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Figure 4.4 Impact of myocardial ischemia reperfusion (IR) on systolic function. Time course 
of myocardial IR-induced changes on (a) ejection fraction (EF) and (b) fractional shortening 
(FS). Combined mean±SEM from 3 experiments are displayed. Experiment 1 measured 
parameters at baseline, 7 days, and 14 days: N = 6-7 per group. Experiment 2 measured 
parameters at baseline, 1 day, and 3 days: N = 2-7 per group. Experiment 3 measured parameters 
at baseline and 1 day: N = 7-12 per group. Total: n = 2-26 per time-group (n=2 in sham group at 
3 days only). Due to sample size differences and experiment differences for each time point, 
analyses were conduct as 3 individual data sets. Analysis A involved ‘1 day’ data corrected for 
baseline using ANCOVA. Analysis B involved ‘3 days’ data corrected for baseline using 
ANCOVA. Analysis C involved ‘7 days’ and ‘14 days’ data corrected for baseline using 
repeated measures ANOVA.  
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Figure 4.5 Impact of myocardial ischemia reperfusion (IR) on diastolic function. 
Myocardial IR-induced changes on (a) E-peak velocity / A-peak velocity (E/A) ratio and (b) 
isovolumic relaxation time (IVRT) at 2 weeks following IR. n = 7-9 per group. P > 0.05 for 
sham vs IR at 2 weeks corrected for baseline  
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Figure 4.6 Correlation between staining methods of fibrosis. (a) Representative images and 
(b) correlation of Picrosirius Red- and Masson’s Trichrome-blue stained heart sections (averaged 
from 4 distances of the heart) at 2 weeks following ischemia reperfusion (IR). n = 27. 
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Figure 4.7 Impact of myocardial ischemia reperfusion (IR) on fibrosis. (a) Representative 1X 
images between groups as well as a zoomed 20X image detailing pattern the of collagen 
deposition in an IR-treated mouse and (b) quantification of collagen deposition from Picrosirius 
Red-stained heart sections (averaged from 8 distances of the heart) at 2 weeks following IR. 
Each set of images has a different scale. Sham: n = 6. IR: n = 8. * P < 0.05  
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Figure 4.8 Impact of myocardial permanent occlusion (PO) on maladaptive ventricular 
remodeling. Impact of permanent ischemia on (a) left ventricular internal diameter (LVID) and 
(b) ejection fraction (EF) as well as (c) representative images and (d) quantification of collagen 
deposition from Picrosirius Red-stained heart sections (averaged from 5 distances of the heart) at 
2 weeks of PO. Sham: n = 5. IR: n = 8. * P < 0.05.  
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Tables 
 
Table 4.1 Impact of myocardial ischemia reperfusion (IR) on mitral pulse Doppler parameters of cardiac 
dysfunction 
 
Parameters  Baseline  2 weeks  P 
Isovolumic contraction time (IVCT), ms 
 sham  11.0 ± 0.9  16.1 ± 2.0  0.421 
 IR  12.2 ± 1.0  13.3 ± 1.5 
Aortic ejection time (AET), ms 
 sham  29.8 ± 2.0  34.1 ± 1.2  0.326 
 IR  28.4 ± 1.8  36.7 ± 1.6 
Early-peak velocity (E), mm/s 
 sham  441.4 ± 39.8  579.9 ± 49.9  0.859  
 IR  457.4 ± 36.5  585.5 ± 64.0 
Atrial-peak velocity (A), mm/s 
 sham  341.7 ± 33.2  402.3 ± 44.6  0.961 
 IR  356.8 ± 25.1  397.7 ± 45.5 
E/A, ratio 
 sham  441.4 ± 39.8  579.9 ± 49.9  0.902 
 IR  457.4 ± 36.5  585.5 ± 64.0 
Deceleration (Dt), ms 
 sham  24.2 ± 2.8  21.9 ± 2.1  0.575 
 IR  27.7 ± 2.9  21.5 ±  2.4 
Deceleration (Dr), mm/s2 
 sham  -19.2 ± 2.1  -27.6 ± 3.8  0.906 
 IR  -18.9 ± 3.2  -28.2 ± 5.3 
Isovolumic relaxation time (IVRT), ms 
 sham  16.4 ± 1.0  14.3 ± 1.9  0.877 
 IR  18.5 ± 1.2  14.2 ± 1.7 
Myocardial performance index (MPI), ratio 
 sham  1.0 ± 0.1  0.9 ± 0.1  0.481 
 IR  1.1 ± 0.1  0.8 ± 0.1 
Comparisons at 2 weeks between sham and IR were corrected for baseline levels. N = 7-9 per group. * P < 0.05 for 
sham vs. IR 
  
 
1
4
3
 
Table 4.2 Impact of myocardial ischemia reperfusion (IR) on cardiac structure over time 
 
Parameters  Baseline  1 day   3 days   7 days   14 days 
LVIDs (mm) 
 sham  1.74 ± 0.10  1.94 ± 0.08  2.08 ± 0.17  1.39 ± 0.11  1.20 ± 0.15  
 IR  1.73 ± 0.09  2.07 ± 0.13  2.09 ± 0.05  1.44 ± 0.19  1.53 ± 0.07  
LVIDd (mm) 
 sham  3.06 ± 0.08  3.24 ± 0.10  3.48 ± 0.02  2.67 ± 0.15  2.49 ± 0.17  
 IR  3.09 ± 0.09  3.14 ± 0.10  3.25 ± 0.11  2.63 ± 0.22  2.71 ± 0.12  
IVSs (mm) 
 sham  1.72 ± 0.05  1.68 ± 0.05  1.69 ± 0.16  1.86 ± 0.08  1.88 ± 0.05  
 IR  1.65 ± 0.03  1.48 ± 0.07  1.49 ± 0.08  1.82 ± 0.07  1.86 ± 0.07  
IVSd (mm) 
 sham  1.19 ± 0.03  1.14 ± 0.04  1.08 ± 0.03  1.33 ± 0.04  1.33 ± 0.04  
 IR  1.13 ± 0.03  1.09 ± 0.04  1.10 ± 0.07  1.36 ± 0.08  1.33 ± 0.07  
LVPWs (mm) 
 sham  1.64 ± 0.07  1.57 ± 0.05  1.49 ± 0.11  1.71 ± 0.11  1.83 ± 0.13  
 IR  1.71 ± 0.04  1.51 ± 0.08  1.48 ± 0.03  1.69 ± 0.13  1.66 ± 0.05  
LVPWd (mm) 
 sham  1.09 ± 0.05  1.13 ± 0.05  1.03 ± 0.00  1.21 ± 0.07  1.38 ± 0.16  
 IR  1.07 ± 0.03  1.03 ± 0.04  0.98 ± 0.05  1.25 ± 0.17  1.27 ± 0.06  
Echocardiography-derived LV mass corrected (mg) 
 sham  104.48 ± 4.89  113.33 ± 5.77  111.97 ± 3.85  104.21 ± 8.57  104.01 ± 4.28  
 IR  99.57 ± 3.17  97.23 ± 4.32  99.93 ± 10.36  104.53 ± 6.10  109.82 ± 7.17  
Combined mean±SEM from 3 experiments are displayed. 
Experiment 1 measured parameters at baseline, 7 days, and 14 days: N = 6-7 per group. Experiment 2 measured parameters at baseline, 1 day, and 3 days: N = 2-
7 per group. Experiment 3 measured parameters at baseline and 1 day: N = 7-12 per group. Total: n = 2-26 per time-group (n=2 in sham group at 3 days only). 
Due to sample size differences and experiment differences for each time point, analyses were conducted as 3 individual data sets. Analysis A involved ‘1 day’ 
data corrected for baseline using ANCOVA. Analysis B involved ‘3 days’ data corrected for baseline using ANCOVA. Analysis C involved ‘7 days’ and ‘14 
days’ data corrected for baseline using repeated measures ANOVA. * P < 0.05. 
IVSd, interventricular septum at diastole; IVSs, interventricular septum at systole; LV, left ventricle; LVIDd, left ventricular internal diameter at diastole; LVIDs, 
left ventricular internal diameter at systole; LVPWd, left ventricular posterior wall at diastole; LVPWs, left ventricular posterior wall at systole
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CHAPTER 5 - THE CONTRIBUTION OF CARDIOMYOCYTE SOLUBLE EPOXIDE 
HYDROLASE TO ACUTE MYOCARDIAL INFARCTION-INDUCED MALADAPTIVE 
VENTRICULAR REMODELING IN MICE 
 
Introduction 
 
Following the acute recovery phases of an AMI, the infarcted and inflamed myocardium 
promotes maladaptive ventricular remodeling, a chronic and progressive pathological process 
that manifests as scar tissue formation (fibrosis) and LV dysfunction within the first few weeks 
to months after the index event (1, 2). Progression of these maladaptive processes, and the 
presence of LV fibrosis and dysfunction, markedly increases the risk of worsening systolic 
and/or diastolic function and the development of clinical heart failure, ventricular arrhythmias 
and sudden cardiac death, and overall mortality (3-5). Thus, this chronic maladaptive remodeling 
process is a key driver of worsened prognosis following AMI. The identification of key 
pathways that regulate remodeling following AMI offers enormous potential to facilitate the 
development of novel therapeutic strategies that prevent the development of heart failure and its 
associated morbidity and mortality. 
CYP epoxygenases from the CYP2J and CYP2C subfamilies catalyze the metabolism of 
arachidonic acid into EETs, which have become increasingly recognized to possess potent anti-
inflammatory, vasodilatory, fibrinolytic, anti-apoptotic, pro-angiogenic, and smooth muscle cell 
anti-migratory effects in the cardiovascular system (6). The life of circulating EETs, however, is 
ephemeral as they are quickly hydrolyzed into the less potent DHETs by sEH. 
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Early chronic preclinical models of IR-induced ventricular remodeling (3-4 weeks of 
reperfusion following 45 minutes of ischemia) have recently been utilized to determine the role 
of EETs in maladaptive remodeling following AMI (7, 8). These data have shown that increasing 
EETs via pharmacological sEH inhibition attenuates myocardial fibrosis and systolic function. 
Although inhibition of sEH to promote the effects of EETs has been proposed as a novel 
cardioprotective therapeutic strategy following AMI (6, 9), more rigorous investigation is 
warranted to further define the contribution of sEH and EETs to the pathogenesis and 
progression of ventricular remodeling. In particular, the direct contribution of increased 
myocardial sEH expression to the pathogenesis and progression of maladaptive ventricular 
remodeling post-AMI in vivo has not been studied to date. Consequently, we investigated the 
role of myocardial sEH in maladaptive ventricular remodeling post-IR in vivo using a transgenic 
mouse model with cardiomyocyte-specific overexpression of human sEH driven by the α-myosin 
heavy chain promoter (α-MHC-EPHX2 mice).  
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Materials and Methods 
 
Mice 
All experiments were completed in adult male mice on a C57BL/6N background. 
Transgenic mice that overexpress human EPHX2 in cardiomyocytes under control of the murine 
α-MHC promoter (α-MHC-EPHX2) were developed on a C57BL/6N background (Xenogen, 
now Taconic, Germantown, NY) by the laboratory of Dr. Darryl Zeldin (NIEHS/NIH; 
unpublished), similar to past studies, and kindly provided for these experiments. Briefly, the 
human sEH cDNA (NM001979.5) was amplified with primers (Fwd: 5′-
TAAGCTTGGCTGCAGACCCGCCGCCATGACG-3′, Rev: 5′-
TAGCGGCCGCTCTACATCTTTGAGACCACC-3′) and subcloned downstream of the murine 
α-MHC promoter and upstream of the human growth hormone (hGH) polyadenylation signal 
(kindly provided by Dr. Jeffrey Robbins, University of Cincinnati) (Figure 5.1a), as described 
previously (10). Linearized constructs were agarose gel-purified, microinjected into pronuclei of 
single cell C57BL/6 mouse embryos, and implanted into pseudopregnant mice. Hemizygous 
founder pups were identified by PCR genotyping of genomic DNA. 
All mice used in these experiments were ages 2-6 months. Heterozygous transgenic mice 
from only one founder mouse line [C57BL/6-Tg(Myh6-EPHX2)12Dcz] were used in the study 
to minimize inter-line variability in the magnitude of sEH overexpression. A subset of the 
control mice were age/sex-matched wildtype littermates from Tr12, however additional wildtype 
C57BL/6N mice were purchased from Charles River Laboratories (Wilmington, MA, USA) and 
used as controls. 
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The α-MHC promoter is expressed almost exclusively in cardiomyocytes (11). 
Characterization of α-MHC-EPHX2 mice were performed by Artiom Gruzdev and colleagues 
(NIEHS/NIH). 
All procedures and experiments were conducted in accordance with the US National 
Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved 
by the Institutional Animal Care and Use Committee at the University of North Carolina at 
Chapel Hill and the National Institute of Environmental Health Sciences. 
 
Myocardial IR injury model 
The LAD coronary artery ligation IR model was utilized to evaluate the impact of 
cardiomyocyte-specific sEH overexpression on ventricular remodeling as described previously 
(Chapter 4). Briefly, the chest cavity was opened to visualize the LAD artery and the artery was 
compressed by tightening a ligature, producing myocardial blanching and electrocardiographic 
S-T segment elevation. After occlusion of the LAD for the desired time (30 minutes; ischemia), 
blood flow was restored by removing the ligature (reperfusion). The chest wall was then closed 
with a prolene or silk suture. Sham surgery mice (control) underwent an identical procedure 
except there was no tightening of ligature.  
At 24 hours following surgery, blood was collected by modified tail-clip technique which 
may reduce stress to mice compared to the use of a restraint device (12). Plasma was then 
separated by centrifugation and stored at -80⁰C for future troponin quantification. 
Mice were euthanized at 2 weeks following IR. Blood was collected through the inferior 
vena cava and plasma was separated by centrifugation, aliquoted, and stored at -80⁰C. Whole 
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hearts were extracted, blotted dry, and, weighed before being fixed for future histological 
analysis. 
A portion of wildtype mice were euthanized at 2 hours or 24 hours following IR. In these 
mice, whole hearts were flash frozen in liquid nitrogen and stored at -80°C for subsequent 
molecular phenotyping after being dissected into LV, right ventricle, and atria upon extraction. 
 
Quantitative real-time PCR 
To determine the impact of myocardial IR on Ephx2 expression in wildtype mice, qPCR 
was performed on LV tissue from the hearts that were stored at -80°C. Briefly, RNA was 
isolated from mouse LV tissue (Qiagen) and reverse transcribed to cDNA (Applied Biosystems). 
Analysis was performed in triplicate using the 7300 Real-Time PCR system (Applied 
Biosystems), as described (13). Expression of myocardial mouse sEH mRNA levels was 
quantified using Taqman Assays on Demand (Applied Biosystems). Data was normalized to 
Gapdh (endogenous reference) and expressed relative to a designated experimental control group 
using the 2-ΔΔCt method (14). 
 
Myocardial necrosis  
Twenty-four hour plasma cardiac troponin I levels were measured by ELISA (Life 
Diagnostics, West Chester, PA), according to the manufacturer instruction, as a biomarker of 
cardiomyocyte necrosis and an early index of infarct size (15). 
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Cardiac structure and function 
Echocardiography on conscious mice was performed at baseline and following IR using a 
Vevo 2100 Imaging System (VisualSonics, Toronto, ON) as previously described (Chapter 4). 
Briefly, M-mode images were traced to measure direct parameters of cardiac structure at baseline 
and 24 hours. The calculated parameters of structure (LV Mass) and systolic function (FS and 
EF) were derived from the direct parameters of structure as well as from LV Vold and LV Vold. 
Pulsed wave Doppler images were traced to measure parameters of systolic, diastolic, and global 
function at baseline and 2 weeks. Heart weight-to-tibia length ratio at 2 weeks was measured as a 
parameter of cardiac size. 
 
Histology 
Fixed hearts were embedded in paraffin, and cut into 5μm transverse sections to measure 
evidence of fibrosis. Specifically, serial interrupted sectioning was performed to the hearts. 
Starting from the apex, the most inferior distance where sections were collected occurred where 
both the left and right ventricle could be visualized. A series of sections (4-6) were collected at 
this distance. The next series of sections were collected at a distance 200 microns superior to the 
previous distance. This was repeated for several distances to cover a large portion of the heart 
where injury was anticipated to occur. For hearts of mice undergoing IR, sections from 8 
distances (spanning 1800 microns from the most inferior distance) were collected per sample. 
For collagen, sections were stained with Picrosirius Red, as described (16). For activated 
myofibroblasts, after being baked at 37⁰C overnight and 60⁰C for 1.5 hours, slides were 
deparaffinized, rehydrated, and blocked for endogenous peroxidase in 3% hydrogen peroxide for 
10 minutes. Sections were then blocked with Rodent Block M (DAKO, Carpinteria, CA) for 
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non-specific binding according to the manufacturer’s protocol. Slides were incubated with mouse 
monoclonal anti-alpha smooth muscle actin (α-SMA) primary antibody (DAKO, Carpinteria, 
CA), diluted 1:400 for two hours at room temperature, followed by Mouse-on-Mouse HRP 
Polymer (Thermo Fisher Scientific, Waltham, MA) for 15 minutes at room temperature. 
Immunoreactivity was visualized by DAB chromogen (Thermo Fisher Scientific). 
For quantification of Picrosirius red stain-derived collagen deposition, digitally scanned 
images of the entire heart section were used to generate staining data using NIH ImageJ 
thresholding technology, as previously described (Chapter 4: Methods, Histology). For anti-α-
SMA stained slides, slides were digitally scanned using ScanScope CS System (Aperio). From 
the digital scans, one 10x zoom image was taken per section of each sample capturing about 1/10 
of the total cross-section. The region that had the most intense anti-α-SMA stain was chosen as 
long there was evidence of collagen deposition based on Picrosirius red stained section from the 
same heart distance. Thresholding ranges were set by averaging the ranges of all samples in a 
representative section for each batch. Imaging and threshold setting was done by an investigator 
blinded to treatment groups. The surface area of staining was normalized to the surface area of 
total myocardial tissue for each section. The resulting % stained value averaged over 8 serial 
sections for each mouse heart generated a single value per mouse that reflected the average 
staining throughout the infarcted region. 
Data were pooled from two independent experiments. In order to control for 
interexperiment variability in the absolute % stain values, values were normalized to the IR 
(wildtype) group within each experiment prior to analysis; thus, the % stain data are presented 
relative to the IR (wildtype) group. 
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Statistical analysis 
Data are expressed as mean±SEM unless stated otherwise. Gene expression, troponin, 
and histology data were log-transformed and compared across experimental groups using one-
way ANOVA followed by Fisher’s LSD post hoc tests (if overall ANOVA was significant). 
Echocardiography data were log-transformed and compared across experimental groups using 
ANCOVA with baseline values set as the covariate followed by Fisher’s LSD post hoc tests (if 
overall ANCOVA was significant). Statistical analyses were performed using SAS 9.2 (SAS 
Institute, Cary, NC). P<0.05 was considered to be statistically significant.  
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Results 
 
Initial characterization of a transgenic mouse model with cardiomyocyte-specific 
overexpression of human sEH driven by the α-myosin heavy chain promoter 
The design of the α-MHC-EPHX2 construct is shown in Figure 5.1a. RNA isolation from 
hearts was done with the RNAeasy Mini kit (Qiagen, Valencia, CA) followed by conversion of 
RNA to cDNA with High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA). 
Native mouse Ephx2 mRNA levels detected by qPCR were not significantly different between α-
MHC-EPHX2 and wildtype mouse hearts (Figure 5.1b), however total mouse (Ephx2) + human 
(EPHX2) sEH mRNA levels were significantly higher in α-MHC-EPHX2 mouse hearts (Figure 
5.1c). Western blotting confirmed the expression of human sEH in whole heart homogenates 
(Figure 5.1d) isolated from α-MHC-EPHX2 but not in wildtype mice. Immunohistochemical 
staining showed that human isoform was abundantly expressed in cardiomyocytes, but not 
kidney or liver tissue of α-MHC-EPHX2 mice (Figure 5.1e). The heart, kidney, and tissue of 
wildtype mice showed no detection of human sEH isoform (Figure 5.1e).  
Levels of the 14,15-EET:DHET ratio were significantly lower in α-MHC-EPHX2 mice 
compared to wildtype mice (Figure 5.1f), suggesting that sEH metabolic function was 
significantly higher in transgenic mice compared to wildtype mice. An ex vivo sEH activity assay 
confirmed that α-MHC-EPHX2 mouse hearts had markedly increased 14,15-EET hydrolysis 
activity compared to wildtype (Figure 5.1g). 
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Myocardial expression of soluble epoxide hydrolase 
Relative murine Ephx2 mRNA levels were not significantly different between IR-treated 
and sham-treated mice in LV tissue at 2 and 24 hours following surgery (Figure 5.2). 
 
Circulating biomarker of myocardial cell death 
Plasma troponin levels in IR-treated wildtype mice were greater than levels in sham-
treated mice, since levels in sham treated mice were undetectable. There was no significant 
difference (P=0.10) in troponin levels between α-MHC-EPHX2 mice and wildtype mice 
undergoing IR (Figure 5.3). 
 
Echocardiograph indices of cardiac function and structure 
For M-mode image-derived parameters of systolic function, there were no significant 
differences in FS (Figure 5.4a) or EF (Figure 5.4b) across sham-treated wildtype, IR-treated 
wildtype, and IR-treated α-MHC-EPHX2 mice at 1 day following IR. 
For Pulsed Wave Doppler image-derived parameters of systolic function, AET and IVCT 
were not significantly different across sham-treated wildtype, IR-treated wildtype, and IR-treated 
α-MHC-EPHX2 mice at 2 weeks following IR (Table 5.1). 
For Pulsed Wave Doppler image-derived parameters of diastolic and global function, 
there were no significant differences in E/A ratio (Figure 5.5a) across sham-treated wildtype, IR-
treated wildtype, and IR-treated α-MHC-EPHX2 mice at 2 weeks following IR. Likewise, there 
were no significant differences for the individual E-peak velocity and A-peak velocity 
components of the E/A ratio (Table 5.2). IVRT was not significantly different across groups 
(Figure 5.5b). Furthermore, deceleration rate and time of mitral valve blood flow during ventricle 
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relaxation were not significantly different across treatment groups at 2 weeks following IR 
(Table 5.2). Finally MPI, an index of global function derived from IVCT and IVRT was also not 
different across groups. 
For cardiac structure, there were no significant differences in ventricle wall thickness 
(IVS, LVPW) at systole or diastole across sham-treated wildtype, IR-treated wildtype, and IR-
treated α-MHC-EPHX2 mice (Table 5.3) at day 1 (adjusted for baseline), demonstrating no 
evidence of either hypertrophy or myocardial wall thinning in any of the experimental groups. 
Echocardiography-derived LV mass (Table 5.3) at day 1 as well as heart weight/ tibial length at 
2 weeks (6.18 ± 0.24, 5.82 ± 0.35, 6.57 ± 0.60 mg/mm; P = 0.49) were also not different between 
sham-treated wildtype, IR-treated wildtype, and IR-treated α-MHC-EPHX2 mice, respectively. 
Finally, no differences were detected in ventricle diameter (LVIDs or LVIDd) across groups 
(Table 5.3). Collectively these echocardiography results demonstrate that there was no evidence 
of differences in systolic function, diastolic function, and cardiac structure across experimental 
groups. 
 
Myocardial fibrosis 
There was a significant difference in collagen deposition staining across sham-treated 
wildtype, IR-treated wildtype, and IR-treated α-MHC-EPHX2 mice (P<0.01; Figure 5.6a) at 2 
weeks of reperfusion. Pairwise comparisons revealed significantly increased collagen deposition 
in IR-treated wildtype mice compared to sham-treated wildtype mice (P<0.01). Likewise, 
collagen deposition in IR-treated α-MHC-EPHX2 was significantly increased compared to IR-
treated wildtype mice (P=0.02). Finally, collagen was significantly higher in IR-treated α-MHC-
EPHX2 mice compared to sham-treated wildtype mice (P<0.01).  
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The extent of staining for activated myofibroblasts was also significantly different across 
sham-treated wildtype, IR-treated wildtype, and IR-treated α-MHC-EPHX2 mice (P<0.01; 
Figure 5.6b). In post-hoc analyses however, the extent of α-SMA staining in wildtype mouse 
hearts was not significantly increased compared to sham-treated wildtype mice (P=0.09). 
Similarly, staining in IR-treated α-MHC-EPHX2 mouse hearts was not significantly increased 
compared to IR-treated wildtype mice (P=0.08). Although these comparisons were not 
significant, the direction of the effect is consistent with out hypothesis that IR-injury induces 
myofibroblast activity, which is further enhanced in IR-treated α-MHC-EPHX2 mice. 
Furthermore, α-SMA staining was significantly correlated with collagen staining (P<0.01, 
r=0.66). Hearts from IR-treated α-MHC-EPHX2 mice had increased staining compared to sham-
treated wildtype mouse hearts (P<0.01).  
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Discussion 
 
This is the first study to evaluate the direct contribution of cardiomyocyte-sEH 
expression to maladaptive ventricular remodeling following AMI in vivo. We demonstrated that 
transgenic mice with overexpression of human sEH in cardiomyocytes exhibited enhanced 
myocardial collagen deposition compared to wildtype controls following AMI, but did not 
exhibit altered cardiac function or structure. These data indicate increased myocardial sEH 
activity is a key mediator of collagen deposition during early chronic ventricular remodeling 
following IR, and suggest that strategies which reduce myocardial sEH activity may have 
therapeutic utility to prevent or delay the long term consequences (heart failure, sudden cardiac 
death) that are promoted by fibrosis. 
The role of sEH in the development and progression of cardiovascular disease has been 
studied in a variety of preclinical models (17). The expression of sEH is significantly elevated in 
two rat models of angiotensin II-induced hypertension including in the aortic intima (18), the 
hypertrophic heart (19), and renal cortical tissue (20). Importantly, both in vitro and in vivo 
studies revealed that these effects were driven by angiotensin II (18). As an initial step in 
determining the role of sEH in maladaptive ventricular remodeling following AMI, we 
investigated whether myocardial Ephx2 expression is induced by myocardial IR. We found that 
IR did not impact myocardial Ephx2 expression acutely following injury. This suggests that 
acute induction of myocardial sEH is not a pathological response to IR in vivo. That being said, 
we measured sEH expression before, but not during the development of maladaptive ventricular 
remodeling. Future studies investigating the impact of IR on Ephx2 expression at subacute and 
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early chronic points are warranted to fully characterize the impact of IR-induced ventricular 
remodeling on changes in myocardial sEH expression and function. 
Although IR did not acutely alter Ephx2 expression, interindividual variation in 
myocardial sEH expression was previously reported to exist within a group of patients with 
CAD. In particular, EPHX2 expression in the heart biopsies of CAD patients was lower if the 
patient had reduced EF (21). Given the aforementioned evidence demonstrating the 
cardioprotective effects of sEH inhibition putatively mediated by EETs in preclinical models of 
maladaptive ventricular remodeling, these findings allude to the possible presence of a 
compensatory downregulation of myocardial sEH expression in the presence of HFrEF. 
However the direct effects of increasing myocardial sEH expression on IR-evoked maladaptive 
ventricular remodeling have not been studied. Consequently, using α-MHC-EPHX2 transgenic 
mice, we investigated the impact of cardiomyocyte-specific overexpression of human sEH on 
structural (ventricle chamber dilatation and wall thinning), functional (systolic dysfunction, 
diastolic dysfunction), and fibrotic (collagen deposition, myofibroblasts activation) changes 
following IR to determine the direct functional contribution of cardiomyocyte sEH to IR-evoked 
maladaptive ventricular remodeling. Our data collectively demonstrated that overexpression of 
cardiomyocyte sEH resulted in enhanced collagen deposition, but did not impact cardiac 
dysfunction or maladaptive structural changes. 
Previous preclinical studies have investigated the role of sEH in post-IR ventricular 
remodeling. Li et al. showed in a mouse model of 45 minutes of LAD occlusion followed by 3 
weeks of reperfusion, that administration of a sEH inhibitor reduced collagen deposition (8), 
consistent with the current findings in which increasing myocardial sEH activity increased 
myocardial fibrosis. However, unlike the current results, sEH modulation also impacted cardiac 
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function and structure following AMI. In particular, sEH inhibition improved FS as well as 
LVID at diastole (8). The different models of AMI may be the cause for the discrepant findings 
between studies. A longer period of ischemia and reperfusion in the Li et al. study may have 
enhanced the remodeling response and thereby enabled the demonstration of an effect from the 
experimental intervention. Indeed, we show that myocardial IR in a model of AMI with a shorter 
ischemia time (30 minutes) and a shorter reperfusion time (2 weeks) did not result in worsened 
cardiac structure (ventricle chamber dilation, wall thinning) (Chapter 4: Results). This may have 
precluded our ability to determine the impact of sEH overexpression on cardiac structure 
following IR. Likewise, our model did not cause significant cardiac dysfunction (Chapter 4: 
Results) thus limiting our ability to determine the impact of cardiomyocyte sEH on cardiac 
function. An investigation of the impact of cardiomyocyte sEH overexpression in an AMI model 
that produces greater levels of maladaptive remodeling such as a permanent ischemia model or 
an IR model of late maladaptive chronic remodeling (by increasing the length of post-AMI 
reperfusion follow-up) would provide further insight into the role of cardiomyocyte sEH on 
maladaptive ventricular remodeling following AMI. 
The fibrotic response following AMI is known to increase myocardial stiffness, precede 
the impairment of cardiac function, and ultimately lead to the development of heart failure 
progression (22). Thus, it is plausible to postulate that α-MHC-EPHX2 mice have greater systolic 
and diastolic dysfunction in the later chronic stages following IR, compared to wildtype mice, at 
least partially due to enhanced myocardial collagen deposition during early chronic ventricular 
remodeling. However, as mentioned above, this hypothesis has not been investigated and needs 
to be tested. Circulating biomarkers of fibrosis predictive of poor prognosis following AMI 
correlate strongly with cardiac function (23). Furthermore, much remains unknown concerning 
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the precise mechanisms linking fibrosis to cardiac dysfunction following AMI (24). Addressing 
this gap in knowledge would provide clarity on the relevance of an experimental effect that alters 
fibrosis but not cardiac function following AMI. This would be of greatest importance if it is 
ultimately found that cardiomyocyte sEH overexpression does not impact cardiac function in the 
late chronic phase following IR. 
Accumulating evidence, across multiple laboratories and species, has demonstrated that 
EETs abrogate a variety of acute pathophysiological responses following myocardial IR, 
including the reduction of left ventricular infarct size (25). Thus, it is unknown whether the 
observed enhancement of cardiac fibrosis in the presence of cardiomyocyte sEH overexpression 
was independent of infarct size following IR. This is of clinical significance, because an EET-
promoting agent indicated to reduce IR injury would most likely be administered to patients 
during or after, and not prior to, the ischemic phase of an AMI. Overexpression of sEH in our 
transgenic mice did not significantly increase troponin levels, which suggests that the 
significantly enhanced myocardial fibrosis observed in these mice may be independent, at least 
in part, of infarct size in vivo. The impact of sEH overexpression on post-IR infarct size is also 
being investigated currently in an ex vivo model of AMI. Three recent studies have provided 
further insight into this important issue, by demonstrating the impact of sEH inhibition on post-
AMI phenotypes. In one study, a sEH inhibitor was administered immediately following 
permanent LAD occlusion in rats; pharmacologic suppression of sEH attenuated LV ejection 
fraction (systolic function) independent of collagen deposition reduction in the infarct zone 
following 5 weeks of occlusion (26). A second study by a separate group utilized a chronic 
model of overt heart failure in rats (permanent LAD ligation for 50 days), but administered a 
sEH inhibitor at distinct time points after the initial phase of infarct healing: 8 days (42-day sEH 
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inhibitor treatment) or 47 days (3-day inhibitor treatment) following LAD occlusion. It was 
discovered that both regimens improved LV ejection fraction at 50 days; however, only long 
term treatment elicited an improvement in LV end-diastolic pressure (diastolic function) (27). A 
third study in mice utilizing a model of IR injury demonstrated that sEH inhibition administered 
a week following AMI was still able to attenuate chronic collagen deposition measured three 
weeks later (7). Collectively, these studies demonstrate that sEH inhibition improves 
maladaptive ventricular remodeling independent of the aforementioned acute reductions in 
infarct size elicited by EETs. Administration of a sEH inhibitor to α-MHC-EPHX2 mice 
following the acute phase of IR would provide further insight on whether the enhanced fibrosis 
was independent of infarct size, and is an important future direction for this line of investigation. 
It is also important to note that the aforementioned effects in previous studies were not 
reported to be related to blood pressure reduction, suggesting that direct EET action on the heart 
is a likely mechanism of cardioprotection.  However, in addition to cardiomyocytes, the heart is 
also composed of fibroblasts, endothelial cells, and vascular smooth muscle cells (28). Although 
the transgene was only expressed in cardiomyocytes, it is unknown which cell types are most 
important to the observed enhancement of cardiac fibrosis in the transgenic mice. Cardiac 
fibroblasts certainly accelerate fibrosis via secretion of growth factors and cytokines (28). 
Furthermore, fibroblasts are the only cell type that synthesize collagen and are the most abundant 
source of ECM proteins. However, endothelial cells, neutrophils, mast cells, lymphocytes, and 
macrophages are other major sources of ECM proteins (28). Studies have shown that 
pharmacologic inhibition of sEH directly blocks the proliferation, differentiation, migration, and 
secretion capacity of fibroblasts (7, 26). Additionally, substantial evidence indicates that EETs, 
through inhibition of NF-κB activation, attenuate inflammation in endothelial cells and 
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monocytes (29) and mitigate macrophage/neutrophil infiltration in the vasculature (30); however, 
these effects have not been extensively studied in the coronary vasculature following myocardial 
ischemic injury. Kompa et al. demonstrated that sEH inhibition impedes the infiltration of 
macrophages in the peri-infarct region of the myocardium in rats following permanent LAD 
ligation. Intriguingly, sEH inhibition did not reduce macrophage infiltration in the infarct region 
of the myocardium (26). Overall, further studies are necessary to determine the relative 
functional role of myocardial cell-type in EET-mediated cardioprotection. Studies in individual 
cell types isolated from the hearts of the transgenic mice following AMI would elucidate which 
cells are most important in the observed enhancement of fibrosis in these mice. 
Even within a specific cell-type of the heart, there are multiple mediators which promote 
fibrosis along the full cascade of its development, as described (Chapter 4: Introduction). Briefly, 
circulating and resident fibroblasts infiltrate the myocardium in the infarct zone and undergo 
rapid proliferation (mediated by FGF-2) followed by activation into myofibroblasts (largely 
mediated by TGF-β). Subsequently, activated myofibroblasts function to produce ECM proteins 
that ultimately cause scar formation (31). LOX mediates the maturation of scar tissue by cross-
linking collagen fibrils. However, before the maturation of the fibrotic scar and after collagen 
fibers are synthesized further, ECM remodeling can occur as a consequence of mediators such as 
osteopontin, fibronectin, TIMPs, and MMPs that regulate ECM turnover (32). Notably, only 
MMP can degrade collagen (2). In renal tissue, Ephx2 disruption reduced the extent of TGF-β 
signaling, fibronectin, activated myofibroblasts, and collagen deposition (33), suggesting that 
sEH may play a role in fibrosis development along the full spectrum of its pathogenesis. It is 
unknown if the observed changes in myocardial collagen deposition reported in the current study 
are a result of increased collagen synthesis upstream of ECM remodeling, impaired collagen 
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proteolytic degradation during the latter phases, or both. We observed that hearts of IR-treated α-
MHC-EPHX2 mice had increased collagen deposition compared to hearts of IR-treated wildtype 
mice (P<0.01), but did not observe a significant difference in activated myofibroblasts between 
these two groups at 14 days following IR (P=0.08). This suggests that the enhanced collagen 
deposition may be, at least in part, a consequence of reduced ECM degradation in α-MHC-
EPHX2 mouse hearts. Of note, the levels of activated myofibroblasts, TGF-β, and osteopontin in 
the mouse heart may peak at 3 days following IR (34). Future studies which investigate the role 
of cardiomyocyte sEH on the time course of the aforementioned mediators in the infarcted heart 
following IR would elucidate the mechanism by which sEH overexpression caused increased 
collagen deposition. For example, in characterizing the IR model used in this study, we measured 
early myocardial expression of mediators important in fibrosis such as LOX and TGF-β in 
wildtype mice (Chapter 4: Results). These markers should also be measured in future studies 
with the transgenic mice. 
There are some limitations to our transgenic mouse model. First, the model exhibits 
supraphysiological levels of sEH expression in cardiomyocytes. However this was a proof of 
concept study to determine the impact of extreme increases in sEH expression on chronic 
phenotypes following AMI. Furthermore, pharmacological inducers of sEH to elucidate the 
effect of enhanced sEH-derived EET hydrolysis are not available, thus genetic modification 
remains the only method to increase sEH-derived hydrolysis of EETs. Moreover, this genetic 
tool offers the advantage of allowing the determination of the role of cardiomyocyte-specific 
sEH in remodeling. Future work investigating the impact of knocking in EPHX2 Lys55Arg and 
EPHX2 Arg287Gln in mice would increase our understanding of the role of common human 
polymorphisms on myocardial remodeling following AMI. A second limitation is that only one 
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founder mouse line was used across all experiments, thus we cannot rule out whether the 
transgene itself or the location where the transgene is inserted is driving the phenotype. 
However, using one mouse line allowed us to control for variation in the expression level of the 
transgene and thereby enhance reproducibility of the phenotype. Furthermore, Gruzdev et al. 
demonstrated in an ex vivo model of IR that two other founder lines showed nearly identical 
phenotypes (unpublished), highly suggesting that insertional mutagenesis by the transgene is 
unlikely to play a role in the observed ventricular remodeling. 
In summary, mice with cardiomyocyte-specific overexpression of human sEH exhibited 
enhanced IR-induced myocardial collagen deposition in vivo. This suggests that lower cardiac 
EETs may promote fibrosis post-AMI; however, future studies are needed to elucidate the 
molecular mechanisms including the direct implication of EETs in these effects.  
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Figures 
 
 
 
Figure 5.1 Characterization of cardiomyocyte-specific soluble epoxide hydrolase (sEH) 
overexpressing transgenic mice. (a) Schematic of the transgenic construct which contains the 
α-myosin heavy chain (α-MHC) promoter, human sEH isoform coding sequence, and polyA 
sequences. Bar graphs show baseline (b) native murine Ephx2 and (c) total sEH (native Ephx2 + 
transgenic EPHX2) expression in the whole heart. (d) A representative immunoblot of human 
sEH protein levels in the whole heart and β-actin loading control. (e) Representative 
immunohistochemistry staining for human sEH in the heart, kidney, and liver of α-MHC-EPHX2 
mice and wildtype (WT) control. (f) Baseline levels of 14,15-EET:DHET ratio in the whole 
heart. (g) Levels of 14,15-DHET (pg) as a measure of myocardial sEH function in an assay 
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where exogenous 14,15-EET was added to isolated protein in the heart tissue of α-MHC-EPHX2 
mice and WT controls. N = 3-5 per group. * P < 0.05. Figures adapted from Gruzdev et al. 
(unpublished). All characterization of transgenic mice was conducted by the Darryl Zeldin lab. 
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Figure 5.2 Impact of myocardial ischemia reperfusion (IR) on soluble epoxide (sEH) 
expression. Bar graph shows the time course of myocardial IR-induced Ephx2 expression in the 
left ventricle (LV) of wildtype mice. Reference group for relative mRNA levels: sham levels at 
24 hours. Sham: n = 3 per group. IR: n = 5 per group. * P < 0.05 for sham vs IR at each time 
point.  
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Figure 5.3 Impact of cardiomyocyte sEH overexpression on myocardial necrosis. Plasma 
troponin levels at 24 hours following ischemia reperfusion (IR) in sham-treated wildtype (WT), 
IR-treated WT, and IR-treated α-myosin heavy chain- (α-MHC)-EPHX2 mice. IR: n = 17-19 per 
group. Sham: n = 8. * P < 0.05 for IR-treated WT versus IR-treated α-MHC-EPHX2. 
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Figure 5.4 Impact of cardiomyocyte soluble epoxide hydrolase (sEH) overexpression on M-
mode image-derived parameters of systolic function. Bar graphs show (a) ejection fraction 
(EF) and (b) fractional shortening (FS) at 1 day following ischemia reperfusion (IR) in sham-
treated wildtype (WT), IR-treated WT, and IR-treated α-myosin heavy chain- (α-MHC)-EPHX2 
mice. Comparisons across groups were conducted at 1 day using ANCOVA with baseline as the 
covariate. IR: n = 17-19 per group. Sham: n = 9.  
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Figure 5.5 Impact of cardiomyocyte soluble epoxide hydrolase (sEH) overexpression on 
diastolic function. Bar graphs show (a) E-wave to A-wave (E/A) ratio and (b) isovolumic 
relaxation time (IVRT) at 2 weeks following ischemia reperfusion (IR) in sham-treated wildtype 
(WT), IR-treated WT, and IR-treated α-myosin heavy chain- (α-MHC)-EPHX2 mice. 
Comparisons across groups were conducted at 2 weeks using ANCOVA with baseline as the 
covariate. n = 7-9 per group.  
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Figure 5.6 Impact of cardiomyocyte soluble epoxide hydrolase (sEH) overexpression on 
fibrosis. (a) Representative 1X images and (b) quantification of Picrosirius Red-stained collagen 
deposition as well as (c) representative 10X images and (d) quantification of anti-α-smooth 
muscle actin- (α-SMA)-stained myofibroblast activation at 2 weeks following ischemia 
reperfusion (IR) in sham-treated wildtype (WT), IR-treated WT, and IR-treated α-myosin heavy 
chain- (α-MHC)-EPHX2 mice. Staining was completed on 8 serial-interrupted heart sections, 
quantified in each sectin, and then averaged across the 8 sections in each mouse. Data are 
expressed relative to the IR-treated WT group. Each set of representative images has a different 
scale. Sham: n = 6. IR: n = 14-15 per group. * P < 0.05 for Fisher’s LSD post hoc test 
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Table 5.1 Impact of cardiomyocyte soluble epoxide hydrolase (sEH) overexpression on Pulsed 
Wave Doppler image-derived parameters of systolic function following ischemia-reperfusion 
(IR) injury. 
 
Parameters   Baseline  2 weeks  P 
Isovolumic contraction time (IVCT), ms 
 sham (wildtype)  11.0 ± 0.9  16.1 ± 2.0  0.55 
 IR (wildtype)  12.2 ± 1.0  13.3 ± 1.5 
 IR (α-MHC-EPHX2) 11.0 ± 2.7  14.0 ± 1.7 
Aortic ejection time (AET), ms 
 sham (wildtype)  29.8 ± 2.0  34.1 ± 1.2  0.49 
 IR (wildtype)  28.4 ± 1.8  36.7 ± 1.6 
 IR (α-MHC-EPHX2) 32.3 ± 2.0  33.8 ± 1.8 
Comparisons across groups were conducted at 2 weeks using ANCOVA with baseline as the covariate. n = 7-9 per 
group. * P < 0.05 (ANCOVA). 
α-MHC, α-myosin heavy chain  
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Table 5.2 Impact of cardiomyocyte soluble epoxide hydrolase (sEH) overexpression on Pulsed 
Wave Doppler image-derived parameters of diastolic and global function following ischemia-
reperfusion (IR) injury. 
 
Parameters   Baseline  2 weeks  P 
Early-peak velocity (E), mm/s 
 sham (wildtype)  441.4 ± 39.8  579.9 ± 49.9  0.77 
 IR (wildtype)  457.4 ± 36.5  585.5 ± 64.0 
 IR (α-MHC-EPHX2) 488.8 ± 50.8  528.5 ± 51.8 
Atrial-peak velocity (A), mm/s 
 sham (wildtype)  341.7 ± 33.2  402.3 ± 44.6  0.46  
 IR (wildtype)  356.8 ± 25.1  397.7 ± 45.5 
 IR (α-MHC-EPHX2) 353.6 ± 49.8  337.8 ± 33.0 
Deceleration (Dt), ms 
 sham (wildtype)  24.2 ± 2.8  21.9 ± 2.1  0.61 
 IR (wildtype)  27.7 ± 2.9  21.5 ± 2.4 
 IR (α-MHC-EPHX2) 21.8 ± 4.2  18.7 ± 1.8 
Deceleration (Dr), mm/s2 
 sham (wildtype)  -19.2 ± 2.1  -27.6 ± 3.8  0.96 
 IR (wildtype)  -18.9 ± 3.2  -28.2 ± 5.3 
 IR (α-MHC-EPHX2) -26.5 ± 5.0  -26.3 ± 2.3 
Myocardial performance index (MPI), ratio 
 sham (wildtype)  1.0 ± 0.1  0.9 ± 0.1  0.54  
 IR (wildtype)  1.1 ± 0.1  0.8 ± 0.1 
 IR (α-MHC-EPHX2) 0.8 ± 0.1  0.9 ± 0.1 
Comparisons across groups were conducted at 2 weeks using ANCOVA with baseline as the covariate. n = 7-9 per 
group. * P < 0.05 (ANCOVA). 
α-MHC, α-myosin heavy chain  
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Table 5.3 Impact of cardiomyocyte soluble epoxide hydrolase (sEH) overexpression on cardiac 
structure following ischemia-reperfusion (IR) injury. 
 
Parameters   Baseline  1 day   P 
LVID, systolic (mm) 
 sham (wildtype)  1.51 ± 0.10  1.94 ± 0.08  0.86 
 IR (wildtype)  1.69 ± 0.10  2.07 ± 0.13 
 IR (α-MHC-EPHX2) 1.52 ± 0.08  1.94 ± 0.13 
LVID, diastolic (mm) 
 sham (wildtype)  2.92 ± 0.10  3.24 ± 0.10  0.57 
 IR (wildtype)  3.05 ± 0.10  3.14 ± 0.10 
 IR (α-MHC-EPHX2) 2.90 ± 0.07  3.07 ± 0.10 
IVS, systolic (mm) 
 sham (wildtype)  1.85 ± 0.04  1.68 ± 0.05  0.12 
 IR (wildtype)  1.64 ± 0.04  1.48 ± 0.07 
 IR (α-MHC-EPHX2) 1.79 ± 0.04  1.70 ± 0.08 
IVS, diastolic (mm) 
 sham (wildtype)  1.24 ± 0.05  1.14 ± 0.04  0.06 
 IR (wildtype)  1.09 ± 0.03  1.09 ± 0.04 
 IR (α-MHC-EPHX2) 1.18 ± 0.04  1.26 ± 0.06 
LVPW, systolic (mm) 
 sham (wildtype)  1.78 ± 0.07  1.57 ± 0.05  0.75 
 IR (wildtype)  1.76 ± 0.04  1.51 ± 0.08 
 IR (α-MHC-EPHX2) 1.81 ± 0.07  1.55 ± 0.07 
LVPW, diastolic (mm) 
 sham (wildtype)  1.16 ± 0.04  1.13 ± 0.05  0.37 
 IR (wildtype)  1.08 ± 0.03  1.03 ± 0.04 
 IR (α-MHC-EPHX2) 1.13 ± 0.04  1.09 ± 0.05 
Echocardiography-derived LV mass corrected (mg) 
 sham (wildtype)  106.04 ± 4.68  113.33 ± 5.77  0.10 
 IR (wildtype)  95.86 ± 3.46  97.23 ± 4.32 
 IR (α-MHC-EPHX2) 98.97 ± 4.24  111.15 ± 6.35 
Comparisons across groups were conducted at 1 day using ANCOVA with baseline as the covariate. IR: n = 17-19 
per group. Sham: n = 8. * P < 0.05 (ANCOVA) 
IVS, interventricular septum; LV, left ventricle; LVID, left ventricular internal diameter; LVPW, left ventricular 
posterior wall  
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CHAPTER 6 - DISCUSSION AND PERSPECTIVE 
 
Summary and Scope 
 
Despite advances in evidence-based medical therapies, CVD has been the leading cause 
of death for over a century and its prevalence is expected to continue to rise tremendously. Most 
notably, CAD, which includes AMI and stable angina, is the primary source of this public health 
burden causing almost half of all CVD deaths. Heart failure, a key clinical outcome of CAD, is 
also a major source of the health burden (1). Recent failures in CAD drug development suggest 
that innovative approaches are needed to mitigate increasing attrition rates and more successfully 
translate novel therapies into clinical practice (2-4). Biomarkers offer considerable promise to 
prospectively identify subsets of CAD patients at high risk of experiencing a cardiovascular 
event that exhibit dysfunction in a specific pathway (putative responders), consequently enabling 
novel therapies that target the pathway to maximize their therapeutic effect and improve 
outcomes. A more thorough understanding of the mechanisms underlying the pathophysiology of 
CAD is necessary to facilitate the development of biomarkers and novel therapeutic strategies 
that ultimately prevent AMI events, delay the development of heart failure, and improve public 
health outcomes. 
CAD is a complex disease involving the development of atherosclerosis along the walls 
of the coronary arteries as well as the formation of an intracoronary thrombus from a ruptured 
atheromatous plaque leading to an ACS (5). Myocardial cell death from an AMI promotes 
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maladaptive ventricular remodeling which leads to the development of heart failure (6). EETs 
yields potent cardiovascular protective effects in preclinical models of cardiovascular disease, 
which suggests that increasing EET levels may be a viable therapeutic strategy for CAD, AMI, 
post-AMI ventricular remodeling (7). Key questions, however, remain to be addressed prior to 
translation of therapeutic EET-promoting strategies into successful proof-of-concept phase I and 
II clinical trials (Appendix B). Thus, the overall aim of this dissertation was to advance our 
understanding of the role of the EET metabolic pathway across the full spectrum of CAD and 
post-AMI consequences as a means to determine the biological and therapeutic importance of 
EETs in the progression of this disease cascade. To accomplish this, we have taken a 
translational approach integrating both preclinical and clinical studies to evaluate the 
contribution of the EET metabolic pathway across the full spectrum of CAD. The major findings 
of this work include 1) the discovery that obstructive CAD is significantly and independently 
associated with lower circulating EET levels secondary to suppressed EET biosynthesis, 2) the 
preliminary, hypothesis-generating observation that EPHX2 Lys55Arg may be associated with 
poor prognosis following AMI, and 3) a demonstration of the key contribution of cardiomyocyte-
derived sEH to the development of fibrosis following AMI. Overall, these results demonstrate 
that the EET metabolic pathway may play a role in the pathophysiology of CAD and its 
associated complications including the development of coronary atherosclerosis, post-AMI early 
ventricular remodeling, and post-AMI mortality. Collectively, these data help to set the 
foundation for future clinical research in this area, including the rational design of prospective, 
biomarker-guided interventional studies in targeted subsets of the CAD population with enriched 
potential to derive clinical benefit from emerging EET-promoting therapies.  
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Key Findings 
 
The clinical course of CAD is always initiated by the development of an atheroma in the 
lumen of the coronary artery and progresses from stable angina to AMI to heart failure to death  
(5). The overall aim of this dissertation was to advance our understanding of the role of the EET 
metabolic pathway across this full spectrum of CAD and post-AMI. 
In Aim 1, we advanced our understanding of the role of the EET pathway in the earlier 
stages of this full CAD spectrum. Namely, we recruited a cohort of patients referred for coronary 
angiography; subjects were at varying stages of atherosclerotic-driven coronary artery stenosis 
where the majority of patients did not have a prior AMI (85%), were not suffering from an AMI 
at the index hospitalization (91%), and did not have a history of heart failure (87%). In order to 
elucidate the relationship between EET levels and the extent of CAD, we utilized a targeted 
metabolomics approach where we quantified a panel of eicosanoids in the participants. This is 
the largest study to date that quantifies EET levels in patients with or at risk for CVD. 
We observed that the presence of atherosclerotic obstructive CAD was significantly 
associated with lower circulating EET levels. It is well established that patients with obstructive 
CAD are at the greatest risk of adverse CV outcomes compared to patients with less extensive 
CAD (8). These findings suggest that CYP-derived EETs may play an important role in the 
pathogenesis and progression of CAD in humans. Validation of the observed relationships in an 
independent cohort is necessary. 
However, other eicosanoids derived from COX, LO, and CYP also play a role in 
cardiovascular disease (7, 9-11). Nevertheless, the association between EETs and CAD was 
significantly more pronounced than other eicosanoid metabolism pathways, further 
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demonstrating an important role for these lipid mediators in the pathophysiology of CAD. 
Although the panel of eicosanoids included 28 metabolites which were derived from various 
biosynthetic enzymes and fatty acid substrates, several other fatty acid metabolites including 
leukotrienes, resolvins, and protectins were not on the panel. Furthermore, it is unknown if 
changes in the levels the parent substrates themselves such as arachidonic acid impacted the 
relationship between EETs and CAD extent. The relative strength of the EET-CAD association 
compared to these other potent mediators is a future area of investigation. 
CAD extent was also associated with lower sum EETs+DHETs (a biomarker of CYP 
epoxygenase-derived EET biosynthesis) as an inverse association, but not EET:DHET ratio (a 
biomarker of sEH-derived EET hydrolysis). These data suggest that the association between EET 
levels and CAD extent may be mediated by suppression of EET synthesis and not an increase in 
EET hydrolysis. Accordingly, it is well-established that inflammatory stimuli suppress CYP-
mediated xenobiotic metabolism through a variety of mechanisms, including cytokine-mediated 
transcriptional downregulation of CYP expression (12); fittingly, inflammatory stimuli also drive 
the development and progression of CAD (13). These findings suggest that suppression of CYP-
mediated EET biosynthesis may be a key pathological consequence of the inflammation-
mediated development and progression of CAD. Future studies are necessary to elucidate the 
mechanisms underlying the association between lower EET levels and advanced CAD in 
humans. 
In a secondary analysis of the coronary angiography patients, we explored the 
relationship between inter-individual variation in EET metabolite levels and risk of a future 
adverse cardiovascular event exclusively in patients with obstructive CAD at baseline. We 
observed a stepwise relationship across the EET tertiles where the highest event incidence 
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occurred in those with the lowest EET levels at baseline. Although this relationship was not 
statistically significant and should be observed with caution due to the small number of events, 
these findings are biologically plausible considering the anti-inflammatory and protective effects 
of EETs in numerous preclinical models of cardiovascular disease.  
Altogether, these findings demonstrated that patients with obstructive CAD are 
predisposed to low EET metabolite levels secondary to suppressed EET biosynthesis, and 
suggest that novel strategies that promote the effects of EETs may have therapeutic promise in 
patients with obstructive CAD. Further investigation in needed to determine relationship between 
the EET metabolic pathway and prognosis in patients with established CAD. Indeed, 
nonobstructive lesions have thinner fibrous caps and are more vulnerable to rupture (5), thus a 
strong relationship between EETs and CAD extent may not equate to a correlation between EETs 
and adverse CV events. 
Although sEH-derived EET hydrolysis was not associated with CAD extent suggesting 
that sEH may not play a role in CAD progression, preclinical and genetic observational studies 
have demonstrated a potential link between sEH and the complications of CAD such as AMI. In 
Aim 2, we advanced our understanding of the role of the EET metabolic pathway in prognosis 
following AMI (later in the clinical course of CAD compared to Aim 1). In particular, using a 
candidate gene approach, we determined the relationship between the EPHX2 p.Lys55Arg 
polymorphism and survival two independent cohorts of AMI patients. INFORM is a 2-center 
cohort of ACS patients with full 5-year mortality data available and TRIUMPH is a 24-center, 
racially-diverse population of AMI patients. We observed that EPHX2 Lys55Arg was associated 
with 5-year mortality following AMI in INFORM, but we were not able to replicate this finding 
in TRIUMPH. Notably, TRIUMPH only had full 2-year mortality data available. Thus, an 
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important issue in this study is the lack of statistical power that may have limited our ability to 
detect differences in TRIUMPH. A repeat analysis when full 5-year mortality data are available 
is necessary to rule out the possibility that lack of sufficient power prevented the INFORM 
results from being replicated in TRIUMPH. Futhermore, considering the impact of CYP-derived 
EET biosynthesis in the inititation and progression of coronary atherosclerosis in Aim 1, the 
association between SNPs in genes encoding for CYP epoxygenase and survival following AMI 
is necessary to fully understand the EET metabolic pathway in post-AMI mortality. 
We investigated mortality in our candidate gene study, because it is an important 
endpoint following AMI; however, maladaptive ventricular remodeling is the key 
pathophysiological process that ultimately drives the progression to heart failure and death 
following AMI (14). Consistent with the overall aim of this translational project to better 
understand the role of the EET metabolic pathway in CAD and its associated complications, we 
used a genetic manipulation approach (Aim 3) to investigate the role of myocardial sEH in 
maladaptive ventricular remodeling post-IR in vivo using a transgenic mouse line with 
cardiomyocyte-specific overexpression of human sEH. However, there are surprising few studies 
that characterize the early maladaptive ventricular remodeling response following IR in mice. A 
more thorough understanding of the pathophysiology of myocardial remodeling following AMI 
in mice will facilitate the design of experimental studies that elucidate the role of therapeutic 
pathways in the disease. Consequently, we first characterized the impact of IR injury (30-minute 
of myocardial ischemia followed by 2 weeks of reperfusion) in mice in vivo. We observed that 
IR induced transient but marked myocardial cell death and inflammation acutely following IR 
and generated substantial fibrosis at an early chronic time point. New approaches are needed to 
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better discriminate between adaptive and maladaptive fibrosis. This is an important future area of 
investigation because novel therapies that attenuate adaptive fibrosis would be deleterious. 
In contrast to induction of myocardial fibrosis, IR did not produce significant changes in 
myocardial structure, systolic function, or diastolic function in early chronic remodeling. This 
finding is in line with data suggesting that the fibrotic response following AMI precedes the 
impairment of cardiac function and structure (15). A future investigation evaluating the impact of 
30-minute myocardial IR in mice on cardiac structure and function at a late chronic time point is 
warranted. 
Altogether, we found that our in vivo mouse model was best suited for investigating the 
impact of intervention fibrotic responses in early chronic myocardial remodeling independent of 
cardiac structure or function. These findings set the foundation for the evaluation of the 
contribution of cardiomyocyte sEH to maladaptive ventricular remodeling in mice post-AMI. We 
discovered that cardiomyocyte-specific overexpression of human sEH exhibited enhanced IR-
induced myocardial collagen deposition during early chronic ventricular remodeling following 
IR. Although, this suggests that myocardial sEH activity is a key mediator of collagen 
deposition, it is unknown whether the observed enhancement of cardiac fibrosis in the presence 
of cardiomyocyte sEH overexpression was independent of infarct size following IR. A few 
studies have shined light on this question, reporting evidence that this effect is independent of 
changes to infarct size (16-18). Administration of a sEH inhibitor to α-MHC-EPHX2 mice 
following the acute phase of IR would provide insight on whether the enhanced fibrosis was 
independent of infarct size, and is an important future direction for this line of investigation. 
Furthermore, it is unknown if the observed changes in myocardial collagen deposition are a 
result of increased collagen synthesis, impaired collagen proteolytic degradation, or both. Our 
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findings suggest that the enhanced collagen deposition may be, at least in part, a consequence of 
reduced ECM degradation in α-MHC-EPHX2 mouse hearts. Future studies which investigate the 
role of cardiomyocyte sEH on the time course of the aforementioned mediators in the infarcted 
heart following IR would elucidate the mechanism by which sEH overexpression caused 
increased collagen deposition. 
In contrast, cardiomyocyte-specific overexpression did not alter systolic function, 
diastolic function, or cardiac structure in early ventricular remodeling. Based on the results of 
our studies characterizing the in vivo IR model in which IR did not produce functional 
impairment or structural damage, it was not surprising that the transgenic mice did not exhibit 
altered structure or function following IR. Fibrosis inevitably leads to some degree of systolic or 
diastolic dysfunction (15), so the relevance of an intervention that never impacts cardiac function 
is unknown. An investigation of the impact of cardiomyocyte sEH overexpression in an AMI 
model that produces greater levels of maladaptive remodeling such as a PO model or an IR 
model of late chronic remodeling would provide further insight into the role of cardiomyocyte 
sEH on cardiac function and structure following AMI. 
Overall, this is the first study to investigate the impact of cardiomyocyte sEH on 
maladaptive ventricular remodeling following AMI. This work opens the door for future studies 
investigating the role of cardiomyocyte-derived sEH in the development of heart disease. The 
direct implication of EETs in this observation is needed to establish that lower cardiac EETs 
promote fibrosis post-AMI. 
Thus, we demonstrated that the EET metabolic pathway may play a role in the 
pathophysiology of CAD and its associated complications including the development of 
coronary atherosclerosis (Aim 1; clinical), post-AMI mortality (Aim 2; clinical), and post-AMI 
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early ventricular remodeling (Aim 3; clinical). In Aim 1, we showed that obstructive CAD is 
strongly associated with lower plasma EETs, thereby identifying a potential subset of the CAD 
population that may be at greater risk of a more aggressive disease course. In Aim 2, we showed 
that a functionally relevant polymorphism associated with increased EET hydrolysis may be 
associated with increased mortality following AMI. In Aim 3, we showed in a mouse model of 
IR-induced maladaptive ventricular remodeling (a key consequence of CAD) that 
cardiomyocyte-specific overexpression of human sEH and putative reduction in cardiac EETs 
enhances collagen deposition. Collectively, these data provide evidence that lower EETs may 
promote deleterious consequences in CAD and post-AMI, and in turn suggest that promoting the 
effects of EETs may have therapeutic utility in CAD and AMI patients predisposed to low 
circulating EET levels. Furthermore, plasma EETs levels or EPHX2 Lys55Arg genotype may be 
promising biomarkers that detect which CAD patients may derive the greatest benefit from EET-
promoting agents. 
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Clinical Implications 
 
Despite advances in evidence-based medical therapies, CAD remains a leading cause of 
mortality in the US (1) and novel therapeutic strategies are needed to further improve outcomes. 
A series of recent failures in CAD drug development suggest that innovative approaches are 
needed to reduce high attrition rates and more successfully translate novel therapies into clinical 
practice (2-4). Compared to the conventional ‘one-size fits all’ methodology to drug 
development, a precision medicine approach has the potential to facilitate the development of 
novel therapeutics candidates and increase the probability of success for these therapies (19). 
This approach prospectively identifies subsets of patients that exhibit dysfunction in a specific 
pathway (putative responders), thereby enabling novel or existing therapies that target the 
pathway to maximize their therapeutic effect and improve outcomes. This approach has shown 
great clinical success in cancer, and is promising in several areas of CVD (Appendix A). 
Importantly, the discovery of biomarkers involved in the pathogenesis of CAD is needed to 
identify subsets of high-risk patients who would derive the greatest benefit from therapies that 
modulate that pathway (20, 21). 
Our study in CAD patients referred for angiography demonstrates that obstructive CAD 
is strongly associated with lower EETs and thereby identifies a subset of the CAD population 
that may be at greater risk. We also showed, in a mouse model of IR-induced maladaptive 
ventricular remodeling (a key consequence of CAD), that cardiomyocyte-specific overexpression 
of human sEH and putative reduction in cardiac EETs enhances collagen deposition. This further 
suggests that lower EETs may promote deleterious consequences post-AMI. Collectively, these 
data provide evidence that promoting the effects of EETs may have therapeutic utility in CAD 
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and AMI patients predisposed to low circulating EET levels. Furthermore, EET levels may be a 
promising biomarker that detects the CAD patients at highest risk of adverse outcomes that may 
derive the greatest benefit from EET-promoting agents. 
Notably, numerous sEH inhibitors have been discovered by drug companies and an 
academic group. Many of these agents have properties favorable to further drug development 
(22). One agent that has shown promise in rodent studies (23) is being developed for chronic 
obstructive pulmonary disease (COPD) in clinical trials (NCT01762774, NCT02006537). In 
addition, EET mimics are being optimized in the early discovery stage into candidates which 
may also show promise in further preclinical studies (24). In parallel, tools for the high-
throughput quantification of CYP-derived eicosanoids in humans are advancing, showing 
promise as a feasible biomarker that can be measured in the clinical setting (25). Thus, the 
technology is in place for the successful development of EET-promoting therapies. 
The findings from this dissertation contribute to the science evaluating the therapeutic 
utility of EET-promoting agents, thereby complimenting the aforementioned advances which 
have improved the profile of drug candidates and the efficiency of the quantification of EET 
metabolic pathway biomarkers. Follow-up preclinical studies elucidating underlying mechanisms 
and follow-up clinical studies which validate our findings across the full spectrum of CAD are 
still needed before this work can truly advance the field; however, positive follow-up results will 
set the foundation for the rational design of prospective, biomarker-guided interventional studies 
in targeted subsets of the CAD population (low EET levels) with enriched potential to derive 
clinical benefit from emerging EET-promoting therapies.  
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Conclusions 
In conclusion, we found that obstructive CAD is significantly and independently 
associated with lower circulating EET levels secondary to suppressed EET biosynthesis using a 
targeted metabolomics approach. In addition, using a candidate gene approach, we observed that 
EPHX2 p.Lys55Arg may be associated with mortality in the AMI subset of an ACS population. 
This paves the way for a validation study in an independent population with full 5-year mortality 
available to substantiate these preliminary findings. Moreover, we characterized a mouse model 
of IR injury-induce maladaptive ventricular remodeling, showing its effect on myocardial cell 
death, inflammation, and collagen induction. This allowed us to ultimately demonstrate that mice 
with cardiomyocyte-specific overexpression of human sEH exhibited enhanced IR-induced 
myocardial collagen deposition. Overall, this dissertation used both pre-clinical and human 
studies to provide insight into the role of the EET metabolic pathway in the pathophysiology of 
CAD and its associated complications. We show that alterations in the EET metabolic pathway 
which are predicted to reduce EET levels may promote the development of coronary 
atherosclerosis, post-AMI early ventricular remodeling, and post-AMI mortality. Collectively, 
this work sets the stage for future studies that investigate the therapeutic utility of modulating 
EETs in CAD patients.  
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APPENDIX A - PHARMACOGENOMICS IN HEART FAILURE: WHERE ARE WE 
NOW AND HOW CAN WE REACH CLINICAL APPLICATION1 
 
Introduction 
 
Heart failure has reached epidemic proportions. Approximately 5 million adults have 
heart failure in the United States with recent projections suggesting that by 2030, the prevalence 
of this syndrome will increase another 25%. (1) Thus, heart failure has tremendous impact on the 
health care system and constitutes a major medical and societal burden. Heart failure is 
characterized by insufficient cardiac performance to meet metabolic requirements or 
accommodate systemic venous return. (2) The body’s neurohormonal system including the renin-
angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS) is activated 
in order to compensate for these deficiencies (2) but activation of these systems contribute to 
worsening heart failure, worsened quality of life, and poor outcomes such as the need for a heart 
transplant, or sudden cardiac death.  (3) Evidence-based medical therapies that suppress these 
responses can substantially reduce the progression of this syndrome. (4-6) Accordingly, 
comprehensive heart failure management guidelines from both the American College of 
Cardiology (ACC)/American Heart Association (AHA) and the Heart Failure Society of America 
(HFSA) recommend specific pharmacological management, mostly focused on neurohormonal 
suppression, to improve outcomes in all patients with heart failure and reduced ejection fraction. 
(7, 8) β blockers and angiotensin converting enzyme (ACE)-inhibitors are considered the 
foundation, but evidence has shown important roles for other therapies which help delay 
progression of heart failure and reduce mortality including angiotensin receptor blockers 
                                                 
1Oni-Orisan, A. & Lanfear, D.E. Pharmacogenomics in heart failure: where are we now and how can we reach 
clinical application? Cardiol Rev  22, 193-8 (2014). 
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(ARB)s, aldosterone antagonists, hydralazine/isosorbide combination, and even device therapies 
such as implanted defibrillators and cardiac resynchronization therapy (CRT). (7, 8) In addition, 
while there is no evidence for mortality benefits with loop diuretics and digoxin, these agents are 
indispensable, improving symptoms and possibly reducing hospitalizations. (9, 10) It is thus 
evident that heart failure patients are currently subjected to a multiplicity of medications to 
achieve maximum benefit and optimized outcomes. This polypharmacy in health failure patients 
is associated with increased risk of toxicity, drug interactions, and poor compliance. (11) Current 
guidelines do offer some advice regarding tailoring of therapy on clinical grounds; for example, 
the HFSA guidelines recommend that factors such as age, ethnicity, heart failure severity, renal 
function, and serum potassium should be used to choose which of the many agents a heart failure 
patient should receive in his or her regimen. (7) However, even in patients who appear to have 
similar clinical factors, a great deal of variability exists in response to treatment. (12) Genetic 
variability in response to heart failure treatment exists (13) and genetic information may 
complement conventional clinical information in tailoring therapy to an individual patient, 
ultimately improving outcomes. The present review focuses on available data from 
pharmacogenomic studies in heart failure medications, particularly focusing on new 
developments over the past 2 years (earlier literature has been nicely described elsewhere (14, 
15)), summarized by medication class. Proof-of-principle findings are presented that are 
important to be aware of, but actionable genetic testing to guide therapeutic choices in heart 
failure remains limited to date. Thus, the review also shows that further work in this area is 
needed before the clinical implementation of heart failure pharmacogenomics becomes a reality, 
and we provide a glimpse of the future needs and directions. 
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Beta adrenergic antagonists 
 
The role of the adrenergic signaling pathway of the SNS in heart failure is characterized 
by a vicious cycle in which chronic stimulation of the adrenergic receptor (AR) by circulating 
catecholamines norepinephrine (NE) and epinephrine promotes cardiac dysfunction that results 
in the release of more adrenergic-stimulating catecholamines and further disease progression. 
(16) While the sub-cellular mechanism of action is not completely elucidated, it is clear that β 
blockers work by suppression of the adrenergic pathway and interruption of this vicious cycle. 
(17) Due to evidence of survival benefit, β blockers have been a mainstay of heart failure 
pharmacotherapy for almost 20 years. (18-20) However, there is great variation in response to β 
blocker therapy including certain subsets of the heart failure population that do not receive the 
same mortality and morbidity benefit. (21, 22) SNPs in the β1-AR (ADRB1), β2-AR (ADRB2), 
α2C AR (ADRA2C), and G-protein receptor kinase 5 (GRK5) genes of the adrenergic system 
may partially explain the variable effects received from β blockade.  In fact, most of the 
published pharmacogenomic literature over the past 2 years concerning heart failure has focused 
on response to β blockers; thus we have given it first and most attention among the drug classes 
of interest. 
β1-AR is the primary pharmacologic target of β blockers. One of the most widely-studied 
polymorphisms for heart failure in ADRB1 is the Arg389Gly variant. Arg389 is associated with 
enhanced adrenergic response to agonist stimulation of β1-AR in vitro (23) and in vivo(24). 
Importantly, in a genetic substudy of the β Blocker Evaluation of Survival Trial (BEST), a 
relationship between β1 genotype and mortality response to treatment with the β blocker 
bucindolol was found.(25) BEST was a large, randomized, clinical trial testing the efficacy of 
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bucindolol in heart failure patients. (26) The trial was terminated prematurely at 2 years due to a 
lack of mortality benefit, though bucindolol significantly improved mortality in the non-black 
subset (~75% of the patients).(26) As a result of clinical failure in the overall population, 
bucindolol was never approved by the FDA for the treatment of heart failure. Notably, 
bucindolol also acts as a potent sympatholytic in addition to its β blocking properties, reducing 
circulating NE levels to a much greater extent than the β blockers FDA-approved for heart 
failure (e.g. carvedilol and metoprolol succinate).(27) This distinct property of bucindolol may 
have reduced NE to deleteriously low levels thereby abrogating cardiac contractility and 
negating any beneficial effects realized through β blockade.(25) In the genetic substudy, Arg389 
homozygotes were found to have a 34% mortality benefit from bucindolol. (25) A greater 
survival rate in patients with this genotype was found when NE levels did not decrease compared 
to baseline, suggesting that an enhanced β blockade affect rather than protection from 
exaggerated sympatholysis may be responsible for reduced mortality in this population. In 
contrast, no clinical benefit was observed in carriers of the Gly389 variant. (25) These results 
were backed up by ex vivo and cell data which also showed that enhanced bucindolol response 
was associated with Arg389. (25) In addition, the results may explain racial differences in 
bucindolol efficacy, as blacks were less likely to carry Arg389 compared to non-blacks. (25) 
However the relatively small difference in allele frequencies between racial groups (0.62 in 
blacks, 0.73 in non-blacks)(25) and contradictory clinical trial data that do not show variation in 
response to β blocker therapy across race(28), suggest that Arg389 does not sufficiently explain 
racial disparities in bucindolol response. 
In addition to the Arg389Gly polymorphism, a variant at codon 49 also has been found to 
influence drug response and clinical adverse outcomes in heart failure patients. Specifically in a 
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population of patients with idiopathic dilated cardiomyopathy, Ser49 homozygotes had worsened 
prognosis (death or cardiac transplantation) compared to Gly49 carriers. (29) This association 
remained present among patients who received β blocker therapy (~39% of the population), 
though the specific β blocker drug patients were taking was not specified. (29) These data were 
supported by mechanistic follow-up studies where cells transfected with Gly49 had increased 
sensitivity to metoprolol as well as enhanced catecholamine-induced β1-AR desensitization, 
which is considered a protective response to heart failure progression. (30)  An expanded clinical 
follow-up confirmed that Gly49 carriers had better survival compared to Ser49 homozygotes, 
suggesting that higher β blocker doses may be warranted in Ser49Ser patients to achieve optimal 
survival response. (31)  
ADRB2 has a role in adrenergic signaling in parallel with ADRB1. Indeed, clinical trial 
data from the COMET trial and experimental evidence both suggest that antagonism of β2 AR is 
at least partially responsible for beneficial effects of carvedilol in heart failure. (32, 33) ADRB2 
genotype may be important in heart failure pathophysiology and response to β blocker therapy. 
Kaye et al. were able to show that among heart failure patients receiving carvedilol, the 
proportion of patients with a favorable EF response to therapy (≥10% improvement in absolute 
LVEF or ≥5% improvement in absolute FS) was significantly higher in Glu27 carriers compared 
to Gln27 homozygous patients(34).  These findings were validated in a larger population.(35)  
Moreover, this effect has been replicated in terms of survival in several subsequent studies. (36-
38)  For example, in a well-treated cohort of advanced heart failure patients (81% were receiving 
β blockers), individuals who carried 2 copies of the ADRB2 Arg16-Gln27 haplotype were more 
likely to die or require a heart transplant.(38) 
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The ADRA2C gene is responsible for the expression of the α2C AR, an autoreceptor 
located on presynaptic adrenergic neurons, which limits the release of NE through a negative 
feedback system. (39, 40) Genetic disruption of α2 ARs in mice resulted in elevated NE levels 
and hearts with significant hypertrophy. (40)  The multiple-nucleotide polymorphism α2C322–
325 deletion (Del) similarly increased risk of developing heart failure in black patients (41), who 
have a minor allele frequency of 0.4 compared with 0.04 in whites (42). In a BEST DNA 
substudy, ADRA2C variability surprisingly did not alter baseline levels of NE or the natural 
course of heart failure progression in placebo-treated patients. ADRA2C genotype, however, did 
affect response to bucindolol treatment. (42) Patients who were carriers of the Del allele had 
enhanced norepinephrine reduction from bucindolol compared to wild-type patients. 
Furthermore, bucindolol was found to improve survival only in α2C322–325 wild-type 
homozygotes. (42) Though the precise mechanisms by which ADRA2C genotype impacts the 
ability of bucindolol to reduce NE levels remain unknown, these results are consistent with 
previous findings(25) that an exaggerated sympatholytic response to bucindolol is associated 
with reduced survival response to bucindolol. 
GRK5 codes for G-protein receptor kinase 5 which desensitize β AR signaling. (43) 
Substitution of Gln at the 41st amino acid position with Leu has been found to be a gain-of-
function allele resulting in enhanced desensitization, (43) analogous to an endogenous β blocking 
effect. In a prospective cohort of African American heart failure patients, who have 10-fold 
higher allele frequencies of this gain-of-function polymorphism than Caucasians, the presence of 
GRK5 Leu41 was just as protective in preventing cardiac death or heart transplant as β blocker 
use. (43) These findings were recapitulated in an expanded population of African American heart 
failure patients: GRK5 Leu41 improved survival. (44) 
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Inconsistencies that contradict the above associations between variants in genes of the 
adrenergic system and survival response to β blockers exist in the literature. For example, the 
significant relationship between ADRB1 Arg389Gly genotype and mortality response to 
bucindolol is less clear with the β blocker therapies FDA-approved for heart failure(27, 45-48); 
however, the aforementioned differences in sympatholytic properties among β blockers may 
explain why the pharmacogenetic association with ADRB1Arg389Gly in heart failure patients is 
inconsistent across members of this drug class. Moreover, De Groote et al. did not find a 
significant genetic association between any of the five aforementioned adrenergic receptor 
polymorphisms and survival in β blocker-treated heart failure patients. (49) An investigation in a 
large registry of heart failure patients with left ventricular dysfunction receiving metoprolol or 
carvedilol showed that individual variants and haplotypes involving ADRB1, ADRB2, and 
ADRA2C were not found to have a significant effect on survival.(27) Altogether, these results 
imply that other factors such as race, disease severity, specific β blocker, and phenotype may 
interact with pharmacogenomic associations. In addition, SNPs may interact with each other and 
attenuate the elucidation of these associations. 
Despite these challenges (or perhaps because of them), the pharmacogenetics of β 
blockers in heart failure continues to be an active area of investigation in recent years. Further 
work has attempted to sort out these inconsistencies, validate findings, and fully characterize the 
subset of optimal responders to β blocker therapy. An approach that continues to be used to 
address contradictions in the literature is the investigation of associations between genetic 
combinations and response to β blocker therapy, rather than individual polymorphisms. (50) This 
strategy has been adopted by multiple investigators in recent years. Petersen et al. observed that 
heart failure patients who were homozygous for ADRB Arg389 and carriers of ADRB2 Gln27 in 
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combination received less survival benefit from carvedilol treatment. (51) In contrast, this 
genotype combination did not impact response to metoprolol, likely due to differences in 
pharmacological properties. (51) More recently, O’Connor et al. have further elucidated the 
interaction of multiple adrenergic polymorphisms on β blocker response with another genetic 
substudy in BEST.(52) In particular they reported an additive loss of bucindolol response in 
terms of morbidity and mortality in carriers of β1 Gly389 and α2C322–325 Del alleles, consistent 
with the effects of the individual SNPs on bucindolol response. (52) And an even more recent 
BEST substudy shows that genotype combinations determined from β1 Gly389 and α2C322–325 
Del interact with response to bucindolol in terms of its efficacy in preventing ventricular 
arrhythmias in heart failure patients(53); this morbidity response to bucindolol is similar to the 
abovementioned mortality response when using the same SNP combinations. Another important 
issue that is often overlooked in heart failure pharmacogenomic studies involves the impact of 
other comorbidities. This issue has been recently explored as well. In a substudy of BEST, atrial 
fibrillation status did not affect response to bucindolol. β1 Arg389 homozygote patients, but not 
β1 Gly389 carriers, had reduced death and hospitalization from bucindolol; which confirms the 
pharmacogenomic association discovered in the full BEST genetic population. (54) On the 
contrary, atrial fibrillation history impacted genetic response to β blockers in a population of 
elderly patients (age > 65) with heart failure. (55) Patients who were β1 Arg389 homozygotes 
and also suffered from atrial fibrillation had blunted heart rate reduction from carvedilol, but not 
bisoprolol; no attenuation in response to therapy was seen with patients in normal sinus rhythm 
regardless of β blocker or genotype (55)  demonstrating that comorbidities may interact with 
pharmacogenetic associations. Indeed β blocker response to adrenergic polymorphisms in acute 
myocardial infarction patients conflict with those seen in heart failure patients.(56) In addition to 
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these studies which look at the impact of gene-gene interactions and comorbidities on 
pharmacogenomic associations, investigators continue to report data on individual 
polymorphisms. In a prospectively recruited population of heart failure patients, Talameh et al. 
showed that β1 Ser49Ser homozygotes, but not Gly49 carriers, had enhanced survival response to 
β blocker therapy, using a larger population to corroborate previous findings that β blocker 
therapy has a greater influence on outcomes only in patients with Ser49Ser genotype. (31, 57) 
Another recent genetic substudy looked at the impact of genotype on dose response in heart 
failure patients receiving metoprolol or carvedilol. (58) β1 Arg389 homozygote patients had 
increased mortality and worsened quality of life from lower β blocker doses, whereas dose did 
not affect outcomes in Gly389 carriers. (58) This contribution is significant, because few have 
assessed quality of life outcomes or gene-dose response in pharmacogenomic heart failure 
studies. (58) Collectively, these recent findings indicate that while progress in this field 
continues, more work is still needed before clinical utility of β blocker pharmacogenomics can 
be achieved. At the current rate, this goal does not seem achievable in the near future; a 
heightened effort is warranted.  
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Drugs targeting the renin-angiotensin-aldosterone system 
 
The RAAS also plays a key role during the development and worsening of heart failure. 
(59)  Several classes of agents for heart failure are available that work at different sites within the 
RAAS to suppress its effects. In particular, ACE inhibitors help to comprise the cornerstone of 
modern heart failure pharmacotherapy and have compelling evidence of survival benefit in 
multiple clinical trials. (60, 61) ACE inhibitors act by blocking ACE-mediated conversion of 
angiotensin I to angiotensin II, thereby reducing vasoconstriction, salt-retention, and hypertrophy 
that occur with this neurohormone. (62)  Genetic modifiers of ACE inhibitor effectiveness have 
been long sought with some early success.  An insertion (I)/deletion (D) polymorphism in ACE is 
responsible for half of the variance in systemic ACE levels; the D allele is associated with 
increased ACE. (63) The presence of this variant is also associated with heart failure incidence 
and severity. (64, 65) Additionally, past research has shown that this polymorphism alters 
response to ACE inhibitors. Cuoco et al. showed in a population of heart failure patients (90% 
receiving ACE inhibitors) that carriers of the D allele had significantly improved LVEF 
compared to wild-type patients after a mean follow-up of ~39 months. (66) In contrast, in a 
population of patients with left ventricular hypertrophy and hypertension receiving ACE 
inhibitors, patients with the D/D genotype had less improvement in hypertrophy. (67) In a third 
study, the presence of the D allele had no impact on mortality in diastolic heart failure patients 
who received ACE inhibitors. (68) This finding that does not concur with either of the above 
results, but does agree with an earlier study in systolic heart failure patients that also showed a 
diminished impact of the polymorphism on outcomes in patients receiving ACE inhibitor 
therapy, specifically at higher doses. (69) 
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Currently, the pharmacogenomic impact of ACE genetic variation in heart failure remains 
a controversial subject.  In a recent genetic substudy of a randomized trial investigating the 
impact of pharmacist intervention on outcomes in heart failure patients (68% receiving ACE 
inhibitors and 13% receiving ARBs at baseline), the ACE I/D polymorphism was not found to be 
associated with the composite of ED visits and hospitalizations. (70)  Further work, including the 
resolution of the aforementioned conflicting data, is necessary to elucidate the potential 
application of using of pharmacogenomic information to guide the therapeutic regimen of RAAS 
drugs in heart failure.  
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Other heart failure therapies 
 
Guidelines recommend additional therapy as adjuncts to β blockers and ACE inhibitors 
for relieving symptoms, delaying the progression of cardiac dysfunction, and improving survival 
in heart failure patients. (7, 8) Among others, adjunct therapies with the most promising 
pharmacogenetic evidence are digoxin and loop diuretics. 
It is fairly well established that digoxin reduces symptoms of heart failure and 
hospitalizations. (10) Digoxin has been used for centuries in heart failure and continues to be 
recommended in this population, but only at doses that correlate with relatively low serum levels 
due to increased mortality at higher levels. (7, 71) Given this narrow therapeutic range, factors 
which impact digoxin concentration may have important clinical implications. P-glycoprotein 
which is coded by ABCB1 plays a role in digoxin elimination.(72) The TTT haplotype is a 
combination of three SNPs (the substitution of thymine at positions 1236, 2677, and 3435) in 
ABCB1 that are highly linked and have been found to be associated with digoxin serum levels. 
(73) In particular, a 2008 study reported that the TTT haplotype was associated with increased 
digoxin levels in a population of elderly Caucasian patients receiving digoxin. (73) This contrasts 
an earlier study that evaluated this association in a small population of heart failure patients did 
not find a significant ABCB1effect on digoxin levels, (74) suggesting that further work 
investigating the pharmacogenetics of digoxin is needed. This area continues to be investigated; 
a recent study confirms that the ABCB1 TTT haplotype may be predictive of elevated digoxin 
concentrations in patients receiving this medication, especially in females. (75) However, similar 
to the 2008 digoxin report mentioned, this 2012 study did not include a population of exclusively 
heart failure patients. The negative finding in heart failure patients hint that perhaps clinical or 
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other factors related to the disease state may override any genetic association altering digoxin 
response. Validation in a larger independent population is necessary to establish if there is a 
genetic link to digoxin levels and clinical response in heart failure patients receiving digoxin.  
Loop diuretics, similar to digoxin, have not been found to have a mortality benefit but are 
the most common agents used for symptomatic relief due to sodium and water retention. They 
act by inhibiting sodium-potassium-chloride luminal transporters in the loop of Henle causing an 
attenuation of the reabsorption of sodium and water. (76) Recently a small study in healthy 
volunteers suggests that genetics may play a clinically-relevant role in response to loop diuretics. 
(77) Polymorphisms in GNB2, ANP, ACE, and ADD1 impacted the excretion amounts of sodium 
chloride, potassium, and calcium. (77) Similar to the pharmacogenetics of digoxin, further work 
including confirmation in heart failure patients and a link to clinical efficacy is a necessary 
fundamental to understand if clinical application is possible.  
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Future prospects for pharmacogenomics 
 
Over the past 15 years the field of pharmacogenetics has spread to include therapy for 
heart failure. Since the earliest periods of discovery, β blocker pharmacogenomics has been the 
most heavily explored, however response to other heart failure therapies also have shown the 
potential to be impacted by genotype. Taken together, the knowledge base summarized above 
demonstrates that genetic information does have the potential to guide therapeutic regimens for 
patients with heart failure and to improve outcomes. Despite this wealth of investigation, 
however, the pharmacogenomics of heart failure therapies still have not reached clinical utility.  
Additional steps are needed before this can be realized. 
First, clarifying the current areas of inconsistency between gene-drug response 
associations should be a high priority. These inconsistencies suggest that complex genetic and 
environmental factors play a role. There needs to be a continued focus on the creation of 
‘polygenic profiles’ which serve as novel biomarkers for the response to heart failure 
medications and allows for the identification of ‘full’, ‘intermediate’, and ‘non-’ responder 
subsets.  Additionally the consideration of comorbidities and other clinical factors are beginning 
to show utility in predicting which subsets of the heart failure population would respond best to 
certain agents; these results require further exploration. 
Secondly, much emphasis has been placed on genes related to the adrenergic system as 
expected considering its great promise in predicting response to β blockers in clinical practice. 
Nonetheless, more attention needs to be placed on emerging pharmacogenetic biomarkers. In 
addition to the aforementioned pharmacogenetic findings that have been investigated in the past 
couple years involving ACE inhibitors, digoxin, and loop diuretics, novel genetic biomarkers in 
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the early phases of discovery have potential to determine drug response in the heart failure 
population. For example, a recent study has shown that variation in genes coding for matrix 
metalloproteinases may interact with response to therapies altering the risk of heart failure 
development in hypertension patients. (78) Furthermore, novel genetic biomarkers have the 
potential to predict response to heart failure therapies beyond pharmacological agents. De Maria 
et al. recently found that among heart failure patients receiving CRT, those who did not achieve 
clinically significant reverse remodeling were more likely to have the NR3C2 minor C allele 
(rs5522 C/T) compared to patients who achieved reverse remodeling. (79) These data, of course 
require validation, but overall, support the potential of emerging genetic predictors of response to 
both pharmacological and non-pharmacological treatment in the early development as well as the 
advanced progression of heart failure. 
Another important step is the continued and expanded use of genetic analyses of heart 
failure randomized clinical trials (Table). These datasets serve as critical platforms to determine 
pharmacogenetic associations because they can supply large cohorts in which the impact of the 
therapy-gene interaction on outcomes can be most clearly demonstrated. Although genetic 
substudies are limited when the initial intervention has already become standard of care since 
this may preclude replication in an independent population, alternates for the validation of 
pharmacogenomic findings exist; these are beyond the scope of this review and are reviewed in 
great depth elsewhere. (80) Furthermore, these types of studies are ideal for emerging therapies 
where they may aid in identifying the best responders to a therapy and reduce the probability of 
drug development failure in clinical trials. As a result of genetic substudies of BEST that have 
provided a wealth of knowledge, bucindolol may be the most auspicious candidate to be 
approved as a heart failure therapy that incorporates a pharmacogenomic-guided strategy. While 
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genetic information is now routinely being collected in clinical trials worldwide (81, 82), it is not 
always being actively utilized or opened for exploration, squandering many great opportunities. 
Ultimately randomized clinical studies of pharmacogenomic-guided therapy would be 
needed to conclusively establish the utility of a pharmacogenomic approach in a clinical setting.  
The authors feel that one pharmacogenetic clinical trial success in heart failure would invigorate 
interest and open the flood gates for future studies. On the other hand, while randomized clinical 
trials represent the definitive proof, it is not a practical endeavor for each genetic variant and 
drug of potential interest. Indeed efforts to incorporate pharmacogenomic-guided decision 
making at the bedside at progressive institutions are taking place without the evidence of 
randomized, prospective trials.(83-85) The medical and scientific community still needs to 
grapple with and decide on the level of evidence required for universal integration of heart 
failure pharmacogenomics in clinical practice. 
In conclusion, progress in the field of heart failure pharmacogenetics continues, but 
further research is necessary. A collective and concerted effort between basic, clinical, and 
translational researchers is merited to achieve its incorporation into guidelines as a standard of 
clinical care.
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Tables 
 
 
Table B.1 Recent heart failure pharmacogenomic findings from clinical trials (2012-present). 
 
Gene (genotype) Parent trial Drug Primary endpoint Association 
ADRA2C (322–325), 
ADRB1 (Arg389Gly) 
BEST* (1) Bucindolol ACM, ACM or 
transplant 
Carriers of Gly389 and Del in combination had 
complete loss of bucindolol response in HF patients 
ADRA2C (322–325), 
ADRB1 (Arg389Gly) 
BEST* (2) Bucindolol Incidence of VT/VF Carriers of Gly389 and Del in combination had 
complete loss of bucindolol response in HF patients 
ADRB1 (Arg389Gly) CIBIS-ELD† (3) Bisoprolol, 
carvedilol 
HR Arg389 homozygotes had reduced carvedilol response 
in elderly (age > 65) HF patients with AF 
ADRB1 (Arg389Gly) BEST* (4) Bucindolol ACM or HFH, CVM 
or CVH, HR 
Arg389 homozygotes had reduced bucindolol response 
in HF patients with AF (for all endpoints but HR) 
ADRB1 (Arg389Gly) HF-ACTION†† (5) Any HF β 
blocker 
ACM or ACH Arg389 homozygotes had reduced β blocker response 
(low doses) in HF patients 
*Efficacy of bucindolol versus placebo in patients with heart failure 
†Efficacy and safety of carvedilol versus bisoprolol in elderly patients with heart failure 
††Efficacy of exercise training versus usual care in patients with heart failure 
ACM, all-cause mortality; ACH, all-cause hospitalization; AF, atrial fibrillation; CVH, cardiovascular hospitalization; CVM, cardiovascular mortality; HF, 
heart failure; HFH, heart failure hospitalization; HR, heart rate; VF, ventricular fibrillation; VT, ventricular tachycardia 
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APPENDIX B - EPOXYEICOSATRIENOIC ACIDS AND CARDIOPROTECTION: THE 
ROAD TO TRANSLATION2 
 
Introduction 
 
Despite major advances in evidence-based medical therapies, cardiovascular disease 
(CVD) remains the leading cause of morbidity and mortality worldwide. In the western world, 
CVD has been the leading cause of death for almost a century and its prevalence is expected to 
continue to rise tremendously (1, 2). Most notably, acute myocardial infarction (AMI) events, 
complications of CVD, are a primary source of the public health burden associated with this 
illness (1, 2). AMI is typically characterized by rupture of an atheromatous plaque resulting in an 
intracoronary thrombus and myocardial ischemia (3). The restoration of blood flow, termed 
ischemia-reperfusion (IR), is imperative to prevent further myocardial cell necrosis. 
Paradoxically, however, IR also triggers injury to the myocardium (4). Consequently, 
identification and characterization of the key pathways that regulate IR injury will facilitate the 
development of novel therapeutic strategies that mitigate IR injury and its pathological 
consequences, thereby reducing the risk of adverse outcomes following AMI. 
It is now well-established that cytochrome P450 (CYP)-derived epoxyeicosatrienoic 
acids (EETs), endogenous lipid metabolites of arachidonic acid, elicit potent anti-inflammatory, 
vasodilatory, fibrinolytic, anti-apoptotic, pro-angiogenic, and smooth muscle cell anti-migratory 
effects in the cardiovascular system (5, 6). Furthermore, accumulating preclinical evidence from 
in vitro, ex vivo, and in vivo models of AMI demonstrate that EETs directly protect the 
myocardium following ischemia via a variety of mechanisms (7-9). Additionally, associations 
                                                 
2Oni-Orisan, A., Alsaleh, N., Lee, C.R. & Seubert, J.M. Epoxyeicosatrienoic acids and cardioprotection: the road to 
translation. J Mol Cell Cardiol  74, 199-208 (2014). 
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between genetic polymorphisms in the CYP epoxygenase pathway and the risk of developing 
CVD have been reported in humans (10). Therefore, therapeutic interventions that promote the 
cardioprotective effects of EETs offer considerable promise as a novel therapeutic strategy to 
reduce sequelae following AMI; however, key questions remain to be addressed prior to 
translation of EET-promoting strategies into successful proof-of-concept phase I and II clinical 
trials. The acute and chronic cardioprotective effects of EETs and underlying mechanisms have 
not been fully characterized. Furthermore, the association between genetic polymorphisms in the 
CYP epoxygenase-EET pathway and poor prognosis has not been studied in patients suffering 
from an AMI. These are currently active areas on investigation. 
This review aims to 1) outline the known cardioprotective effects of EETs and underlying 
mechanisms with a particular focus on myocardial IR injury, 2) describe studies in human 
cohorts that demonstrate a relationship between EETs and associated pathways with the risk of 
coronary artery disease (CAD), and 3) discuss preclinical and clinical areas that require further 
investigation in order to increase the probability of successfully translating this rapidly emerging 
body of evidence into a clinically applicable therapeutic strategy for AMI.  
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The CYP epoxygenase pathway 
 
Arachidonic acid is metabolized by CYP epoxygenase enzymes to form bioactive EETs 
(Fig. 1) (11). CYP2J and CYP2C epoxygenases are the primary source of all four EET 
regioisomers (5,6-, 8,9-, 11,12-, and 14,15- EETs) (12). Each regioisomer is composed of 2 
different stereoisomers (R,S or S,R configuration) (12). CYP2J2, CYP2C8 and CYP2C9 are 
extensively and constitutively expressed in human heart tissue (13, 14). The predominant fate of 
EETs is through rapid metabolism by soluble epoxide hydrolase (sEH) into 
dihydroxyeicosatrienoic acids (DHETs), which generally have less biological activity (6, 7). 
EPHX2 codes for human sEH (15) and is expressed in a multitude of cell types (16). Importantly, 
sEH is highly expressed in the myocardium (16). 
In parallel, arachidonic acid is also metabolized by cyclooxygenase, lipoxygenase and 
CYP hydroxylase enzymes to produce biologically active metabolites that play a functional role 
in myocardial IR injury (17-19). In addition to arachidonic acid-derived products, other members 
of the n-6 polyunsaturated fatty acid (PUFA) family (most notably linoleic acid) and of the n-3 
PUFA family such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) play a role 
in cardiovascular disease (20). CYP-dependent epoxy-derivatives of these PUFAs are also potent 
biological mediators in the cardiovascular system and may be subsequently metabolized into 
vicinal diols by epoxide hydrolases (12, 21, 22). Although these emerging data are beyond the 
scope of this review, we summarize select examples from the literature throughout the review 
that will stimulate future research in this area. 
A variety of pharmacologic and genetic strategies have been utilized to characterize the 
functional role of EETs in preclinical studies. Administration of exogenous EETs and synthetic 
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EET analogs has been utilized as agonists to characterize the direct cardioprotective effects of 
EETs (23). The synthetic analog 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) has the 
unique property of exhibiting putative EET receptor antagonist-like activity (24), and 
consequently has also been very useful to study EET action. An alternative approach is to target 
enzymes involved in the biosynthesis (CYP epoxygenases) and metabolism (sEH) of endogenous 
EETs. Notably, cardiomyocyte-specific CYP2J2 overexpression (α-MHC-CYP2J2-transgenic 
[Tr] mice), global disruption of Ephx2 (Ephx2-/- mice), and pharmacologic inhibition of sEH 
have each been utilized to increase EETs in vivo and study the contribution of the CYP 
epoxygenase-EET pathway to cardioprotection (25-27).  
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Acute EET effects following IR 
 
Accumulating evidence, across multiple laboratories and species, has demonstrated that 
EETs abrogate a variety of acute pathophysiological responses following myocardial IR, 
including the reduction of left ventricular infarct size and improved recovery of left ventricular 
function (Table 1) (8). Furthermore, as outlined in more detail below, EETs elicit these 
cardioprotective effects through multiple mechanisms, namely through activation of prosurvival 
signaling, attenuation of apoptosis, and promotion of mitochondrial protection acutely following 
IR (Table 1, Fig. 2B). 
 
Promotion of prosurvival signaling 
Numerous signal-transduction pathways are activated following IR, dictate the extent of 
cell survival following myocardial injury, and thus are pro-survival therapeutic targets for 
cardioprotection (28, 29). Our group has shown that α-MHC-CYP2J2-Tr mice exhibit increased 
myocardial DHET biosynthesis (the stable metabolite of EETs) and improved left ventricular 
developed pressure (LVDP) following 20 minutes of ischemia and 40 minutes of reperfusion 
compared to wild-type littermate controls (30). This cardioprotection was thought to be mediated 
by putative mitochondrial KATP (mitoKATP) channel-derived and p42/p44 mitogen-activated 
protein kinase (p42/p44 MAPK) prosurvival signaling (30). The exogenous administration of 
11,12-EET produced a similar recovery of ventricular function (30).  Further evidence of 
improved recovery of LVDP following IR was observed in Ephx2-/- mice, which was reversed by 
14,15-EEZE implicating that the effect was promulgated directly by EETs. Infarct size was also 
reduced in these mice (31). These actions were mediated via activation of sarcolemma KATP 
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(sarcKATP) and mitoKATP channels as well as phosphatidylinositol-3 kinase (PI3K) signaling 
(31). Results in canine and rat models of AMI have confirmed the role of KATP channels in EET-
mediated cardioprotection (32-34). 
Further research has brought the role of prosurvival signaling in EET-mediated 
cardioprotection to a more detailed level of understanding. Evidence suggests the timing of EET 
administration relative to IR injury is important and that EET-mediated cardioprotection is 
regulated by the activation of sarcKATP channels only if EETs are administered  during the 
ischemic period (35). Selective inhibition of PI3K was found to attenuate improved LVDP and 
infarct size from an agent that possesses both EET-mimetic and sEH inhibitory properties, 
implicating class-I isozymes of PI3K in EET-mediated cardioprotection (36). Moreover, 
phosphatidylinositol-3 kinase-alpha (PI3Kα) was reported to be the specific isoform within the 
class-I PI3K family that was implicated in EET-mediated protection (37). Interestingly, these 
effects occurred through a PI3Kα-dependent activation of sarcKATP channels (37).  Results from 
another study conflict with this data by showing that EETs activate sarcKATP channels 
independent of PI3K-mediated pathways (38). Experimental factors such as species (rats versus 
mice), EET regioisomer (14,15-EETs versus 11,12 EETs), and inhibitor (wortmannin versus PI-
103) may explain these discordant findings. Indeed, evidence from a study that improved LVDP 
following IR injury with 11,12-EET that was absent in 14,15-EET at the same dose suggests that 
the cardioprotective potency of EETs may vary by regioisomer (39). Studies have also 
implicated endothelial NO synthase (eNOS) (35), signal transducer and activator of transcription 
3 (STAT3) (40), brain natriuretic peptide (BNP) (41), and opioid receptor (42) signaling in EET-
mediated cardioprotection. Overall, work remains necessary to further delineate the relative 
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contribution of specific signaling pathways and regioisomers to the cardioprotective effects of 
EETs. 
 
Attenuation of apoptosis 
It is well-established that activation of apoptosis promotes infarct size and worsens 
recovery of cardiac function following IR injury (43). Importantly, EETs possess potent anti-
apoptotic properties in cardiomyocytes. Cultured cells from neonatal rat hearts and a mouse atrial 
lineage (HL-1) that were pretreated with EETs had reduced expression of multiple markers of 
apoptosis and maintained rhythmic myocyte beating after 8 hours of hypoxia and 16 hours of 
reoxygenation (44). In a subsequent study, the anti-apoptotic properties of EETs were further 
demonstrated in isolated myocardium from patients with cardiovascular disease, highlighting the 
observation that cellular mechanisms of EET-mediated cardioprotection in rodents also occur in 
the human heart (38). 
 
Preservation of mitochondrial function and structure 
Mitochondria provide the primary source of energy that fuels the contractile apparatus 
and act as key regulators of cell survival and death (45). IR injury can cause significant 
mitochondrial damage resulting in cellular death and cardiac dysfunction (45). Specifically 
ischemia causes the mitochondrial permeability transition pore (mPTP), a non-specific pore in 
the inner membrane of mitochondria, to open allowing free passage of molecules <1.5 kDa (46). 
The accumulation of these molecules in the mitochondria due to prolonged pore opening results 
in mitochondrial dysfunction and integrity and eventually leads to irreversible cell death (46). 
Signal transduction pathways, including a large proportion of those mentioned previously that 
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are implicated in EET-mediated cardioprotection, converge onto the mPTP thereby promoting or 
suppressing its opening following cardiac injury (47). In addition, the mitochondrial membrane 
potential (ΔΨm), which reflects the electrochemical gradient important for ATP generation, 
influences mPTP opening: its depletion following cardiac injury enhances mPTP opening (46). 
Agents that prevent these processes have been found to reduce infarct size and improve recovery 
of cardiac function (43).  Emerging evidence demonstrates that EETs possess potent protective 
effects directly limiting mitochondria damage.  For example, hearts from α-MHC-CYP2J2-Tr 
mice had limited mitochondrial swelling and fragmentation following IR compared to hearts 
from wild-type littermate controls (48). Cell culture experiments demonstrated that exogenous 
administration of EETs slowed the loss of ΔΨm and prevented opening of the mPTP following 
the induction of stress to cardiac cells; this was reversed by 14,15-EEZE (48, 49). And recent 
data show that EET-mediated protection of mitochondria involves regulating an autophagic 
response, which shifts the cell pathway in starved cardiac cells from death via apoptosis or 
necrosis toward survival, representing a novel prosurvival mechanism in cardiac cells (50). 
However, an important issue that remains unknown is how the EET protective signals reach the 
mitochondria and preserve its structure.  One potential mechanism implicates caveolins 
(cardioprotective structural proteins) in the EET-mediated preservation of mitochondrial 
structural integrity following IR (51). In particular, compared to untreated wild-type mice, 
plasma membrane and mitochondria isolated from the hearts of Ephx2-/-  and EET-treated wild-
type mice exhibited an attenuated IR-induced loss of caveolin-1 (Cav-1), but not caveolin-3 
(Cav-3) isoform expression (51). Altogether, these results underscore the important role of 
preserving mitochondrial function and architecture following IR injury. 
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Altogether, these preclinical findings in acute models of IR have made important 
contributions to the characterization of EET-mediated cardioprotection, confirming a direct 
protective effect of EETs on cardiomyocytes and offering mechanistic insight. It is worth 
reemphasizing that a structure-activity relationship exists with EETs based on the observations 
that 1) the endogenously formed EET regioisomers exert their biological effects at varying 
potencies, and 2) synthetic analogs of EETs agonize and antagonize their effects at varying 
degrees (52). This is the main reason why, although it remains to be discovered, at least one 
EET-specific receptor (whether at the cell surface or intracellularly) is widely believed to exist 
(9, 53). Thus, identification and characterization of an EET receptor would provide critical 
insight into the diverse biological effects of EETs, including cardioprotection, and drive future 
research and drug discovery.  
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Chronic EET effects following ischemia reperfusion 
 
Following the acute recovery phases of an AMI, the infarcted and inflamed myocardium 
chronically promotes LV remodeling, which manifests as scar tissue formation (fibrosis), LV 
dysfunction, and ultimately heart failure (54, 55). Fibrosis following AMI leads to electrical 
conduction abnormalities, which predispose patients to ventricular arrhythmias and higher risk of 
sudden cardiac death (56). Thus, this chronic maladaptive remodeling process is associated with 
worsened prognosis following AMI (57). 
Chronic preclinical models of ischemic cardiomyopathy have recently been utilized to 
determine the impact of increasing EETs on longer term endpoints following AMI. In a mouse 
model of post-AMI heart failure, where the left anterior descending (LAD) coronary artery was 
occluded for 45 minutes followed by 3 weeks of reperfusion, administration of a sEH inhibitor 
reduced collagen deposition (fibrosis), reduced arrhythmia, and improved LV fractional 
shortening (systolic function) (58). However, it is important to note that the sEH inhibitor was 
administered three days before the induction of AMI; thus it is unknown whether the observed 
attenuation of cardiac remodeling was derived independently of infarct size reduction and the 
other beneficial actions of EETs that occur acutely following IR. In a clinical situation, a 
pharmacological agent indicated to reduce IR injury would most likely be administered during or 
after, and not prior to, the ischemic phase. Three recent studies have provided insight into this 
important issue. In one study, a sEH inhibitor was administered immediately following 
permanent LAD occlusion in rats; pharmacologic suppression of sEH attenuated LV ejection 
fraction (systolic function) independent of collagen deposition reduction in the infarct zone 
following 5 weeks of occlusion (59). A second study by a separate group utilized a more chronic 
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model of heart failure in rats (permanent LAD ligation for 50 days), but administered a sEH 
inhibitor at distinct time points after the initial phase of infarct healing: 8 days (42-day sEH 
inhibitor treatment) or 47 days (3-day inhibitor treatment) following LAD occlusion (60). It was 
discovered that both regimens improved LV ejection fraction at 50 days; however, only long 
term treatment elicited an improvement in LV end-diastolic pressure (diastolic function) (60). A 
third study in mice utilizing a model of IR injury demonstrated that sEH inhibition administered 
a week following AMI was still able to attenuate chronic collagen deposition measured three 
weeks later (61). Collectively, these studies demonstrate that sEH inhibition improves 
maladaptive chronic ventricular remodeling independent of the aforementioned acute reductions 
in infarct size elicited by EETs. It is also important to note that these effects were not reported to 
be related to blood pressure reduction, suggesting that direct action on cardiomyocytes is a likely 
mechanism of cardioprotection. More rigorous investigation, including the use of other 
pharmacologic and genetic tools that promote or depress the effects of EETs, is warranted to 
further define the contribution of sEH and EETs to the pathogenesis and progression of ischemic 
cardiomyopathy.  
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Chronic EET effects in non-ischemic cardiomyopathy 
 
Non-ischemic cardiomyopathy is caused by variety of factors unrelated to an AMI (i.e., 
longstanding hypertension) and is a source of devastating consequences including arrhythmia, 
left ventricular dysfunction, heart failure, and mortality (62). Importantly, EETs have been found 
to be cardioprotective in rodent models of non-ischemic cardiomyopathy. Furthermore, in the 
majority of models, these protective effects were not reported to be dependent on blood pressure 
lowering. 
Inhibition of sEH was found to reverse transverse aortic constriction (TAC)-induced 
cardiac hypertrophy (63). Furthermore, angiotensin II, a potent driver of cardiac hypertrophy, 
upregulates sEH expression in cardiomyocytes and pharmacologic sEH inhibition attenuates 
angiotensin II-induced cardiac hypertrophy (64). CYP2J overexpression also reversed decline in 
cardiac function from tumor necrosis factor alpha (TNF-α) administration to rats (65) and 
prevented the development of TAC-induced arrhythmias in mice (66). These results are 
confirmed when sEH is modulated genetically, as Ephx2-/- mice were protected from cardiac 
dysfunction and arrhythmia following chronic high dose angiotensin II treatment or TAC 
banding (67). Spontaneously hypertensive heart failure rats were found to have increased 
transcript levels of Ephx2 and lower 14,15-EET levels compared to spontaneously hypertensive 
rats that do not develop heart failure, further suggesting an important role for sEH-mediated EET 
hydrolysis in the development of heart failure unrelated to IR injury and AMI (67). In contrast to 
preclinical models of IR, EET-mediated cardioprotection in non-ischemic cardiomyopathy has 
not been demonstrated in non-rodent models and remains an important future direction for this 
line of investigation.  
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EET action in cardiac non-myocytes 
 
In addition to cardiomyocytes, the heart is composed of fibroblasts, endothelial cells, and 
vascular smooth muscle cells (68). It is clear that these other cell types are important in the 
production and action of EETs in the heart (Fig. 2A); however, the contribution of EETs that act 
on or are produced by these other cell types to the cardioprotection phenotype observed in 
preclinical studies is less certain. 
 
Action of EETs derived from cardiac endothelial cells on myocardial cells 
CYP epoxygenases and sEH are highly expressed in endothelial cells (69, 70). Isolated 
hearts from transgenic mice with endothelial sEH or CYP2J2 overexpression (Tie2-sEH-Tr and 
Tie2-CYP2J2-Tr mice) did not alter the recovery of LVDP or infarct size following IR compared 
to wild-type mice, demonstrating that endothelial-derived EETs do not have a significant impact 
on acute myocardial recovery in this model of IR injury (71). Intriguingly, isolated hearts from 
transgenic mice with endothelial CYP2C8 overexpression (Tie2-CYP2C8-Tr mice) had 
worsened LVDP and infarct size compared to hearts from wild-type mice (71). This 
demonstrates that the specific CYP epoxygenase isoform catalyzing the formation of EETs in the 
endothelium appears to play an important role in cardiac function in mice (71). Increased parallel 
production of reactive oxygen species (ROS) and linoleic acid-derived metabolites were found to 
be the cause of the enhanced IR injury in Tie2-CYP2C8-Tr mice (71). Specifically, CYP2C8 
overexpression catalyzed the formation of epoxyoctadecaenoic acids (EpOMEs, leukotoxin) 
from linoleic acid in endothelial cells, which are subsequently metabolized by sEH to 
dihydroxyoctadecaenoic acids (DHOMEs, leukotoxin diol) (71). Enhanced endothelial DHOME, 
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along with reactive oxygen species (ROS), formation mediated the cardiodepressive phenotype 
observed in Tie2-CYP2C8-Tr, but not Tie2-CYP2J2-Tr, mice (71). It remains unclear whether 
similar CYP isoform specific effects occur in cardiomyocytes. 
 
Action of EETs derived from cardiac endothelial cells on cardiac smooth muscle cells 
Endothelial-derived EETs exert their vasodilatory action in coronary vessels through 
calcium-activated potassium channel (Kca)-dependent hyperpolarization of smooth muscle cells 
independent of prostaglandin or NO synthesis (72, 73). Interestingly, this effect has been found 
to be greatest in smaller coronary arterioles, rather than larger epicardial coronary arteries (74). 
Despite these findings, EET-mediated vasodilation in the setting of IR injury and its putative 
beneficial effect of aiding in the perfusion of oxygenated blood to ischemic regions of the heart 
remain unclear. Altogether, further work is necessary to validate the role of endothelial EETs in 
cardioprotection, especially in in vivo and chronic models of AMI. 
 
Action of EETs in cardiac endothelial cells  
Endothelial-derived EETs have well-established pro-angiogenic properties through a 
multitude of signaling pathways that are reviewed in great detail elsewhere (75). Experimental 
studies demonstrate that angiogenesis is associated with cardioprotection in chronic phases 
following IR (76). Few studies have investigated the role of EET-derived angiogenesis in 
cardioprotection following IR and as a result this topic remains poorly understood. One report 
revealed that inhibition of sEH promotes capillary tube formation (angiogenesis) in the isolated 
endothelial progenitor cells (EPCs) of post-AMI patients (compared to control subjects) through 
the EET–PPARγ pathway (77). It is unknown if these effects occur with in vivo administration of 
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a sEH inhibitor. Moreover, the EPCs were derived from whole blood and the effect of sEH 
inhibitor specifically on coronary vasculature formation was not evaluated (77). Finally, it 
remains to be determined if these effects impact myocardial recovery following AMI. 
Consequently, further work is necessary to confirm and better understand these findings. 
 
Action of EETs on inflammatory cells and cardiac fibroblasts 
We mentioned earlier that inflammation promotes cardiac remodeling and fibrosis 
following myocardial IR injury. Although they are not a permanent cellular component of the 
myocardium, bone-marrow derived inflammatory cells such as monocytes and neutrophils drive 
this inflammatory process when they infiltrate the site of injury  following IR (78). Substantial 
evidence indicates that EETs, through inhibition of nuclear factor-kappaB (NF-κB) activation, 
attenuate inflammation in endothelial cells and monocytes (6) and mitigate 
macrophage/neutrophil infiltration in the vasculature (79); these effects have not been 
extensively studied in the coronary vasculature following myocardial ischemic injury. Kompa et 
al. demonstrated that sEH inhibition impedes the infiltration of macrophages in the peri-infarct 
region of the myocardium in rats following permanent LAD ligation (59). Intriguingly, sEH 
inhibition did not reduce macrophage infiltration in the infarct region of the myocardium (59). 
Further investigation is warranted to fully characterize the contribution of inflammation 
reduction in EET-mediated cardioprotection. Inflammation precedes the development of chronic 
myocardial fibrosis during the following IR injury. Cardiac fibroblasts accelerate this 
maladaptive remodeling via secretion of growth factors and cytokines (68). Inhibition of sEH has 
been found to directly block the proliferation, differentiation, migration, and secretion capacity 
of fibroblasts (59, 61). More work is necessary to directly implicate EETs in sEH inhibition-
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mediated fibroblast suppression and to provide further mechanistic insight into this effect. 
Overall, further studies are necessary to determine the functional role of these cell-types in EET-
mediated cardioprotection relative to cardiomyocytes.  
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Clinical studies investigating the role of EETs in the progression of CVD 
 
Since pharmacological tools that directly and specifically manipulate EETs are currently 
not available for clinical use, we and others have relied on genetic and biomarker-driven 
observational studies to understand the role of the CYP epoxygenase-EET pathway in human 
CVD. Associations between the risk of developing a cardiovascular event and polymorphisms in 
genes coding for CYP2J2 (80-82), CYP2C8/9 (82, 83), and sEH (EPHX2) (84-89) have been 
discovered. Studies evaluating genetic variation and risk of CVD development have been 
summarized in great detail elsewhere (10) and continue to be an active area of investigation (88, 
89). 
Inconsistencies in the strength of the associations between genetic variation in the CYP 
epoxygenase-EET pathway and CVD susceptibility have been reported across studies, 
suggesting that the relationship is likely complex and most profound in certain subsets of the 
population (10). For instance, associations between EPHX2, CYP2J2 and CYP2C8 variants and 
CAD risk have often been most pronounced in cigarette smokers (81, 82, 84, 87). Although the 
mechanism remains unclear, this suggests that the pathologic impact of genetic predisposition to 
alter CYP-derived EET levels may be greatest in the presence of underlying cardiovascular 
dysfunction. Indeed, modulation of CYP-derived EETs has minimal impact on basal 
cardiovascular function in preclinical models; whereas, the blood pressure lowering, anti-
inflammatory, and cardioprotective effects are most substantial upon induction of a pathologic 
stimulus (6). The relationship between genetic and metabolic variation in CYP epoxygenase-
EET pathway genes and prognosis in patients with established CAD, however, has not been 
investigated and requires rigorous study.  
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Recently, we measured circulating eicosanoid metabolite concentrations in a cohort of 
patients with established and stable CAD and a corresponding population of healthy volunteers 
at low risk for CAD (90). The 14,15-EET:DHET ratio in plasma (a biomarker of sEH metabolic 
function) was significantly greater in CAD patients relative to healthy volunteers suggesting that 
sEH metabolic function was suppressed in the presence of established CAD (90). In 
concordance, plasma EET levels were also higher in CAD patients (90). Given the 
aforementioned evidence demonstrating the cardioprotective effects of EETs in preclinical 
models of CVD, these findings allude to the possible presence of a compensatory increase in 
EET levels in the presence of established CAD. Interestingly, this observation is consistent with 
a prior study in which myocardial biopsies obtained patients who developed heart failure 
(defined as ejection fraction < 45%) secondary to CAD exhibited lower EPHX2 mRNA 
expression compared to the biopsies obtained from control CAD patients without evidence of 
heart failure (67). However, these preliminary observations must be interpreted with caution until 
further studies validate the observed differences in additional populations. 
Despite the observed presence of lower sEH metabolic function and higher EET levels in 
this population of patients with established CAD, compared to healthy volunteer controls, 
substantial inter-individual variation in the 14,15-EET:DHET ratio and EET levels existed within 
the CAD population and the presence of obesity, advanced age, and cigarette smoking were the 
strongest predictors of low 14,15 EET:DHET ratios (higher sEH metabolic function) and low 
EETs (90, 91). Consistent with the aforementioned preclinical evidence demonstrating the 
cardiovascular protective effects of EETs, lower 14,15-EET:DHET ratios (i.e., higher sEH 
metabolic function) and lower EET levels were significantly associated with pro-inflammatory 
phenotypes predictive of poor prognosis (higher circulating levels of the chemokine monocyte 
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chemoattractant protein-1 and cellular adhesion molecules) (91). Importantly, these associations 
were independent of clinical factors (91). Taken together, these initial findings suggest that the 
subset of CAD patients with enhanced sEH metabolic function and low EET levels may be 
predisposed to poorer prognosis and thus likely to derive therapeutic benefit from an intervention 
that promotes the biological effects of EETs. However, subsequent studies remain necessary to 
first determine the association between inter-individual variation in the CYP epoxygenase-EET 
pathway and prognosis (i.e., clinical outcomes rather than surrogate markers) in patients with 
existing CAD. 
Importantly, evaluation of genetic and metabolic variation in the CYP epoxygenase-EET 
pathway, biomarkers of cardiovascular inflammation and cardiac remodeling, and prognosis in 
patients during and following the acute stage of an AMI has not been completed to date. 
Completion of such studies offers enormous potential to facilitate initial translation of the 
aforementioned growing body of preclinical evidence and guide the rational design of 
prospective, proof-of-concept clinical trials that aim to evaluate the cardioprotective effects of 
novel therapeutic strategies that promote the effects of EETs following an AMI.  
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Discussion: key considerations prior to initiation of proof-of-concept clinical trials 
 
Despite major medical advances over the past four decades, there still exists a major need 
to develop cardioprotective therapies that reduce death and improve quality of life in AMI 
patients. Over the past decade, there have been numerous unsuccessful clinical trials involving 
novel AMI therapeutics that had shown initial promise in preclinical studies (4). These failures 
underscore the complex pathophysiology of AMI and suggest that full preclinical elucidation 
into the cardioprotective effects of candidate agents is necessary to increase the probability for 
success in clinical trials. Past clinical trial failures were likely a consequence of being rushed 
through development before obtaining rigorous mechanistic insight in preclinical studies, and 
were therefore wrought by limitations in their design (4). Specifically, important study design 
details such as timing and dose of intervention were determined based on theoretical evidence 
and not validated a priori in animal models of AMI (4). Investigating the effects of a 
cardioprotective strategy across multiple experimental systems in vitro, ex vivo, and in vivo and 
ensuring that preclinical findings can be replicated across these experimental systems before 
human testing would allow for full mechanistic elucidation, facilitate a more accurate prediction 
of which drug candidates should be carried forward to humans, and ultimately improve clinical 
trial design. Significant initiatives have already begun to alleviate these major preclinical 
challenges in AMI therapy translation. For example, an NIH consortium of investigators called 
CAESAR (Consortium for preclinicAl assESsment of cARardioprotective therapies) has been set 
up to examine therapies in preclinical studies using the same rigorous standards that are used in 
clinical trials to ensure reproducibility and screen for truly effective therapeutic candidates (92). 
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Considering the thousands of interventions that have been reported to be cardioprotective 
in preclinical studies over the past few decades (92), it is not feasible for every promising 
intervention to be evaluated through this mechanism. Thus, a collective and collaborative effort 
between basic, clinical, and translational scientists using the same rigorous standards is needed to 
develop therapeutic strategies that promote the cardioprotective effects of EETs. In addition to 
the aforementioned issues in the development of therapeutic strategies for AMI, further 
considerations must be kept in mind in order to facilitate specifically the translation of EET-
promoting strategies into successful proof-of-concept phase I and II clinical trials. 
 
Development of therapeutic strategies that promote EET action in humans 
The successful development of this strategy for AMI is only as promising as the 
pharmacologic agents that modulate the CYP epoxygenase-EET pathway. The potential for 
clinical translation of exogenous EET administration is limited due to its short half-life and poor 
solubility. Synthetic EET analogs overcome this limitation. Historically, synthetic EET analogs 
conducive to in vivo dosing were not available (23); however, in recent years, a novel generation 
of EET analogs have been developed. These improved agents are orally bioavailable and reach 
therapeutic levels in live animals as illustrated by their protective effects in in vivo rodent models 
of renal injury (93, 94). Despite this steadfast improvement, lack of a known EET receptor 
continues to slow progress in this area. Discovery of the putative EET receptor(s) would further 
contribute to the field by elucidating structure-activity relationships and facilitating the design of 
agents with further improvements; efforts are ongoing. 
Over the past decade, a variety of selective and potent sEH inhibitors have been 
optimized through structure-activity relationship techniques. The history of sEH inhibitor 
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development is akin to that of EET analog development: compared to earlier members of the 
class, newer sEH inhibitors possess pharmacokinetic properties in animals predicted to be more 
favorable for oral human administration. Thus these agents are being actively developed and 
evaluated in both academic and pharmaceutical industry laboratories for a variety of indications 
and offer considerable promise as a therapeutic strategy for ischemic CVD (21, 95).  Thus, the 
sEH inhibitors and synthetic EET analogs are the most conducive therapeutic strategies poised 
for translation into humans in the near future. Investigators should prudently select new 
generation agents from these classes to evaluate their effects, especially in chronic and in vivo 
preclinical models of AMI where drugs ideal for chronic dosing are most important. 
 
Potential unintended effects of increasing EET levels 
EETs have a myriad of biological functions and therapeutically promoting these actions 
has the potential to cause unintended effects that should be considered. For instance, as 
mentioned earlier, EETs have potent vasodilatory effects. Although this could be beneficial in 
hypertensive patients, delayed restoration of blood pressure may have played a role in the 
increased mortality of Ephx2-/- mice observed in a model of cardiac arrest-induced hypotension 
followed by cardiopulmonary resuscitation (CPR) (96). The precise cause of death, including the 
direct role of EETs, remains unknown, but these data may have important clinical implications 
since cardiac arrest and hypotensive shock are complications of AMI. Future preclinical studies 
are warranted to replicate these findings and implicate EETs as the causative mediator of this 
effect. 
Despite their vasodilatory effects in the peripheral and coronary vasculature, EETs have 
vasoconstrictive effects in the pulmonary vasculature and may be important mediators in 
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pulmonary hypertension (97, 98). Ephx2-/-mice develop pulmonary vascular remodeling, right 
ventricular hypertrophy, and reduced exercise capacity (pulmonary hypertension) (99). 
Interestingly, these phenotypes were not replicated in wild-type mice receiving chronic 
administration of a sEH inhibitor (99). This suggests that the role of EETs and sEH in pulmonary 
hypertension is complex and further work is necessary to determine if EET-mediated pulmonary 
vasoconstriction is deleterious in the setting of an AMI or chronic cardiac remodeling. 
Similar to Kca-mediated hyperpolarization of smooth muscle cells to induce vasodilation, 
EETs activate Kca-mediated hyperpolarization in platelets (100). This leads to reduced platelet 
activation and prevents platelet adhesion to endothelial cells (100). Such findings have been 
recapitulated in vivo in the skin muscle of hamsters (101) and in the cerebral arterioles of mice 
(102). As agents that promote the EETs progress through development, we believe that the 
clinical relevance of this anti-platelet effect is enormous considering the well-established 
importance of long-term, anti-platelet therapies in patients suffering from an AMI (103, 104). Of 
note, epoxydocosapentaenoic acids (EDPs) and epoxydocosapentaenoic acid (EEQs), which are 
CYP-dependent epoxy-derivatives of DHA and EPA, respectively (Fig. 1), are potent inhibitors 
of platelet aggregation (105). Further preclinical studies are needed to grasp the potential 
additive/synergistic benefit of epoxyeicosanoid anti-platelet effects on top of their 
cardioprotective effects, specifically in the coronary arteries during IR injury. 
EETs enhanced tumorigenesis and multiorgan metastasis in multiple mouse models of 
cancer (106, 107). Specifically, these enhanced effects were observed in Ephx2-/-, Tie2-CYP2J2-
Tr, and Tie2-CYP2C8-Tr mice; observed after the direct administration of EETs and sEH 
inhibitors; and mediated via the pro-angiogenic (VEGF-secreting) properties of EETs in the 
endothelium (106). Though these effects have not been observed to occur in the absence of 
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spontaneous tumor models, these findings raise a serious concern about the potential cancer 
causing ability of therapies that increase endogenous EET levels. Importantly, the pro-
angiogenic effects of EETs also promote wound healing and tissue regeneration (108, 109), 
which may be beneficial in myocardial recovery following IR injury. Furthermore, EDPs inhibit 
tumor growth and metastasis through anti-angiogenic effects (110); however, the impact of the 
synthetic EET analogs on these phenotypes has not been well characterized. More studies are 
clearly necessary to determine the role of CYP epoxygenase-EET and parallel metabolic 
pathways in the regulation of angiogenesis, especially in the setting of an AMI. 
In addition to studying these biological effects of EETs for the purpose of understanding 
potential risks and benefits, this knowledge can also guide early drug design of EET-promoting 
agents. For example, a new series of sEH inhibitors have been modified to reduce their pro-
angiogenic properties while maintaining potent and selective sEH inhibition (111). Similarly, 
modification of synthetic EET analogs can alter their biological properties (112), (analogous to 
the aforementioned varying potencies across EET regioisomers). In fact, data suggests that EET-
mediated cancer cell proliferation is regioisomer-specific (113). Consequently, further research 
in this area is clearly needed to select the most promising compounds for further development 
and subsequent translation into clinical studies. Furthermore, considering the complex course of 
pathological events in response to IR injury in the myocardium, optimizing the timing, dose, 
duration, and route of administration of EET-modulating therapeutics will be essential to 
maximize the cardioprotective benefits while minimizing the potential harmful effects of these 
strategies. 
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The use of clinically relevant models of AMI including assessing the impact of 
comorbidities 
An additional reason for drug development failure is the evaluation of candidate agents in 
animal models that are not clinically-relevant and therefore poorly mimic the AMI patient 
population (92). Indeed, the majority of preclinical AMI models in the literature involve young, 
healthy animals lacking the comorbid conditions that are typically associated with the AMI 
population in humans (4). Importantly, efforts have begun to determine the impact of these 
conditions on EET-mediated cardioprotection. For instance, it is well known that aging, a risk 
factor highly prevalent in the AMI population, exacerbates myocardial IR injury (28). 
Cardioprotection from cardiomyocyte-specific CYP2J2 overexpression in the isolated hearts of 
young α-MHC-CYP2J2-Tr mice were lost in aged α-MHC-CYP2J2-Tr hearts following global 
IR injury (114). However, this loss was regained when aged α-MHC-CYP2J2-Tr hearts were 
perfused with a sEH inhibitor, suggesting that pharmacological inhibition of sEH activity 
remains cardioprotective even in aged hearts (114). Future studies in clinically-relevant AMI 
models are needed in order to determine if the cardioprotective effects of EETs are influenced by 
conditions such as aging, diabetes, and obesity. 
 
Subsets of the AMI population may derive greater benefit from agents that promote the 
cardioprotective effects of EETs 
Even after addressing all of the aforementioned considerations in the translation of EET-
promoting therapeutics, the innate heterogeneity of the AMI population is an important barrier to 
the successful translation of AMI therapeutics (4) as novel treatments may not work in broad 
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populations. As technology advances and we enter an era of personalized medicine, genetic and 
biochemical biomarkers offer considerable promise to identify which patients are defective in the 
specific pathway that the drug targets, are at increased risk of poor prognosis, and may derive the 
most benefit from that therapeutic intervention. Thus, selective administration of EET promoting 
therapy to a pre-identified population of ‘responders’ predisposed to low EET levels may 
increase the probability of clinical trial success. Notably, the EPHX2 Lys55Arg polymorphism is 
a promising genetic biomarker that may help identify patients predisposed to low EET levels 
since variant carriers have enhanced sEH metabolic function and increased risk of incident CAD 
(84). Moreover, direct measurement of EET levels has the potential to identify these patients. 
Indeed, higher throughput methods to quantify eicosanoids in a clinical setting have been found 
to be precise, accurate, and feasible (115). Altogether, further work is necessary to determine 1) 
which biomarkers can best identify the subset of AMI patients with reduced EET levels and 2) if 
these patients have poorer prognosis before the initiation of clinical trials that test whether 
interventions are likely to be most effective in those subsets.  
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Summary/ Conclusion 
 
After a 1997 paper reported that EETs were cardioprotective in ex vivo and in vitro 
models (39), it took about 10 years before the first in vivo reports began to recapitulate these 
findings. Since then, much attention has been focused on the role of the CYP epoxygenase-EET 
pathway in AMI and the potential for therapeutic modulation of this pathway to improve 
outcomes in humans. In parallel, the improvement of experimental strategies to manipulate the 
pathway through pharmacologic and genetic approaches has allowed for great advances in the 
knowledge surrounding EET-mediated cardioprotection. Evidence for the beneficial effects of 
EETs has been replicated using multiple species, experimental heart disease models, and 
phenotypes relevant to cardioprotection, which underscores the great promise of this therapeutic 
strategy. Most of the data in the literature highlight the acute role of EETs in prosurvival 
pathway-mediated mitochondrial preservation in cardiomyocytes following AMI, but EETs have 
also been found to attenuate chronic cardiac remodeling and elicit protective effects in other cell 
types following AMI. It remains unknown whether EETs cause deleterious effects that could 
outweigh these cardioprotective benefits. Moreover, it is poorly understood if modulation of 
parallel epoxide and diol metabolites derived from other PUFAs impacts this benefit-risk ratio. 
Consequently, further work will be critical to move this line of investigation closer to clinical 
trials. 
Ultimately, randomized controlled trials will be necessary to determine the benefits and 
risks of therapeutic strategies that promote the effects of EETs in patients experiencing an AMI. 
Before advancing promising agents that promote the effects of EETs into clinical trials, 
additional preclinical and human investigations are needed in order to lay an essential foundation 
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for the rational design of these future prospective trials and select the agent, dosing strategy, and 
patient population most likely to circumvent clinical failure. A concerted effort to address these 
prerequisites will serve to improve the probability of translational success from a rapidly 
emerging body of evidence into a clinically applicable therapeutic strategy for patients with 
AMI.  
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Figures 
 
 
 
Figure B.1 Cytochrome P450 (CYP) epoxygenase–epoxyeicosatrienoic acid (EET) and 
parallel pathways. Through the activation of cytosolic phospholipase A2 (cPLA2) in 
cardiomyocytes followingAMI,membrane-bound fatty acids are released into the cytosol and 
subsequently metabolized by CYP epoxygenases to form biologically active eicosanoids. The 
CYP2J and CYP2C epoxygenases produce four regioisomers of EETs from arachidonic acid 
(AA) that elicit various biological effects. These bioactive epoxyeicosanoids are extensively 
hydrolyzed by soluble epoxide hydrolase into the less biologically active 
dihydroxyeicosatrienoic acid (DHET) metabolites. DHA, docosahexaenoic acid; DHEQ, 
dihydroxy-eicosatetraenoic acid; DHOME, dihydroxyoctadecaenoic acid; DiHDPA, dihydroxy-
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docosapentaenoic acid; EDP, epoxydocosapentaenoic acid; EEQ, epoxyeicosatetraenoic acid; 
EPA, eicosapentaenoic acid; EpOME, epoxyoctadecaenoic acid; LA, linoleic acid. 
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Figure B.2 Epoxyeicosatrienoic acid (EET) cardioprotection in the heart. A) EETs elicit 
action in cardiac endothelial cells (pro-angiogenic, anti-inflammatory), smooth muscle cells 
(vasodilatory), fibroblasts (anti-fibrotic), and inflammatory cells (anti-inflammatory). 
These effects may protect the myocardium following IR injury. B) EETs derived from 
cardiomyocytes (CMs) elicit direct cardioprotection of the myocardium during the acute 
phase following IR injury. They activate prosurvival signaling pathways, many of which 
converge ontomitochondria and promote its preservation. BNP, B-type natriuretic peptide; 
CAM, cell adhesion molecules; EC, endothelial cell; EGFR, epidermal growth factor 
receptor; ENK, enkephalin; IR, ischemia reperfusion; MCP-1, monocyte chemoattractant 
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protein-1; mitoKATP, mitochondrial ATP-activated K+ channel; mPTP, mitochondrial 
permeability transition pore; NF-κB, nuclear factor-κB; NPR-A, natriuretic peptide receptor 
type-A; p42/p44MAPK, p42/p44 mitogen-activated protein kinase; PI3K, phosphoinositide 
3-kinase; sarcKATP, sarcolemmal ATP-activated K+ channel; SMC, smooth muscle cell; 
STAT3, signal transducer and activator of transcription.  
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Tables 
 
Table B.1 Mechanisms underlying direct cardioprotective effects of epoxyeicosatrienoic 
acids (EETs) on cardiomyocytes 
EET action Model Mechanisms 
Reduced 
myocardial cell 
death and apoptosis 
 
Hypoxia-
reoxygenation (in 
vitro); OGD/RGR 
(in vitro) 
 
PI3K/Akt signaling (36, 38, 44) 
KATP channel signaling (37, 38) 
STAT3 signaling (40) 
Improved recovery 
of left ventricular 
developed pressure 
 
Global ischemia and 
reperfusion (ex vivo) 
 
KATP channel signaling (30, 31, 37, 48) 
p42/p44 MAPK signaling (30) 
PI3K/Akt signaling (30, 31, 36, 41, 116) 
BNP/NPR-A signaling (41) 
Opioid signaling (42)  
Protein phosphatase 2A signaling (114) 
Reduced leukotoxin diol levels (114) 
Reduced oxidative stress (114) 
Preservation of caveolin-1 (51)  
 
Reduced left 
ventricular infarct 
size 
 
Global ischemia and 
reperfusion 
(ex vivo);  Ischemia-
reperfusion (in vivo) 
PI3K/Akt signaling (31, 36) 
KATP channel signaling (26, 31-35, 37) 
STAT3 signaling (40)  
Opioid signaling (42) 
eNOS activation (35) 
Initial ROS formation (34) 
Inhibition of mPTP opening (35) 
 
Reduced chronic 
left ventricular 
remodelinga 
 
Ischemia-
reperfusion (in vivo) 
 
 
Increased eNOS : iNOS ratio (60) 
Reduced myocardial collagen deposition (58-61) 
Reduced cardiac fibroblast activation (59)  
Reduced inflammatory cytokines (58, 61) 
Reduced macrophage infiltration (59)  
Reduced oxidative stress (60) 
aChronic ischemia-reperfusion involved reperfusion periods of at least 2 weeks following ischemia 
Akt, protein kinase B; BNP, B-type natriuretic peptide; eNOS, endothelial nitric oxide synthase; iNOS, 
inducible nitric oxide synthase; KATP, ATP-activated K+ channel; mPTP, mitochondrial permeability 
transition pore; NPR-A, natriuretic peptide receptor type-A; OGD, oxygen and glucose deprivation; p42/p44 
MAPK, p42/p44 mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase; RGR, reoxygenation and 
glucose repletion; ROS, reactive oxygen species; STAT3, signal transducer and activator of transcription 3  
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